Henrik Zetterberg
#54,341
Most Influential Person Now
Swedish neurochemist
Henrik Zetterberg 's AcademicInfluence.com Rankings
Henrik Zetterberg medical Degrees
Medical
#343
World Rank
#490
Historical Rank
Neurochemistry
#1
World Rank
#1
Historical Rank
Download Badge
Medical
Henrik Zetterberg 's Degrees
- Masters Biochemistry Uppsala University
Why Is Henrik Zetterberg Influential?
(Suggest an Edit or Addition)According to Wikipedia, Henrik Zetterberg is a Swedish professor of neurochemistry at the University of Gothenburg, where he is the Head of the Department of Neurochemical Pathophysiology and Diagnostics. He is also the leader of the Fluid biomarkers for neurodegenerative diseases group at University College London. The groups work on developing early tests for dementia.
Henrik Zetterberg 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cerebrospinal fluid and plasma biomarkers in Alzheimer disease (2010) (1675)
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study (2006) (1628)
- CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis (2016) (1271)
- Defeating Alzheimer's disease and other dementias: a priority for European science and society (2016) (1172)
- CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. (2009) (1139)
- Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
- Gut microbiome alterations in Alzheimer’s disease (2017) (999)
- Neurofilaments as biomarkers in neurological disorders (2018) (939)
- Alzheimer's disease (2006) (827)
- Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis (2017) (668)
- Clearance systems in the brain—implications for Alzheimer disease (2015) (632)
- Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010) (616)
- Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (2008) (603)
- TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis (2014) (580)
- The Neuropathology and Neurobiology of Traumatic Brain Injury (2012) (572)
- Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. (2012) (571)
- Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood (2013) (495)
- Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) (492)
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia (2020) (463)
- Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa (2016) (452)
- Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts (2020) (452)
- Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. (2010) (446)
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. (2020) (444)
- Identification of tissue-specific cell death using methylation patterns of circulating DNA (2016) (437)
- Clearance systems in the brain-implications for Alzheimer disease. (2015) (434)
- Neurofilament light chain as a biomarker in neurological disorders (2019) (425)
- Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. (2012) (402)
- Amyloid biomarkers in Alzheimer's disease. (2015) (402)
- Biomarkers for Alzheimer's disease: current status and prospects for the future (2018) (396)
- The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers (2011) (385)
- CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts (2018) (380)
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. (2019) (379)
- Traumatic brain injuries (2016) (373)
- Plasma β-amyloid in Alzheimer’s disease and vascular disease (2016) (370)
- Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic (2018) (370)
- Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study (2015) (353)
- Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. (2019) (342)
- sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers (2016) (341)
- Plasma tau in Alzheimer disease (2016) (337)
- PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. (2010) (333)
- Total and phosphorylated tau protein as biological markers of Alzheimer’s disease (2010) (328)
- Neurochemical aftermath of amateur boxing (2006) (328)
- Blood biomarkers for brain injury in concussed professional ice hockey players. (2014) (328)
- Current state of Alzheimer’s fluid biomarkers (2018) (327)
- Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. (2016) (326)
- Plasma tau levels in Alzheimer's disease (2013) (324)
- Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. (2014) (322)
- Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration (2020) (322)
- Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization (2008) (320)
- A Practical Guide to Immunoassay Method Validation (2015) (320)
- Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia (2016) (317)
- Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease (2017) (310)
- CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease (2016) (287)
- Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment (2007) (270)
- Monitoring disease activity in multiple sclerosis using serum neurofilament light protein (2017) (269)
- Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease (2010) (260)
- The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? (2014) (258)
- Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease (2015) (256)
- Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 (2020) (256)
- Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment (2010) (252)
- Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid (2010) (248)
- Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need (2018) (247)
- Serum neurofilament light protein predicts clinical outcome in traumatic brain injury (2016) (245)
- CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma (2012) (245)
- Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease (2015) (242)
- Pathways to Alzheimer's disease (2014) (239)
- Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid (2016) (239)
- Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) (228)
- Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. (2008) (225)
- CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival (2014) (225)
- Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. (2012) (224)
- Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis (2017) (224)
- Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease (2016) (220)
- Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women (2006) (217)
- The Role of Biomarkers in Clinical Trials for Alzheimer Disease (2006) (216)
- Steroid‐Responsive Encephalitis in Coronavirus Disease 2019 (2020) (214)
- Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports (2017) (213)
- Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease (2019) (212)
- Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. (2015) (211)
- Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic (2017) (210)
- Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
- CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings (2012) (209)
- A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease (2021) (207)
- Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease (2016) (206)
- Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss? (2009) (205)
- Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. (2015) (204)
- Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) (204)
- Fluid biomarkers in Alzheimer’s disease – current concepts (2013) (203)
- Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. (2013) (203)
- SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease (2014) (202)
- Plasma Aβ in Alzheimer's disease—up or down? (2006) (201)
- CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study (2010) (201)
- Consensus guidelines for lumbar puncture in patients with neurological diseases (2017) (197)
- Resistance to autosomal dominant Alzheimer’s in an APOE3-Christchurch homozygote: a case report (2019) (196)
- Blood-based NfL (2017) (196)
- Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease (2010) (193)
- Longitudinal stability of CSF biomarkers in Alzheimer's disease (2007) (193)
- A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes (2015) (192)
- Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid β-peptides in human cerebrospinal fluid (2011) (190)
- The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease (2018) (188)
- Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau (2018) (186)
- Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. (2015) (185)
- Determination of β-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry (2006) (185)
- Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies (2014) (185)
- CSF biomarkers predict a more malignant outcome in Alzheimer disease (2010) (184)
- Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease (2018) (184)
- Fluid biomarkers in Alzheimer disease. (2012) (182)
- Fluid biomarkers for mild traumatic brain injury and related conditions (2016) (178)
- Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link (2018) (177)
- Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease (2013) (176)
- Reporting standards for studies of diagnostic test accuracy in dementia (2014) (174)
- Cerebrospinal fluid markers for prediction of Alzheimer's disease (2003) (174)
- Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid (2020) (174)
- Increased CSF neurogranin concentration is specific to Alzheimer disease (2016) (172)
- Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study (2016) (170)
- Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease (2019) (170)
- Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology (2021) (169)
- CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease (2018) (168)
- Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease (2014) (165)
- CSF biomarkers and clinical progression of Parkinson disease (2015) (164)
- Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos (2002) (164)
- Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias (2020) (163)
- Age and diagnostic performance of Alzheimer disease CSF biomarkers (2012) (163)
- Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study (2018) (163)
- Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans (2011) (162)
- A novel pathway for amyloid precursor protein processing (2011) (162)
- APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons (2015) (162)
- Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. (2014) (160)
- Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline (2020) (159)
- Biological markers of amyloid β-related mechanisms in Alzheimer's disease (2010) (157)
- Plasma neurofilament light chain predicts progression in progressive supranuclear palsy (2016) (154)
- Molecular biomarkers of Alzheimer's disease: progress and prospects (2018) (153)
- Idiopathic normal-pressure hydrocephalus (2013) (151)
- Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. (2013) (149)
- Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration (2016) (148)
- Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod (2018) (147)
- Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures (2021) (147)
- G‐quadruplex‐binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo (2017) (147)
- Neurological consequences of traumatic brain injuries in sports (2015) (145)
- Blood-based molecular biomarkers for Alzheimer’s disease (2019) (145)
- Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. (2007) (145)
- Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease (2015) (145)
- Plasma neurofilament light chain concentration in the inherited peripheral neuropathies (2018) (145)
- Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype (2017) (144)
- Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies (2020) (144)
- Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults (2017) (143)
- Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. (2011) (143)
- Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen‐2) demonstrate excessive p53‐dependent apoptosis and neuronal loss (2006) (141)
- Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases (2015) (140)
- Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations (2020) (139)
- CSF Aβ42 predicts early-onset dementia in Parkinson disease (2014) (139)
- Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. (2015) (138)
- Serum neurofilament light in familial Alzheimer disease (2017) (138)
- Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. (2007) (138)
- Amyloid and tau cerebrospinal fluid biomarkers in HIV infection (2009) (137)
- Blood-based biomarkers for Alzheimer's disease: towards clinical implementation (2021) (136)
- Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. (2007) (136)
- Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients (2014) (136)
- Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study (2017) (135)
- Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected (2020) (135)
- Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. (2015) (134)
- Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest (2019) (134)
- Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype (2009) (133)
- Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. (2009) (133)
- The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020) (133)
- Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative (2020) (133)
- Biomarkers for tau pathology (2019) (132)
- The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk (2019) (131)
- 18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease (2017) (131)
- Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium (2013) (131)
- APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42 (2004) (130)
- Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease (2013) (130)
- Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid (2013) (130)
- Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders (2019) (130)
- A multicentre validation study of the diagnostic value of plasma neurofilament light (2021) (130)
- Microglial activation and tau propagate jointly across Braak stages (2021) (129)
- Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease (2020) (129)
- Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype (2007) (128)
- Biomarkers in dementia: clinical utility and new directions (2014) (126)
- Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. (2012) (125)
- Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF (2005) (125)
- Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease (2008) (124)
- An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid (2006) (124)
- Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease (2016) (124)
- Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid. (2014) (124)
- Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity (2010) (124)
- Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia (2017) (121)
- Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis (2015) (121)
- Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma (2013) (119)
- Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. (2010) (119)
- Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease (2017) (119)
- Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration (2017) (118)
- Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia (2013) (118)
- Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease (2010) (117)
- Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers (2017) (117)
- Review: Tau in biofluids – relation to pathology, imaging and clinical features (2017) (117)
- Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
- Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. (2010) (115)
- Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis (2017) (115)
- Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease (2020) (115)
- Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly. (2016) (114)
- Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration (2019) (114)
- Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis (2018) (113)
- Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease (2015) (113)
- C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease (2015) (112)
- Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease (2013) (112)
- Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls (2015) (111)
- Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients (2010) (111)
- Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. (2012) (111)
- Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. (2005) (110)
- Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS (2016) (110)
- Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility (2011) (110)
- A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. (2013) (108)
- Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. (2014) (108)
- Neurofilament light and tau as blood biomarkers for sports-related concussion (2018) (107)
- Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study (2021) (107)
- Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis (2014) (106)
- Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology (2018) (106)
- Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. (2015) (106)
- Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment (2010) (106)
- The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease (2016) (106)
- Cerebrospinal fluid biomarkers of white matter lesions – cross‐sectional results from the LADIS study (2010) (105)
- Amyloid β and APP as biomarkers for Alzheimer’s disease (2010) (104)
- Inflammatory biomarkers in Alzheimer's disease plasma (2019) (104)
- Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study (2016) (104)
- Monitoring of 30 marker candidates in early Parkinson disease as progression markers (2016) (103)
- Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? A pilot study. (2011) (103)
- Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease (2018) (103)
- A common challenge in older adults: Classification, overlap, and therapy of depression and dementia (2017) (103)
- Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease (2021) (102)
- The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals (2014) (102)
- Serum Neurofilament Light in American Football Athletes over the Course of a Season. (2016) (101)
- Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease (2010) (101)
- Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment (2017) (100)
- Increased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer’s disease (2004) (100)
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease (2021) (100)
- CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation. (2017) (99)
- Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms. (2014) (99)
- Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease (2019) (98)
- Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls (2017) (98)
- Neurofilaments: neurobiological foundations for biomarker applications. (2020) (98)
- Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease (2018) (98)
- A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury (2019) (98)
- Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. (2014) (97)
- Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. (2009) (97)
- Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study. (2017) (97)
- Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease (2010) (96)
- Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum (2020) (96)
- Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease (2009) (95)
- A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation (2018) (95)
- Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids (2016) (95)
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. (2021) (95)
- Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer’s disease: a pilot study (2019) (94)
- The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease (2021) (94)
- A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease (2010) (94)
- Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease (2014) (93)
- Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease (2021) (92)
- Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. (2012) (92)
- S-100B is superior to NSE, BDNF and GFAP in predicting outcome of resuscitation from cardiac arrest with hypothermia treatment. (2010) (92)
- Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall (2010) (91)
- Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosis (2017) (91)
- Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease (2013) (91)
- SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses (2021) (90)
- Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction (2015) (90)
- Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection (2014) (90)
- Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease (2020) (90)
- Early predictors of mortality in parkinsonism and Parkinson disease (2018) (89)
- Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections (2013) (89)
- Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment (2017) (89)
- Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus (2014) (89)
- Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method (2011) (88)
- Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. (2016) (88)
- Microstructural white matter alterations in preclinical Alzheimer’s disease detected using free water elimination diffusion tensor imaging (2017) (88)
- CSF T-Tau/Aβ42 Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer’s Disease (2012) (88)
- Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke (2016) (88)
- Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment (2016) (87)
- Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis (2018) (87)
- Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke (2014) (87)
- The Gothenburg MCI study: Design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up (2016) (86)
- Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. (2010) (86)
- Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery: Results From the CAPACITY and ARCADIAN Studies (2018) (86)
- Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. (2016) (86)
- Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. (2012) (85)
- Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2021) (85)
- A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid (2015) (84)
- An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. (2015) (84)
- Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications (2004) (84)
- Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders (2018) (84)
- Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions (2014) (83)
- Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study (2012) (83)
- Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP (2018) (83)
- Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study (2022) (83)
- An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders (2020) (82)
- Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia (2015) (82)
- A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease (2018) (82)
- CSF A beta 42/A beta 40 and A beta 42/A beta 38 ratios: better diagnostic markers of Alzheimer disease (2016) (82)
- The immune response of the human brain to abdominal surgery (2017) (82)
- An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid. (2012) (81)
- Characterization of tau in cerebrospinal fluid using mass spectrometry. (2008) (81)
- Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease (2016) (81)
- Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis (2020) (81)
- Plasma BDNF Levels Vary in Relation to Body Weight in Females (2012) (81)
- Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis (2017) (81)
- NFL is a marker of treatment response in children with SMA treated with nusinersen (2019) (80)
- Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. (2016) (80)
- Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1–42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40 (2018) (80)
- Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease (2009) (80)
- Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. (2014) (79)
- Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum (2020) (79)
- CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease (2014) (79)
- Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease (2019) (79)
- Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI (2020) (78)
- Postoperative delirium is associated with increased plasma neurofilament light. (2019) (78)
- Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study (2012) (78)
- Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology (2018) (78)
- Association of complement factor H Y402H gene polymorphism with Alzheimer's disease (2008) (78)
- Familial Alzheimer’s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid-beta (2019) (78)
- A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2019) (77)
- Association of pro-ghrelin and GHS-R1A gene polymorphisms and haplotypes with heavy alcohol use and body mass. (2008) (77)
- Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease (2020) (77)
- Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders (2016) (77)
- Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics (2021) (77)
- Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample (2014) (77)
- Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. (2018) (77)
- Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome (2019) (77)
- Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease (2012) (76)
- CSF biomarker variability in the Alzheimer's Association quality control program (2013) (76)
- Biomarker-based dissection of neurodegenerative diseases (2011) (76)
- Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease (2012) (76)
- Blood-based biomarkers for Alzheimer’s disease—An update (2019) (76)
- O3-01-04 Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry (2006) (76)
- Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease (2014) (76)
- The taqI DRD2 A1 allele is associated with alcohol-dependence although its effect size is small. (2006) (75)
- Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia (2020) (75)
- Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity (2020) (75)
- Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. (2011) (75)
- Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum (2019) (74)
- The role of clusterin in amyloid-β-associated neurodegeneration. (2014) (74)
- Serum tau and neurological outcome in cardiac arrest (2017) (74)
- Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. (2012) (74)
- Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. (2011) (74)
- Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease (2018) (74)
- Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases (2016) (74)
- APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. (2004) (74)
- Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. (2015) (74)
- Biomarkers in Sporadic and Familial Alzheimer's Disease. (2015) (74)
- A 9-Year Prospective Population-Based Study on the Association Between the APOE*E4 Allele and Late-Life Depression in Sweden (2015) (74)
- Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease (2016) (73)
- Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression (2020) (73)
- Serum neurofilament light in familial Alzheimer disease A marker of early neurodegeneration (73)
- Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease (2019) (73)
- Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract (2010) (73)
- Cerebrospinal fluid biomarkers for Alzheimer's disease. (2009) (73)
- The Gothenburg H70 Birth cohort study 2014–16: design, methods and study population (2018) (73)
- Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease (2012) (73)
- Plasma and CSF neurofilament light (2019) (73)
- Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic (2018) (73)
- Clinical proteomics in neurodegenerative disorders (2008) (73)
- The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans (2015) (72)
- Military risk factors for Alzheimer's disease (2013) (72)
- Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study (2019) (72)
- BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System (2012) (72)
- The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review (2018) (72)
- Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease (2016) (72)
- Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease (2018) (72)
- Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers (2019) (71)
- Assessing tissue damage in multiple sclerosis: a biomarker approach (2014) (71)
- Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia (2016) (71)
- Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment (2020) (71)
- Aspects of beta-amyloid as a biomarker for Alzheimer's disease. (2007) (71)
- Novel Trimodal MALDI Imaging Mass Spectrometry (IMS3) at 10 μm Reveals Spatial Lipid and Peptide Correlates Implicated in Aβ Plaque Pathology in Alzheimer's Disease. (2017) (71)
- Human iPS-Derived Astroglia from a Stable Neural Precursor State Show Improved Functionality Compared with Conventional Astrocytic Models (2018) (71)
- Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players. (2016) (70)
- Identification of Novel APP/Aβ Isoforms in Human Cerebrospinal Fluid (2009) (70)
- Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. (2015) (70)
- CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. (2014) (70)
- Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology‐based cohort (2017) (70)
- Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment. (2011) (70)
- Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis (2019) (70)
- Bidirectional links between Alzheimer's disease and Niemann–Pick type C disease (2014) (69)
- CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients (2017) (69)
- Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up (2021) (69)
- Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans (2012) (69)
- Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease (2014) (69)
- Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross‐validation study against amyloid PET (2016) (68)
- To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease (2010) (68)
- The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events (2015) (68)
- Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid. (2014) (67)
- Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease (2013) (67)
- Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease (2018) (67)
- Neurofilament light as a biomarker in traumatic brain injury (2020) (67)
- Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone (2016) (67)
- The Cerebrospinal Fluid in Multiple Sclerosis (2019) (67)
- Expression of the gene encoding the ghrelin receptor in rats selected for differential alcohol preference (2011) (67)
- Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding (2015) (67)
- Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later (2018) (67)
- Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study (2021) (67)
- Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer’s disease (2012) (66)
- Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson’s disease – a multicenter study (2014) (66)
- Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. (2009) (66)
- The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. (2013) (66)
- Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly (2014) (66)
- The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics (2018) (66)
- The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers (2021) (66)
- Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism (2010) (66)
- Validation of Alzheimer’s disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI) (2009) (65)
- Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly (2012) (65)
- Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers (2017) (65)
- Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial (2020) (65)
- Altered Concentrations of Amyloid Precursor Protein Metabolites in the Cerebrospinal Fluid of Patients with Bipolar Disorder (2013) (65)
- The Past and the Future of Alzheimer’s Disease Fluid Biomarkers1 (2018) (65)
- CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease (2016) (65)
- Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. (2018) (64)
- Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. (2021) (64)
- Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration (2020) (64)
- Barrier Properties and Transcriptome Expression in Human iPSC‐Derived Models of the Blood–Brain Barrier (2018) (64)
- Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment (2019) (63)
- The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. (2014) (63)
- Measuring longitudinal cognition: Individual tests versus composites (2018) (63)
- Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice (2012) (63)
- Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke (2017) (63)
- First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression (2015) (63)
- The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease (2018) (62)
- Development and assessment of sensitive immuno‐PCR assays for the quantification of cerebrospinal fluid three‐ and four‐repeat tau isoforms in tauopathies (2012) (62)
- No neurochemical evidence for brain injury caused by heading in soccer (2007) (62)
- Acute sleep deprivation increases serum levels of neuron-specific enolase (NSE) and S100 calcium binding protein B (S-100B) in healthy young men. (2014) (62)
- Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations (2020) (62)
- Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis (2009) (62)
- Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease (2012) (61)
- Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS (2012) (61)
- Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study (2020) (61)
- The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia (2011) (61)
- Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football. (2016) (61)
- Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. (2011) (61)
- The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease (2014) (61)
- Variants of CYP46A1 may interact with age and APOE to influence CSF Aβ42 levels in Alzheimer’s disease (2004) (61)
- Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. (2005) (60)
- Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development (2017) (60)
- Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease (2016) (60)
- Altered cognitive performance and synaptic function in the hippocampus of mice lacking C3 (2014) (60)
- Cerebrospinal fluid tau, Aβ, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration (2018) (60)
- Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients (2014) (60)
- Abnormality in glutamine–glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study (2016) (60)
- An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead (2019) (60)
- Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis (2020) (60)
- Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study (2020) (60)
- Targeted proteomics in Alzheimer’s disease: focus on amyloid-β (2008) (60)
- Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau (2019) (59)
- Increased CSF biomarkers of angiogenesis in Parkinson disease (2015) (59)
- Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression (2018) (59)
- Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer’s disease (2018) (59)
- From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. (2018) (59)
- Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain. (2019) (59)
- A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease (2019) (59)
- CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms (2020) (59)
- Histology-Compatible MALDI Mass Spectrometry Based Imaging of Neuronal Lipids for Subsequent Immunofluorescent Staining. (2017) (58)
- Alzheimer's disease in Down syndrome: An overlooked population for prevention trials (2018) (58)
- Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. (2010) (58)
- Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases (2018) (58)
- SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration. (2011) (58)
- Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70 (2020) (58)
- Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia (2020) (58)
- Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration (2017) (57)
- CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults (2017) (57)
- CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders (2013) (57)
- A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort (2019) (57)
- Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival (2017) (57)
- Synaptic retrogenesis and amyloid-beta in Alzheimer's disease. (2009) (57)
- YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis (2016) (57)
- &ggr;-Secretase-dependent amyloid-&bgr; is increased in Niemann-Pick type C: A cross-sectional study(e–Pub ahead of print)(CME) (2011) (57)
- CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology (2019) (56)
- Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. (2015) (56)
- Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease (2010) (56)
- The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. (2012) (56)
- Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes (2017) (56)
- Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases (2010) (56)
- Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers (2013) (56)
- Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection (2013) (55)
- Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer’s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry (2016) (55)
- The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study (2019) (55)
- Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers. (2015) (55)
- CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. (2011) (55)
- CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics (2019) (55)
- Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism (2016) (55)
- NfL as a biomarker for neurodegeneration and survival in Parkinson disease (2020) (55)
- Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections (2013) (55)
- Fluid Biomarkers for Synaptic Dysfunction and Loss (2020) (54)
- Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. (2012) (54)
- Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET (2016) (54)
- Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements (2016) (54)
- Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression (2019) (54)
- Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges (2015) (54)
- Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. (2019) (54)
- Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment (2015) (54)
- Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection (2018) (54)
- Plasma tau protein in comatose patients after cardiac arrest treated with therapeutic hypothermia (2011) (54)
- Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17 (2022) (54)
- Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease (2019) (54)
- Neurofilament light protein in blood predicts regional atrophy in Huntington disease (2018) (53)
- Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. (2017) (53)
- Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort (2019) (53)
- Proteomic blood profiling in mild, severe and critical COVID-19 patients (2020) (53)
- An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum (2020) (53)
- Monitoring of β-amyloid dynamics after human traumatic brain injury. (2014) (53)
- Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma (2019) (53)
- Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease (2019) (52)
- Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease (2015) (52)
- Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
- Tau oligomers in cerebrospinal fluid in Alzheimer's disease (2017) (52)
- Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study. (2016) (52)
- Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation (2016) (52)
- Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. (2009) (52)
- Sex differences in the genetic predictors of Alzheimer's pathology. (2019) (51)
- CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment (2015) (51)
- Prevalence of preclinical Alzheimer disease Comparison of current classification systems (51)
- Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. (2011) (51)
- Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease (2013) (51)
- Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease (2014) (51)
- Understanding the cause of sporadic Alzheimer’s disease (2014) (51)
- Sustained release of neuron-specific enolase to serum in amateur boxers (2009) (50)
- Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer’s Disease (2017) (50)
- Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease (2016) (50)
- Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD (2018) (50)
- Sleep oscillation-specific associations with Alzheimer’s disease CSF biomarkers: novel roles for sleep spindles and tau (2019) (50)
- Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease (2016) (50)
- The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease (2022) (49)
- Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study. (2020) (49)
- Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease (2017) (49)
- Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke (2019) (49)
- CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies (2010) (49)
- Association of the RAGE G82S polymorphism with Alzheimer’s disease (2010) (48)
- Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration (2013) (48)
- Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid (2010) (48)
- CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment (2014) (48)
- CSF Biomarkers (2009) (48)
- Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. (2019) (48)
- Influence of the apolipoprotein E ε4 allele on human embryonic development (2002) (48)
- PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers (2017) (48)
- MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study (2018) (48)
- Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics (2019) (48)
- Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals (2019) (47)
- Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid (2010) (47)
- Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease (2018) (47)
- Transcranial Doppler microembolic signals and serum marker evidence of brain injury during transcatheter aortic valve implantation (2012) (47)
- Spinal cerebrospinal fluid volume in healthy elderly individuals (2011) (47)
- Genetic variation of the ghrelin signaling system in females with severe alcohol dependence. (2010) (47)
- Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer's disease. (2021) (46)
- Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease (2018) (46)
- Prevalence of preclinical Alzheimer disease (2018) (46)
- Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment (2009) (46)
- Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry (2016) (46)
- Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis (2016) (46)
- Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. (2010) (46)
- Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection (2013) (45)
- Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease (2020) (45)
- Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study (2012) (45)
- The glial marker YKL‐40 is decreased in synucleinopathies (2013) (45)
- Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion. (2003) (45)
- A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology (2016) (45)
- Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease. (2009) (45)
- Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability (2017) (45)
- Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome (2018) (45)
- Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders (2011) (45)
- Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy (2018) (45)
- Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy (2017) (45)
- HSV1 VP1-2 deubiquitinates STING to block type I interferon expression and promote brain infection (2020) (45)
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
- Update on biomarkers for amyloid pathology in Alzheimer's disease. (2018) (44)
- In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury (2019) (44)
- Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease. (2012) (44)
- Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy (2018) (44)
- Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. (2016) (44)
- Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction (2019) (44)
- Brain Amyloid-Beta Fragment Signatures in Pathological Ageing and Alzheimer's Disease by Hybrid Immunoprecipitation Mass Spectrometry (2015) (44)
- Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment (2009) (44)
- Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. (2016) (44)
- Alzheimer’s disease—subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies (2016) (44)
- CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies (2009) (44)
- Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. (2012) (44)
- PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation (2019) (44)
- Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. (2016) (44)
- Explorative and targeted neuroproteomics in Alzheimer's disease. (2015) (44)
- Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. (2012) (43)
- Thrombocytopenia in early alcohol withdrawal is associated with development of delirium tremens or seizures. (2009) (43)
- Fluid markers of traumatic brain injury (2015) (43)
- Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition (2015) (43)
- No association of salivary total tau concentration with Alzheimer's disease (2018) (43)
- Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid (2014) (43)
- Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury. (2019) (43)
- CSF biomarkers in delirium: a systematic review (2018) (43)
- Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers (2018) (43)
- Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. (2018) (43)
- CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection (2018) (43)
- Applying fluid biomarkers to Alzheimer's disease. (2017) (43)
- Open‐heart surgery increases cerebrospinal fluid levels of Alzheimer‐associated amyloid β (2013) (43)
- Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders (2013) (43)
- Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus (2016) (42)
- Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers (2017) (42)
- Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau (2021) (42)
- Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias (2019) (42)
- Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease (2020) (42)
- Neurofilament relates to white matter microstructure in older adults (2018) (42)
- Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers (2017) (42)
- Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples (2013) (42)
- Mutated Thyroid Hormone Transporter OATP1C1 Associates with Severe Brain Hypometabolism and Juvenile Neurodegeneration. (2018) (42)
- Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report (2019) (42)
- A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations (2017) (42)
- Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 (2021) (42)
- Measurement of Aβ1–42 in cerebrospinal fluid is influenced by matrix effects (2012) (42)
- Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease (2013) (42)
- Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals (2014) (42)
- Identification of an important potential confound in CSF AD studies: aliquot volume (2013) (42)
- Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease (2017) (42)
- No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons (2011) (42)
- Cystatin C in cerebrospinal fluid and multiple sclerosis (2007) (42)
- Amyloid-beta 42 adsorption following serial tube transfer (2014) (41)
- Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease (2020) (41)
- CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD (2019) (41)
- Steroid-responsive encephalitis in Covid-19 disease (2020) (41)
- Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis (2017) (41)
- Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease (2021) (41)
- The transcobalamin codon 259 polymorphism influences the risk of human spontaneous abortion. (2002) (41)
- Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19 (2020) (41)
- Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. (2013) (41)
- Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. (2020) (41)
- Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation (2015) (41)
- Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles (2018) (41)
- Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis (2008) (41)
- Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis (2013) (41)
- Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long‐term outcome in patients with autoimmune encephalitis (2016) (40)
- Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid (2017) (40)
- Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. (2016) (40)
- “Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain” (2020) (40)
- Synaptic vesicle protein 2A as a potential biomarker in synaptopathies (2019) (40)
- Fluid biomarkers in frontotemporal dementia: past, present and future (2020) (40)
- Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments (2015) (40)
- Promoter-Proximal Regulatory Elements Involved in oriP-EBNA1-Independent and -Dependent Activation of the Epstein-Barr Virus C Promoter in B-Lymphoid Cell Lines (2001) (40)
- Plasma tau is increased in frontotemporal dementia (2018) (40)
- Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies (2019) (40)
- Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms (2018) (40)
- Sex-specific genetic predictors of Alzheimer’s disease biomarkers (2018) (40)
- Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage? (2013) (39)
- Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice (2017) (39)
- Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis (2016) (39)
- Blood–brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV (2016) (39)
- Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics (2018) (39)
- Salivary Biomarkers for Alzheimer’s Disease and Related Disorders (2019) (39)
- Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants. (2018) (39)
- Rarity of the Alzheimer disease-protective APP A673T variant in the United States. (2015) (39)
- Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility (2022) (39)
- Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup (2018) (39)
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (38)
- Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein-Barr virus-transformed lymphoid cells in latent and lytic stages of infection. (1999) (38)
- Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure (2020) (38)
- Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer’s disease and in mild cognitive impairment due to AD (2016) (38)
- Neurogranin as a predictor of memory and executive function decline in MCI patients (2018) (38)
- Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. (2018) (38)
- Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis (2015) (38)
- Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients (2007) (38)
- Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease (2020) (38)
- The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease. (2003) (38)
- Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis (2015) (38)
- A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease (2017) (38)
- Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. (2012) (37)
- Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease (2019) (37)
- Brain immune cells undergo cGAS-STING-dependent apoptosis during herpes simplex virus type 1 infection. (2020) (37)
- Blood–cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment (2014) (37)
- β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage (2014) (37)
- CSF Beta-amyloid 1-42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. (2018) (37)
- Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease (2019) (37)
- Comparative Evaluation of MS-based Metabolomics Software and Its Application to Preclinical Alzheimer’s Disease (2018) (37)
- The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview. (2016) (36)
- Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease (2011) (36)
- Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. (2011) (36)
- Neurofilaments in progressive multiple sclerosis: a systematic review (2020) (36)
- Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson's Disease. (2019) (36)
- NFL blood levels are moderated by subconcussive impacts in a cohort of college football players (2019) (36)
- Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. (2018) (36)
- Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies (2009) (36)
- Converging molecular pathways in human neural development and degeneration (2010) (36)
- Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group (2021) (36)
- Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis (2019) (36)
- Amyloid-β metabolism in Niemann-Pick C disease models and patients (2012) (36)
- Effects of methylprednisolone on blood-brain barrier and cerebral inflammation in cardiac surgery—a randomized trial (2018) (36)
- Cerebrospinal fluid biomarkers mirror rate of cognitive decline. (2013) (36)
- Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD (2017) (36)
- Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: A biomarker of blood–cerebrospinal fluid barrier permeability (2010) (36)
- Biomarker-guided clustering of Alzheimer's disease clinical syndromes (2019) (35)
- Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study (2018) (35)
- Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay (2019) (35)
- Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease (2009) (35)
- Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome. (2014) (35)
- Serum neurofilament light chain in progressive supranuclear palsy. (2018) (35)
- Reward-Related Genes and Personality Traits in Alcohol-Dependent Individuals: A Pilot Case Control Study (2011) (35)
- KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD (2019) (35)
- Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study. (2017) (35)
- Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia (2018) (35)
- Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment (2018) (35)
- Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come? (2012) (35)
- Potential human transmission of amyloid β pathology: surveillance and risks (2020) (35)
- Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses (2010) (34)
- Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men (2020) (34)
- Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development (2019) (34)
- Biomarkers in Relation to Cognitive Reserve in Patients with Mild Cognitive Impairment – Proof of Concept (2009) (34)
- 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework (2021) (34)
- Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change (2022) (34)
- Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. (2020) (34)
- Is there a CSF biomarker profile related to depression in elderly women? (2010) (34)
- Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease (2016) (34)
- Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers (2014) (34)
- Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. (2007) (34)
- Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer’s disease and other neurodegenerative diseases (2015) (34)
- Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) (34)
- Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease. (2015) (34)
- B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia (2009) (34)
- Analysis of amino-terminal variants of amyloid-β peptides by capillary isoelectric focusing immunoassay. (2013) (34)
- Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease (2013) (34)
- No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. (2002) (34)
- Determining Amyloid-β Positivity Using 18F-AZD4694 PET Imaging (2020) (34)
- Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. (2017) (34)
- The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases (2015) (34)
- Changes in CSF acetyl‐ and butyrylcholinesterase activity after long‐term treatment with AChE inhibitors in Alzheimer’s disease (2011) (33)
- Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest (2021) (33)
- A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer’s disease (2019) (33)
- Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. (2015) (33)
- Evolving Character of Chronic Central Nervous System HIV Infection (2014) (33)
- Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease (2021) (33)
- Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. (2017) (33)
- Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury (2021) (33)
- Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis (2014) (33)
- Prediction of Alzheimer’s Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides (2008) (33)
- Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults (2020) (33)
- Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis (2019) (33)
- Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers (2021) (33)
- Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study (2015) (33)
- Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. (2016) (33)
- Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. (2015) (33)
- The lipocalins retinol-binding protein-4, lipocalin-2 and lipocalin-type prostaglandin D2-synthase correlate with markers of inflammatory activity, alcohol intake and blood lipids, but not with insulin sensitivity in metabolically healthy 58-year-old Swedish men. (2010) (33)
- Calcium supplementation and risk of dementia in women with cerebrovascular disease (2016) (33)
- Combination of Hippocampal Volume and Cerebrospinal Fluid Biomarkers Improves Predictive Value in Mild Cognitive Impairment (2010) (33)
- Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study (2014) (33)
- Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer’s disease in late-middle-aged adults (2019) (32)
- The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer’s disease (2018) (32)
- Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. (2008) (32)
- Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study (2015) (32)
- Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology (2019) (32)
- Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. (2019) (32)
- Putamen volume and its clinical and neurological correlates in primary HIV infection (2016) (32)
- Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin (2019) (32)
- Largest GWAS (N=1,126,563) of Alzheimer's Disease Implicates Microglia and Immune Cells (2020) (32)
- Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy (2018) (32)
- Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition (2019) (32)
- SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases (2019) (32)
- Single lipid vesicle assay for characterizing single-enzyme kinetics of phospholipid hydrolysis in a complex biological fluid. (2013) (32)
- Functional Interaction of Nuclear Factor Y and Sp1 Is Required for Activation of the Epstein-Barr Virus C Promoter (2003) (32)
- Head trauma in sports – clinical characteristics, epidemiology and biomarkers (2019) (32)
- The zebrafish amyloid precursor protein-b is required for motor neuron guidance and synapse formation. (2013) (32)
- Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity (2020) (32)
- Interleukin 9 alterations linked to alzheimer disease in african americans (2019) (32)
- Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. (2019) (32)
- Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain (2020) (31)
- Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease. (2012) (31)
- Familial Alzheimer's Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. (2021) (31)
- Infection of Brain Pericytes Underlying Neuropathology of COVID-19 Patients (2021) (31)
- The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: a randomized placebo controlled study. (2004) (31)
- Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia (2003) (31)
- The distribution of apolipoprotein E genotype over the adult lifespan and in relation to country of birth. (2015) (31)
- Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia (2019) (31)
- Evaluating Amyloid-beta Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease (2013) (31)
- Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls (2015) (31)
- Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. (2013) (31)
- Human cerebrospinal fluid increases the excitability of pyramidal neurons in the in vitro brain slice (2015) (31)
- Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. (2016) (31)
- Biomarkers for Alzheimer’s disease beyond amyloid and tau (2019) (31)
- CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4 (2013) (31)
- Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy (2019) (31)
- Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. (2015) (31)
- Amyloid β1–40 Quantification in CSF: Comparison between Chromatographic and Immunochemical Methods (2007) (31)
- Transcobalamin Polymorphism and Serum Holo-Transcobalamin in Relation to Alzheimer’s Disease (2004) (31)
- Influence of the apolipoprotein E epsilon4 allele on human embryonic development. (2002) (30)
- The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis (2013) (30)
- Levels of ADAM10 are reduced in Alzheimer’s disease CSF (2018) (30)
- Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria. (2015) (30)
- Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid (2019) (30)
- Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. (2015) (30)
- Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease (2016) (30)
- Genome-scale metabolic network reconstruction of model animals as a platform for translational research (2021) (30)
- Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. (2019) (30)
- Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals Aβ Aggregation Dependent Anionic Lipid Accumulations and Metabolism. (2018) (30)
- Cardiomyopathy with lethal arrhythmias associated with inactivation of KLHL24 (2019) (30)
- Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities (2018) (30)
- Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments (2014) (30)
- Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis (2007) (30)
- The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology (2017) (30)
- Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease. (2018) (30)
- The association between plasma homocysteine and coronary heart disease is modified by the MTHFR 677C>T polymorphism (2013) (30)
- Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis (2018) (30)
- Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants (2012) (30)
- A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals (2015) (30)
- Amyloid-related biomarkers for Alzheimer's disease. (2008) (30)
- Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study (2022) (29)
- Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2018) (29)
- Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress (2017) (29)
- Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium. (2016) (29)
- The cerebrospinal fluid proteome in HIV infection: change associated with disease severity (2012) (29)
- Hyperphosphorylation of tau protein in superficial CNS siderosis (2008) (29)
- Models of the blood-brain barrier using iPSC-derived cells (2019) (29)
- Association of nAChR gene haplotypes with heavy alcohol use and body mass (2009) (29)
- Evolution and clustering of prodromal parkinsonian features in GBA1 carriers (2019) (29)
- Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy (2022) (29)
- High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection (2017) (29)
- Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium (2017) (29)
- Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies (2013) (29)
- Intrathecal treatment trial of rituximab in progressive MS (2018) (29)
- Astroglial activation and altered amyloid metabolism in human repetitive concussion (2017) (29)
- Analytical aspects of molecular Alzheimer's disease biomarkers. (2012) (29)
- The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease (2018) (29)
- Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. (2018) (29)
- Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. (2012) (28)
- Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches (2019) (28)
- Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease (2019) (28)
- CSF neurogranin or tau distinguish typical and atypical Alzheimer disease (2018) (28)
- Expanding the cerebrospinal fluid endopeptidome (2017) (28)
- Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration (2021) (28)
- Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis (2021) (28)
- Improved Differential Diagnosis of Alzheimer’s Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers (2019) (28)
- Genome-wide association study identifies MAPT locus influencing human plasma tau levels (2017) (28)
- Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome (2020) (28)
- The Cytosolic Loop of the γ-Secretase Component Presenilin Enhancer 2 Protects Zebrafish Embryos from Apoptosis* (2006) (28)
- Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy (2014) (28)
- Erratum: Clearance systems in the brain—implications for Alzheimer diseaser (2016) (28)
- Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset (2019) (28)
- The effects of different familial Alzheimer’s disease mutations on APP processing in vivo (2017) (27)
- Characterization of the Brain β-Amyloid Isoform Pattern at Different Ages of Tg2576 Mice (2011) (27)
- Relevance of biomarkers across different neurodegenerative (2020) (27)
- Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg (2020) (27)
- High education may offer protection against tauopathy in patients with mild cognitive impairment. (2010) (27)
- Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C. (2011) (27)
- CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau (2018) (27)
- Elevated cerebrospinal fluid levels of prostaglandin E2 and 15‐(S)‐hydroxyeicosatetraenoic acid in multiple sclerosis (2009) (27)
- Automated cerebrospinal fluid cell count--new reference ranges and evaluation of its clinical use in central nervous system infections. (2014) (27)
- Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease? (2015) (27)
- Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. (2009) (27)
- A novel ARC gene polymorphism is associated with reduced risk of Alzheimer’s disease (2012) (27)
- Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy (2019) (27)
- Biomarkers for Microglial Activation in Alzheimer's Disease (2011) (27)
- Animal Models for Concussion: Molecular and Cognitive Assessments—Relevance to Sport and Military Concussions (2015) (27)
- The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention (2014) (27)
- CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia (2019) (27)
- Review: Fluid biomarkers for frontotemporal dementias (2018) (27)
- Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. (2007) (27)
- Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease (2019) (27)
- Neuroendocrine assessment of serotonergic, dopaminergic, and noradrenergic functions in alcohol-dependent individuals. (2012) (27)
- GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. (2019) (27)
- Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis (2018) (27)
- Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers (2021) (27)
- Longitudinal change in regional brain volumes with exposure to repetitive head impacts (2019) (27)
- Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults (2022) (26)
- Differential early subcortical involvement in genetic FTD within the GENFI cohort (2021) (26)
- Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach* (2014) (26)
- Label‐free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals (2016) (26)
- Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition. (2017) (26)
- Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies (2021) (26)
- Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases. (2009) (26)
- Dopamine D2 receptor genotype is associated with increased mortality at a 10-year follow-up of alcohol-dependent individuals. (2010) (26)
- Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease (2018) (26)
- Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression (2020) (26)
- Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology (2018) (26)
- Plasma Markers of Neurodegeneration Are Raised in Friedreich’s Ataxia (2018) (26)
- Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements (2018) (26)
- A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease (2016) (26)
- Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes (2021) (26)
- Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy (2020) (26)
- Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down’s Syndrome (2014) (25)
- Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases (2020) (25)
- Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease (2020) (25)
- Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial (2020) (25)
- Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances (2021) (25)
- Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons (2020) (25)
- Impaired synaptic function is linked to cognition in Parkinson's disease (2017) (25)
- CSF in Alzheimer's disease. (2014) (25)
- Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment (2011) (25)
- Blood Biomarkers: Democratizing Alzheimer’s Diagnostics (2020) (25)
- Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. (2019) (25)
- Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study (2020) (25)
- cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases (2010) (25)
- Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (25)
- Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates (2011) (25)
- Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer’s disease (2019) (25)
- Cerebrospinal fluid biomarkers in cardiac arrest survivors. (2014) (25)
- Intracranial arterial four-dimensional flow is associated with metrics of brain health and Alzheimer's disease (2015) (25)
- Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase (2018) (25)
- Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) (25)
- C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease (2017) (25)
- Heritability and genetic variance of dementia with Lewy bodies (2018) (25)
- Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium (2018) (25)
- First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays (2020) (24)
- Serum visinin-like protein-1 in concussed professional ice hockey players (2015) (24)
- White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study (2019) (24)
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease (2021) (24)
- The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau (2021) (24)
- Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. (2019) (24)
- Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies (2018) (24)
- Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative (2021) (24)
- Methylenetetrahydrofolate Reductase Genetic Polymorphisms in Patients with Primary Open-Angle Glaucoma (2007) (24)
- Erratum: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study (Lancet Neurology (2006) 5 (228-34)) (2006) (24)
- 18 FAV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer ’ s disease (2017) (24)
- Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function. (2015) (24)
- The stability of AQT processing speed, ADAS‐Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer’s disease (2010) (24)
- Cerebrospinal fluid protein reactions during non‐neurological surgery (2007) (24)
- No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion (2018) (24)
- First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study (2015) (24)
- Neuroinflammatory markers associate with cognitive decline after major surgery: Findings of an explorative study (2020) (24)
- Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. (2014) (24)
- Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study (2018) (24)
- Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging (2021) (24)
- Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light (2022) (23)
- TAU Haplotype and the Saitohin Q7R Gene Polymorphism Do Not Influence CSF Tau in Alzheimer’s Disease and Are Not Associated with Frontotemporal Dementia or Parkinson’s Disease (2005) (23)
- APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease (2016) (23)
- Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum (2019) (23)
- Haemoglobin causes neuronal damage in vivo which is preventable by haptoglobin (2020) (23)
- Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis (2021) (23)
- Differential effects of neurodegeneration biomarkers on subclinical cognitive decline (2019) (23)
- Human plasma biomarker responses to inhalational general anaesthesia without surgery. (2020) (23)
- Proteomics profiling of single organs from individual adult zebrafish. (2010) (23)
- Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals (2016) (23)
- Monitoring concussion in a knocked-out boxer by CSF biomarker analysis (2015) (23)
- Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy (2021) (23)
- Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. (2016) (23)
- Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele (2016) (22)
- Cognitive Reserve in Relation to Abeta42 in Patients Converting from MCI to Dementia – A Follow-Up Report (2009) (22)
- Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification (2021) (22)
- Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases (2020) (22)
- Inhibiting the Ca2+ Influx Induced by Human CSF (2017) (22)
- Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study (2016) (22)
- Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease (2013) (22)
- Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. (2013) (22)
- Serum neurofilament light chain withstands delayed freezing and repeated thawing (2020) (22)
- Converging pathways of chromogranin and amyloid metabolism in the brain. (2010) (22)
- Cerebrospinal fluid biomarkers in neurological diseases in children. (2013) (22)
- Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with APOE ɛ4 (2018) (22)
- Contribution of CSF biomarkers to early‐onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures (2020) (21)
- The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). (2017) (21)
- Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry (2016) (21)
- Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations (2017) (21)
- Hydrolysis of a lipid membrane by single enzyme molecules: accurate determination of kinetic parameters. (2015) (21)
- Induction of Amyloid-β42 Production by Fipronil and Other Pyrazole Insecticides. (2018) (21)
- Problems associated with fluid biomarkers for Parkinson's disease. (2010) (21)
- Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease (2019) (21)
- Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders (2017) (21)
- Functional interaction of Oct transcription factors with the family of repeats in Epstein-Barr virus oriP. (2005) (21)
- Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers (2018) (21)
- Urate as a marker of development and progression in Parkinson's disease. (2011) (21)
- The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis (2017) (21)
- Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid? (2016) (21)
- Ex vivo18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway (2017) (21)
- Alzheimer's disease markers in the aged sheep (Ovis aries) (2017) (21)
- Cognitive impairment in Glucocerebrosidase (GBA)‐associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles (2017) (21)
- Binding of human proteins to amyloid-β protofibrils. (2015) (21)
- Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update (2017) (21)
- Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers (2017) (21)
- Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson’s disease (2011) (21)
- Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas (2019) (21)
- Comparing progression biomarkers in clinical trials of early Alzheimer’s disease (2020) (20)
- The accuracy and robustness of plasma biomarker models for amyloid PET positivity (2022) (20)
- Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis (2015) (20)
- Blood biomarkers indicate mild neuroaxonal injury and increased amyloid β production after transient hypoxia during breath-hold diving (2016) (20)
- Evaluation of the Performance of Novel Aβ Isoforms as Theragnostic Markers in Alzheimer’s Disease: From the Cell to the Patient (2012) (20)
- Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies (2013) (20)
- Acute symptomatic seizures and epilepsy after mechanical thrombectomy (2020) (20)
- CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia (2018) (20)
- Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF (2020) (20)
- Pinpointing plaques with PIB (2006) (20)
- Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke (2019) (20)
- Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease (2020) (20)
- Plasma neurofilament light chain concentration is increased in anorexia nervosa (2019) (20)
- Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials. (2012) (20)
- Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. (2017) (20)
- Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease (2010) (20)
- A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease (2020) (20)
- Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity (2014) (20)
- Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. (2014) (20)
- Air pollution and biomarkers of Alzheimer’s disease in cognitively unimpaired individuals (2020) (20)
- Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem (2015) (20)
- Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease (2021) (20)
- Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease (2017) (20)
- A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer’s Disease (2019) (20)
- Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. (2016) (19)
- Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease? (2010) (19)
- Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios (2018) (19)
- Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study. (2022) (19)
- Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia (2020) (19)
- Low vitamin D status in relation to cardiovascular disease and mortality in Swedish women - Effect of extended follow-up. (2017) (19)
- Variability in the kinesin light chain 1 gene may influence risk of age-related cataract (2007) (19)
- Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients – A PET/MR study (2021) (19)
- Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay (2016) (19)
- Polymorphisms in dopamine‐associated genes and cognitive decline in Parkinson's disease (2017) (19)
- AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy (2021) (19)
- Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid (2021) (19)
- Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease (2022) (19)
- Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy (2012) (19)
- Increased levels of inflammatory immune mediators in vitreous from pseudophakic eyes. (2015) (19)
- Association of plasma P-tau181 with memory decline in non-demented adults (2021) (19)
- APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease (2020) (19)
- Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring (2022) (19)
- Neurogranin Levels in Cerebrospinal Fluid: A New Addition to the Alzheimer Disease Diagnostic Toolbox. (2015) (19)
- Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy (2021) (19)
- Ionized calcium in human cerebrospinal fluid and its influence on intrinsic and synaptic excitability of hippocampal pyramidal neurons in the rat (2019) (19)
- Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia (2018) (19)
- Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease (2020) (19)
- Plasma neurofilament light chain as a potential biomarker in Charcot‐Marie‐Tooth disease (2020) (18)
- Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons (2018) (18)
- Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study (2020) (18)
- Semagacestat's fall: where next for AD therapies? (2013) (18)
- No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF (2016) (18)
- Biochemical markers in Alzheimer's disease clinical trials. (2010) (18)
- Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest (2019) (18)
- Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. (2015) (18)
- Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. (2021) (18)
- Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome (2021) (18)
- Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias (2020) (18)
- Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. (2021) (18)
- CSF antithrombin III and disruption of the blood-brain barrier. (2009) (18)
- Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection (2017) (18)
- Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study (2018) (18)
- Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies (2017) (18)
- Effect of ponezumab on CSF biomarkers: Pooled analysis of phase IIa studies in subjects with mild-to-moderate Alzheimer's disease (2012) (18)
- What is a certified reference material? (2012) (18)
- Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease (2020) (18)
- Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease (2021) (18)
- Vitamin D supplementation and neurofilament light chain in multiple sclerosis (2018) (18)
- Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes (2019) (18)
- Seven day pre-analytical stability of serum and plasma neurofilament light chain (2021) (18)
- Cerebrospinal fluid α‐synuclein levels in Parkinson's disease – changed or unchanged? (2014) (17)
- Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias (2021) (17)
- Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression (2021) (17)
- Plasma ACE2 species are differentially altered in COVID‐19 patients (2021) (17)
- P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease (2021) (17)
- Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders (2019) (17)
- Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. (2019) (17)
- Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems (2010) (17)
- Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome (2021) (17)
- Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real‐world investigation (2021) (17)
- ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration (2020) (17)
- Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis (2017) (17)
- Future Screening for Incipient Alzheimer’s Disease – The Influence of Prevalence on Test Performance (2009) (17)
- A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia (2021) (17)
- Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults (2020) (17)
- Serum levels of LIGHT in MS (2013) (17)
- Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes (2015) (17)
- Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. (2019) (17)
- Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease (2010) (17)
- CEREBROSPINAL FLUID TAU, Aβ, AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION (2018) (17)
- Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total‐Aβ42/Aβ40 ratio (2015) (17)
- Multiple EBNA1-binding sites within oriPI are required for EBNA1-dependent transactivation of the Epstein-Barr virus C promoter. (2004) (17)
- Effects of γ-Secretase Inhibition on the Amyloid β Isoform Pattern in a Mouse Model of Alzheimer’s Disease (2009) (17)
- Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum (2021) (17)
- In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease (2020) (17)
- Cerebrospinal fluid insulin during non-neurological surgery (2010) (17)
- Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. (2019) (17)
- Association of Early β-Amyloid Accumulation and Neuroinflammation Measured With [11C]PBR28 in Elderly Individuals Without Dementia (2021) (17)
- Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection (2019) (17)
- The association of circulating amylin with β‐amyloid in familial Alzheimer's disease (2021) (17)
- Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia (2018) (17)
- Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage. (2020) (16)
- Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease (2022) (16)
- The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease (2015) (16)
- One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury (2021) (16)
- Chemical imaging of evolving amyloid plaque pathology and associated Aβ peptide aggregation in a transgenic mouse model of Alzheimer’s disease (2019) (16)
- Cerebrospinal fluid biomarkers of β‐amyloid metabolism and neuronal damage in epileptic seizures (2014) (16)
- Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration (2020) (16)
- Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep (2019) (16)
- Aβ42/Aβ40 and Aβ42/Aβ38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer’s Disease: A Pilot Study (2018) (16)
- CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease (2020) (16)
- The Expression of Transthyretin and Amyloid-β Protein Precursor is Altered in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. (2015) (16)
- A comprehensive screening of copy number variability in dementia with Lewy bodies (2019) (16)
- Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease (2020) (16)
- Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease (2015) (16)
- High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis (2017) (16)
- TOMM40 poly-T Variants and Cerebrospinal Fluid Amyloid Beta Levels in the Elderly (2011) (16)
- Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease (2010) (16)
- High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid (2017) (16)
- Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease? (2008) (16)
- Neurofilament light protein levels in cerebrospinal fluid predict long‐term disability of Guillain‐Barré syndrome: A pilot study (2018) (16)
- A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans (2016) (16)
- Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review (2018) (16)
- Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer’s Disease and Other Neurodegenerative Disorders (2017) (16)
- Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders (2016) (16)
- Cognitive stimulation in the workplace, plasma proteins, and risk of dementia: three analyses of population cohort studies (2021) (16)
- F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease (2017) (16)
- Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease (2018) (16)
- Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren’s syndrome (2020) (16)
- Growth factors and neurotrophins in patients with stress-related exhaustion disorder (2019) (16)
- Progression from Mild to Pronounced MCI Is Not Associated with Cerebrospinal Fluid Biomarker Deviations (2011) (16)
- Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair (2016) (15)
- Cohort Analysis of the Association of Delirium Severity with Cerebrospinal Fluid Amyloid-Tau-Neurodegeneration Pathologies. (2021) (15)
- Additional evidence for antagonistic pleiotropic effects of APOE (2009) (15)
- Plasma amyloid β—quo vadis? (2015) (15)
- C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning (2016) (15)
- Plasma Abeta in Alzheimer's disease--up or down? (2006) (15)
- An accurate fully automated panel of plasma biomarkers for Alzheimer's disease (2022) (15)
- MONITORING THE SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA (SAPPA) AND BETA (SAPPB) FRAGMENTS IN PLASMA AND CSF FROM HEALTHY INDIVIDUALS TREATED WITH BACE INHIBITOR AZD3293 IN A MULTIPLE ASCENDING DOSE STUDY: PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATE (2014) (15)
- Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease (2020) (15)
- Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers (2021) (15)
- EPHA2 Polymorphisms in Estonian Patients with Age-Related Cataract (2014) (15)
- Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery (2019) (15)
- Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions – The LADIS Study (2012) (15)
- Aβ1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases (2013) (15)
- CACNA1C polymorphism and altered phosphorylation of tau in bipolar disorder. (2016) (15)
- Neurofilament light predicts neurological outcome after subarachnoid haemorrhage (2021) (15)
- Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. (2016) (15)
- Blood Biomarkers for Alzheimer’s Disease in Down Syndrome (2021) (15)
- Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype (2020) (15)
- Genetic Association of CDC2 with Cerebrospinal Fluid Tau in Alzheimer’s Disease (2005) (15)
- The predictive value of T-tau and AB1-42 levels in idiopathic normal pressure hydrocephalus (2017) (15)
- Use of CSF biomarkers in Alzheimer’s disease clinical trials (2009) (15)
- State-dependent alterations in cerebrospinal fluid A&bgr;42 levels in cognitively intact elderly with late-life major depression (2016) (15)
- The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee (2004) (15)
- β-Amyloid precursor protein-b is essential for Mauthner cell development in the zebrafish in a Notch-dependent manner. (2016) (15)
- Cerebrospinal Fluid Levels of Interleukin-8 in Delirium, Dementia, and Cognitively Healthy Patients. (2020) (14)
- Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder. (2013) (14)
- Early levels of GFAP and NF-L in predicting the outcome of mild TBI (2019) (14)
- Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort (2020) (14)
- No Association of LOXL1 Gene Polymorphisms with Alzheimer’s Disease (2011) (14)
- CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET (2021) (14)
- Increased amyloidogenic APP processing in APOE epsilon 4-negative individuals with cerebral beta-amyloidosis (2016) (14)
- Biomarkers of Cerebral Injury for Prediction of Postoperative Cognitive Dysfunction in Patients Undergoing Cardiac Surgery. (2021) (14)
- Biomarkers reflecting different facets of Alzheimer’s disease (2008) (14)
- Alzheimer's disease biomarkers in Black and non‐Hispanic White cohorts: A contextualized review of the evidence (2021) (14)
- Pathognomonic cerebrospinal fluid findings in Bing–Neel syndrome (2011) (14)
- Methylenetetrahydrofolate reductase genetic polymorphisms in patients with cataract. (2005) (14)
- A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. (2019) (14)
- Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease (2021) (14)
- Dementia and CSF‐biomarkers for Alzheimer's disease predict mortality after acute hip fracture (2019) (14)
- NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. (2020) (14)
- Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls (2017) (14)
- Neural and Nonneural Contributions to Wrist Rigidity in Parkinson's Disease: An Explorative Study Using the NeuroFlexor (2015) (14)
- The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort. (2017) (14)
- Monte Carlo feature selection and rule-based models to predict Alzheimer’s disease in mild cognitive impairment (2012) (14)
- Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease (2010) (14)
- Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease (2020) (14)
- Extrinsic Amyloid-Binding Dyes for Detection of Individual Protein Aggregates in Solution (2018) (14)
- Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics (2021) (14)
- Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm (2021) (14)
- Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury (2020) (14)
- CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly (2012) (14)
- Cell stemness is maintained upon concurrent expression of RB and the mitochondrial ribosomal protein S18-2 (2020) (14)
- Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers (2019) (14)
- Transient increase in CSF GAP-43 concentration after ischemic stroke (2018) (14)
- Imatinib treatment and Aβ42 in humans (2014) (14)
- Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance (2022) (14)
- False-negative result in the detection of an IgM monoclonal protein by capillary zone electrophoresis. (2004) (14)
- Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight. (2021) (13)
- Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms (2022) (13)
- Apolipoprotein E ϵ4 is positively related to spatial performance but unrelated to hippocampal volume in healthy young adults (2016) (13)
- Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapy-A pilot study. (2019) (13)
- Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated Aβ42 Species Aβ5-42. (2019) (13)
- Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial (2019) (13)
- Apolipoprotein E polymorphism in aneurysmal subarachnoid haemorrhage in West Sweden (2016) (13)
- Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays (2020) (13)
- Specific Triazine Herbicides Induce Amyloid-β42 Production. (2016) (13)
- Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases (2018) (13)
- Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET (2022) (13)
- Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease (2013) (13)
- Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics (2021) (13)
- Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment (2017) (13)
- Association between APOE Genotype and Change in Physical Function in a Population-Based Swedish Cohort of Older Individuals Followed Over Four Years (2016) (13)
- Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions (2021) (13)
- Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study (2017) (13)
- CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design (2022) (13)
- Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study (2021) (13)
- Polygenic risk scores for Alzheimer's disease are related to dementia risk in APOE ɛ4 negatives (2021) (13)
- Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) (13)
- CSF Beta-amyloid 1-42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. (2018) (13)
- Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women (2011) (13)
- HOTMAQ: A Multiplexed Absolute Quantification Method for Targeted Proteomics. (2019) (13)
- Second Generation γ-Secretase Modulators Exhibit Different Modulation of Notch β and Aβ Production* (2012) (13)
- Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. (2019) (13)
- Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster (2016) (13)
- CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. (2019) (13)
- Cerebrospinal fluid markers of extracellular matrix remodelling, synaptic plasticity and neuroinflammation before and after cranial radiotherapy (2018) (13)
- Correction to: Relevance of biomarkers across different neurodegenerative diseases (2020) (13)
- CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers (2018) (13)
- Chronic traumatic encephalopathy: fluid biomarkers. (2018) (13)
- Detection of early-stage Alzheimer’s pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients (2019) (12)
- High Serum Serotonin Predicts Increased Risk for Hip Fracture and Nonvertebral Osteoporotic Fractures: The MrOS Sweden Study (2018) (12)
- Following spatial Aβ aggregation dynamics in evolving Alzheimer’s disease pathology by imaging stable isotope labeling kinetics (2021) (12)
- Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease (2021) (12)
- Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury (2019) (12)
- Signs of neuroaxonal injury in preeclampsia-A case control study. (2021) (12)
- Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years (2022) (12)
- Amyloid processing in COVID‐19‐associated neurological syndromes (2022) (12)
- Association of Aortic Stiffness With Biomarkers of Neuroinflammation, Synaptic Dysfunction, and Neurodegeneration (2021) (12)
- Multiplexing and multivariate analysis in neurodegeneration. (2012) (12)
- Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury (2020) (12)
- Comment on “An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice” (2014) (12)
- Biological CSF markers of Alzheimer's disease. (2008) (12)
- Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease (2018) (12)
- Neuromodulation of fast‐spiking and non‐fast‐spiking hippocampal CA1 interneurons by human cerebrospinal fluid (2016) (12)
- Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview (2021) (12)
- Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study (2017) (12)
- Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals (2021) (12)
- Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission (2020) (12)
- Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing‐remitting MS (2018) (12)
- Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP. (2021) (12)
- β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification (2020) (12)
- LRP10 in α-synucleinopathies (2018) (12)
- Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers (2021) (12)
- Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus (2020) (12)
- Exposure to wireless phone emissions and serum beta-trace protein. (2010) (11)
- Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species (2018) (11)
- The global Alzheimer's Association round robin study on plasma amyloid β methods (2021) (11)
- Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease (2010) (11)
- Plasma Neurofilament Light Chain predicts cognitive progression in prodromal and clinical dementia with Lewy Bodies (2021) (11)
- Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease (2019) (11)
- Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants (2021) (11)
- Genetic Variation in FOXO3 is Associated with Self-Rated Health in a Population-Based Sample of Older Individuals (2018) (11)
- Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid (2019) (11)
- Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation (2020) (11)
- Neurochemical biomarkers to study CNS effects of COVID‐19: A narrative review and synthesis (2021) (11)
- Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia (2020) (11)
- Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury (2020) (11)
- Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury (2020) (11)
- S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies. (2018) (11)
- Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity. (2017) (11)
- Baseline Results: The Association between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study. (2020) (11)
- Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease (2022) (11)
- Diagnostic value of plasma neurofilament light: A multicentre validation study (2020) (11)
- The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk (2018) (11)
- Lower CSF interleukin-6 predicts future depression in a population-based sample of older women followed for 17 years (2013) (11)
- Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults. (2020) (11)
- Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (11)
- No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau) (2017) (11)
- Apolipoprotein E polymorphism in patients with cataract (2004) (11)
- The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases (2021) (11)
- Amyloid precursor protein-b facilitates cell adhesion during early development in zebrafish (2019) (11)
- Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly (2021) (11)
- Anti-SARS-CoV2 antibody responses in serum and cerebrospinal fluid of COVID-19 patients with neurological symptoms. (2021) (11)
- New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) (11)
- Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings (2020) (11)
- Blood biomarkers for Alzheimer's disease and related disorders (2022) (11)
- A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease (2019) (10)
- Evolving Relevance of Neuroproteomics in Alzheimer's Disease. (2017) (10)
- Postoperative troponin increases after noncardiac surgery are associated with raised neurofilament light: a prospective observational cohort study. (2020) (10)
- Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers (2021) (10)
- Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. (2021) (10)
- Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum (2021) (10)
- Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography (2022) (10)
- The transcobalamin codon 259 polymorphism should be designated 776C>G, not 775G>C. (2003) (10)
- Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease (2019) (10)
- PET Tau and Amyloid-beta Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers (vol 60, pg 283, 2017) (2018) (10)
- TREM2 expression in the brain and biological fluids in prion diseases (2021) (10)
- Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. (2015) (10)
- Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers (2022) (10)
- Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. (2017) (10)
- Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. (2020) (10)
- Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. (2019) (10)
- The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis. (2011) (10)
- Fluid biomarkers in Alzheimer's disease - current (2013) (10)
- Cognitive function in very old men does not correlate to biomarkers of Alzheimer’s disease (2017) (10)
- Cognitive and neuronal link with inflammation: a longitudinal study in people with and without HIV infection. (2020) (10)
- Neurofilament‐light in former athletes: a potential biomarker of neurodegeneration and progression (2020) (10)
- Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. (2020) (10)
- DIAGNOSTIC VALUE OF CEREBROSPINAL FLUID NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE CLASSIFICATION OF PRODROMAL AND ALZHEIMER’S DISEASE DEMENTIA (2016) (10)
- Cerebrospinal fluid viral load and biomarkers of neuronal and glial cells in Ramsay Hunt syndrome (2016) (10)
- Plasma neurofilament light chain levels predict improvement in late phase after stroke (2021) (10)
- Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3 (2022) (10)
- MS risk genes are transcriptionally regulated in CSF leukocytes at relapse (2013) (10)
- Central Nervous System Lipocalin‐Type Prostaglandin D2‐Synthase is Correlated with Orexigenic Neuropeptides, Visceral Adiposity and Markers of the Hypothalamic‐Pituitary‐Adrenal Axis in Obese Humans (2011) (10)
- Parkinson’s disease: evolution of cognitive impairment and CSF Aβ1–42 profiles in a prospective longitudinal study (2018) (10)
- A Non-APOE Polygenic Risk Score for Alzheimer’s Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds (2021) (10)
- The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. (2013) (10)
- The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain (2018) (10)
- Association between thyroid hormone levels and monoaminergic neurotransmission during surgery (2007) (10)
- APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment (2015) (10)
- Plasma proteins, cognitive decline, and 20‐year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies (2021) (10)
- Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers (2020) (10)
- Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout (2019) (10)
- A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence? (2018) (10)
- Low fasting serum insulin and dementia in nondiabetic women followed for 34 years (2018) (10)
- Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. (2015) (10)
- Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events (2020) (10)
- High-throughput analysis of sulfatides in cerebrospinal fluid using automated extraction and UPLC-MS/MS[S] (2017) (10)
- The impact of social networks and APOE ε4 on dementia among older adults: tests of possible interactions (2018) (10)
- Neuroimaging and biomarker evidence of neurodegeneration in asthma. (2021) (10)
- Neurofilament light chain in the vitreous humor of the eye (2020) (10)
- Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings (2022) (10)
- Acute hyperglycaemia leads to altered frontal lobe brain activity and reduced working memory in type 2 diabetes (2021) (10)
- Cerebrospinal fluid in the dementias. (2017) (10)
- Association between cerebrospinal fluid biomarkers of neuronal injury or amyloidosis and cognitive decline after major surgery. (2020) (9)
- Kinesin Light Chain 1 Gene Haplotypes in Three Conformational Diseases (2010) (9)
- An amylin and calcitonin receptor agonist modulates alcohol behaviors by acting on reward-related areas in the brain (2020) (9)
- Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology (2020) (9)
- Neurological symptoms and blood neurofilament light levels (2021) (9)
- Neurochemical Markers of Traumatic Brain Injury: Relevance to Acute Diagnostics, Disease Monitoring, and Neuropsychiatric Outcome Prediction (2021) (9)
- CSF YKL‐40 and GAP‐43 are related to suicidal ideation in older women (2017) (9)
- Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. (2022) (9)
- Serum erythropoietin and outcome after ischaemic stroke: a prospective study (2016) (9)
- TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels (2021) (9)
- Specific patterns of whole-brain structural covariance of the anterior and posterior hippocampus in young APOE ε4 carriers (2017) (9)
- Critical Illness Polyneuropathy and Myopathy in COVID-19 Patients: A Prospective Observational Intensive Care Unit Cross-Sectional Cohort Study (2020) (9)
- A multi-center study of neurofilament assay reliability and inter-laboratory variability (2020) (9)
- Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease (2021) (9)
- Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice? (2015) (9)
- Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview (2021) (9)
- Inflammatory markers of CHMP2B-mediated frontotemporal dementia (2018) (9)
- Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study (2018) (9)
- Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. (2020) (9)
- Tauomics and Kinetics in Human Neurons and Biological Fluids (2018) (9)
- The recency ratio is associated with reduced CSF glutamate in late-life depression (2017) (9)
- Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial (2021) (9)
- Post-acute blood biomarkers and disease progression in traumatic brain injury (2022) (9)
- Interactions between dietary patterns and genetic factors in relation to incident dementia among 70-year-olds (2021) (9)
- Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease (2018) (9)
- Central and peripheral leptin and agouti‐related protein during and after pregnancy in relation to weight change (2018) (9)
- Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls (2020) (9)
- Genetic Variation of Superoxide Dismutases in Patients with Primary Open-angle Glaucoma (2013) (9)
- Plasma pNfH levels differentiate SBMA from ALS (2019) (9)
- Update on fluid biomarkers for concussion (2016) (9)
- Update of the original HDLS kindred: divergent clinical courses (2012) (9)
- Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation (2022) (9)
- Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults (2021) (8)
- Replication study of plasma proteins relating to Alzheimer's pathology (2021) (8)
- Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption. (2020) (8)
- Superoxide Dismutase Gene Polymorphisms in Patients with Age-related Cataract (2013) (8)
- Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis (2022) (8)
- Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders (2019) (8)
- Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation (2022) (8)
- Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. (2018) (8)
- A Season of American Football Is Not Associated with Changes in Plasma Tau. (2017) (8)
- Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis (2019) (8)
- Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease (2021) (8)
- The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients (2021) (8)
- Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance (2020) (8)
- The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid (2019) (8)
- Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease (2022) (8)
- Biomarkers for Alzheimer disease – current status and prospects for the future (2018) (8)
- Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration? (2020) (8)
- Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. (2020) (8)
- Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins (2021) (8)
- Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in Alzheimer's disease patients. (2020) (8)
- Cerebrospinal fluid catecholamines in Alzheimer’s disease patients with and without biological disease (2022) (8)
- Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study (2021) (8)
- Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies (2021) (8)
- Neurochemical measures co-vary with personality traits: Forensic psychiatric findings replicated in a general population sample (2010) (8)
- Publisher Correction: Microglial activation and tau propagate jointly across Braak stages (2021) (8)
- Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate (2019) (8)
- Serum 25-hydroxy vitamin D levels in middle-aged women in relationship to adiposity and height trajectories over three decades (2016) (8)
- Cerebrospinal fluid levels of insulin, leptin, and agouti‐related protein in relation to BMI in pregnant women (2016) (8)
- Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data (2019) (8)
- Tau, s-100 calcium-binding protein B, and neuron-specific enolase as biomarkers of concussion-reply. (2014) (8)
- Association of Depressive Symptoms With Postoperative Delirium and CSF Biomarkers for Alzheimer's Disease Among Hip Fracture Patients. (2021) (8)
- Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity (2022) (8)
- Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder (2019) (8)
- Memory in individuals with mild cognitive impairment in relation to APOE and CSF Aβ42 (2010) (8)
- Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington's disease: the prospective HD-CSF study (2020) (8)
- [Alzheimer's disease - the most common cause of dementia]. (2020) (8)
- Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature (2022) (8)
- Low Cerebrospinal Fluid Aβ42 and Aβ40 are Related to White Matter Lesions in Cognitively Normal Elderly (2018) (8)
- Gut microbiome alterations in Alzheimer’s disease (2017) (8)
- Postanoxic electrographic status epilepticus and serum biomarkers of brain injury. (2020) (8)
- Comparison of plasma and CSF Neurofilament-light in an MS trial (2019) (7)
- Apolipoprotein E genotypes and longevity across dementia disorders (2018) (7)
- Circulating levels of vascular endothelial growth factor and post‐stroke long‐term functional outcome (2020) (7)
- Study protocol: ASCRIBED: the impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood BiomarkErs of brain inflammation and injury in dementia: a study in acute hip fracture patients (2019) (7)
- The PPAR-α gene in Alzheimer's disease: Lack of replication of earlier association (2009) (7)
- Cerebrospinal fluid GAP-43 in early multiple sclerosis (2018) (7)
- Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus (2021) (7)
- Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission. (2013) (7)
- Association of deranged cerebrovascular reactivity with brain injury following cardiac arrest: a post-hoc analysis of the COMACARE trial (2021) (7)
- Enhanced xeno-free differentiation of hiPSC-derived astroglia applied in a blood–brain barrier model (2019) (7)
- Serum biomarkers of brain injury after uncomplicated cardiac surgery: Secondary analysis from a randomized trial (2022) (7)
- Biomarker modeling of Alzheimer’s disease using PET-based Braak staging (2022) (7)
- Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. (2019) (7)
- Associations between mean arterial pressure during cardiopulmonary bypass and biomarkers of cerebral injury in patients undergoing cardiac surgery: secondary results from a randomized controlled trial. (2020) (7)
- The recency ratio is related to CSF amyloid beta 1‐42 levels in MCI‐AD (2018) (7)
- Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology. (2009) (7)
- Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer (2020) (7)
- MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis (2002) (7)
- Protein aggregate formation permits millennium-old brain preservation (2020) (7)
- No Association of VEGF Polymorphims with Alzheimer’s Disease (2010) (7)
- Re: "The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve". (2006) (7)
- CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB (2021) (7)
- BRain health and healthy AgeINg in retired rugby union players, the BRAIN Study: study protocol for an observational study in the UK (2017) (7)
- Detection of Glial Fibrillary Acidic Protein in Patient Plasma Using On-Chip Graphene Field-Effect Biosensors, in Comparison with ELISA and Single-Molecule Array (2021) (7)
- γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C (2010) (7)
- Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. (2015) (7)
- Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients (2016) (7)
- CSF AND PLASMA LEVELS OF INFLAMMATION DIFFERENTIALLY RELATE TO CNS MARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND NEURONAL DAMAGE (2017) (7)
- Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration. (2017) (7)
- Head‐to‐head comparison of amplified plasmonic exosome Aβ42 platform and single‐molecule array immunoassay in a memory clinic cohort (2020) (7)
- Estrogen-related Polymorphisms in Estonian Patients with Age-related Cataract (2015) (7)
- Peptidomic analysis of cartilage and subchondral bone in OA patients (2019) (7)
- Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients (2022) (7)
- Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus (2021) (7)
- Synergistic Association between Plasma Aβ1–42 and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia (2021) (7)
- Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium (2021) (7)
- The APOE Genotype in Idiopathic Normal Pressure Hydrocephalus (2016) (7)
- Validation of a new assay for α-synuclein detection in cerebrospinal fluid (2017) (7)
- Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury (2020) (7)
- Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults (2020) (7)
- Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis (2022) (7)
- Complement gene single nucleotide polymorphisms and biomarker endophenotypes of Alzheimer's disease. (2013) (7)
- Use of wireless phones and serum β-trace protein in randomly recruited persons aged 18–65 years: a cross-sectional study (2012) (7)
- Second Generation gamma-Secretase Modulators Exhibit Different Modulation of Notch beta and A beta Production (2012) (7)
- Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis. (2020) (7)
- Antemortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. (2022) (7)
- Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort (2021) (7)
- Protofibrillar and Fibrillar Amyloid-β Binding Proteins in Cerebrospinal Fluid. (2018) (7)
- Hypertension in spontaneously hypertensive rats occurs despite low plasma levels of homocysteine. (2008) (7)
- Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: A 25-Year Follow-Up Study (2018) (7)
- Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease (2020) (7)
- The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease (2018) (7)
- Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging (2021) (7)
- Dextran- versus crystalloid-based prime in cardiac surgery: A prospective randomized pilot study. (2020) (6)
- Dissecting IWG-2 typical and atypical Alzheimer's disease: Insights from cerebrospinal fluid analysis (2015) (6)
- Breaking the cycle (2019) (6)
- Detection of α-Synuclein in Biological Samples Using Mass Spectrometry. (2019) (6)
- Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum (2022) (6)
- A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. (2016) (6)
- Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds (2020) (6)
- Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation (2022) (6)
- Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses (2022) (6)
- Updating Our Definitions of Parkinson’s Disease for a Molecular Age (2018) (6)
- Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation (2022) (6)
- Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis (2021) (6)
- Low-dose γ-secretase inhibition increases secretion of Aβ peptides and intracellular oligomeric Aβ (2017) (6)
- Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment (2021) (6)
- Seizures, CSF neurofilament light and tau in patients with subarachnoid haemorrhage (2018) (6)
- Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients (2022) (6)
- Repeated lumbar punctures within 3 days may affect CSF biomarker levels (2019) (6)
- A β dimer-containing human cerebrospinal fluid disrupts synaptic plasticity : prevention by systemic passive immunization (2009) (6)
- Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons (2022) (6)
- Update on amyloid‐β homeostasis markers for sporadic Alzheimer's disease (2009) (6)
- In-Depth Site-Specific O-Glycosylation Analysis of Glycoproteins and Endogenous Peptides in Cerebrospinal Fluid (CSF) from Healthy Individuals, Mild Cognitive Impairment (MCI), and Alzheimer's Disease (AD) Patients. (2021) (6)
- Multicentre longitudinal study of fluid and neuroimaging BIOmarkers of AXonal injury after traumatic brain injury: the BIO-AX-TBI study protocol (2020) (6)
- Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection (2016) (6)
- Hallmarks of neurodegenerative diseases (2023) (6)
- Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study (2020) (6)
- Admission Levels of Interleukin 10 and Amyloid β 1–40 Improve the Outcome Prediction Performance of the Helsinki Computed Tomography Score in Traumatic Brain Injury (2020) (6)
- Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts (2022) (6)
- Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease. (2020) (6)
- No changes in HIV suppression and inflammatory markers in CSF in patients randomly switched to DTG + 3TC (Spanish HIV/AIDS Research Network, PreEC/RIS 62). (2020) (6)
- Tracking the potential involvement of metabolic disease in Alzheimer's disease-Biomarkers and beyond. (2020) (6)
- Evidence of Neuroinflammation and Blood–Brain Barrier Disruption in Women with Preeclampsia and Eclampsia (2021) (6)
- Review Articles CSF Ab1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease (2014) (6)
- Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection (2019) (6)
- The clinical value of fluid biomarkers for dementia diagnosis – Authors' reply (2016) (6)
- Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. (2021) (6)
- APOE ε4 and the long arm of social inequity: estimated effects of socio-economic status and sex on the timing of dementia onset (2018) (6)
- Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration (2022) (6)
- Life course, genetic, and neuropathological associations with brain age in the 1946 British Birth Cohort: a population-based study. (2022) (6)
- Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. (2019) (6)
- Sex influences clinical phenotype in frontotemporal dementia (2022) (6)
- Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology. (2019) (6)
- Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy (2021) (6)
- Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease? (2020) (6)
- Parkinson’s disease with restless legs syndrome—an in vivo corneal confocal microscopy study (2021) (6)
- Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume (2021) (6)
- Fluid Biomarkers for Chronic Traumatic Encephalopathy (2020) (6)
- Plasma p‐tau181 shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau (2021) (6)
- Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies (2022) (6)
- Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 (2021) (6)
- Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability (2022) (6)
- Plasma β‐secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD (2021) (5)
- Ab40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer’s Disease (2010) (5)
- The impact of Tween 20 on repeatability of amyloid β and tau measurements in cerebrospinal fluid (2015) (5)
- Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-β42 and White Matter Microstructure in Cognitively Healthy Adults. (2020) (5)
- Prion protein quantification in cerebrospinal fluid as a tool for prion disease drug development (2018) (5)
- Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection (2021) (5)
- The influence of the R47H TREM2 variant on microglial exosome profiles (2021) (5)
- Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women (2019) (5)
- Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity (2020) (5)
- Serum tau concentration after diving - an observational pilot study. (2019) (5)
- Brain Injury in COVID-19 is Associated with Autoinflammation and Autoimmunity (2021) (5)
- Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease (2021) (5)
- Sleep deprivation and plasma biomarkers for Alzheimer's disease. (2019) (5)
- Gamma-glutamyltransferase in alcohol use disorders: Modification of decision limits in relation to treatment goals? (2010) (5)
- A Western‐style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's disease—A population‐based cross‐sectional study among 70‐year‐olds (2021) (5)
- Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to β-amyloid positivity. (2022) (5)
- New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia (2018) (5)
- Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study (2015) (5)
- Ubiquitin Carboxyl-Terminal Esterase LI (UCHLI) SI8Y Polymorphism in Patients with Cataracts (2011) (5)
- Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results (2004) (5)
- The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals (2015) (5)
- Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study (2021) (5)
- Slowing gait speed precedes cognitive decline by several years (2022) (5)
- Biomarkers in frontotemporal dementia. (2014) (5)
- The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors (2022) (5)
- Plasma amyloid-β ratios in autosomal dominant Alzheimer’s disease: the influence of genotype (2021) (5)
- [There is a strong evidence that professional boxing results in chronic brain damage. The more head punches during a boxer's career, the bigger is the risk]. (2005) (5)
- Levels of ADAM10 are reduced in Alzheimer’s disease CSF (2018) (5)
- Mass spectrometry analysis of tau and amyloid‐beta in iPSC‐derived models of Alzheimer’s disease and dementia (2021) (5)
- CSF and blood biomarkers for Alzheimer ’ s disease : a systematic review and meta-analysis (2019) (5)
- Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjögren’s syndrome (2013) (5)
- Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives (2021) (5)
- Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study (2021) (5)
- Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study” [EBioMedicine 3 (216) 135–140] (2016) (5)
- Imatinib treatment and A beta 42 in humans (2014) (5)
- The role of lysozyme in Alzheimer’s disease (2015) (5)
- TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer’s disease biomarker levels (2020) (5)
- Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization (2022) (5)
- Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage. (2020) (5)
- Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population (2021) (5)
- Increased serum concentrations of intestinal alkaline phosphatase in peritoneal dialysis. (2005) (5)
- Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2 (2021) (5)
- Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains (2020) (5)
- Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury (2020) (5)
- Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1 (2020) (5)
- Cerebrospinal fluid biomarkers of glial and axonal injury in cervical spondylotic myelopathy. (2021) (5)
- Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non‐demented individuals with autosomal‐dominant Alzheimer's disease (2021) (5)
- Association of APOE ɛ4 and Plasma p-tau181 with Preclinical Alzheimer’s Disease and Longitudinal Change in Hippocampus Function (2021) (5)
- Biomarker Modelling of Early Molecular Changes in Alzheimer’s Disease (2014) (5)
- Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus (2021) (5)
- Biomarkers for dementia in Latin American countries: Gaps and opportunities (2022) (5)
- Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study. (2021) (5)
- Quality Assessment of 25(OH)D, Insulin, Total Cholesterol, Triglycerides, and Potassium in 40-Year-Old Frozen Serum (2015) (5)
- Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study (2022) (5)
- APOE-ε4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks (2020) (5)
- Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study. (2015) (5)
- Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease (2021) (5)
- Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers (2022) (5)
- Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies (2021) (5)
- Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease. (2012) (5)
- Alzheimer’s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients (2022) (5)
- Breaking the cycle Reversal of fl ux in the tricarboxylic acid cycle by dimethyl fumarate (2019) (5)
- Alzheimer‐like pathology in trisomy 21 cerebral organoids amenable to pharmacological inhibition reveals BACE2 as a gene‐dose‐sensitive AD‐suppressor in human brain (2020) (4)
- Neurofilament Protein and Antineurofilament Antibodies Following Traumatic Brain Injury-Reply. (2017) (4)
- DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA Aβ BIOMARKER ASSAYS (2018) (4)
- Alzheimer disease Cerebrospinal Fluid biomarker in Cognitively Normal Subjects : Multicenter 1 Study 2 (2015) (4)
- Biomarkers of neurodegeneration (2014) (4)
- Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia (2022) (4)
- A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice (2022) (4)
- Potential of heart fatty-acid binding protein, neurofilament light, interleukin-10 and S100 calcium-binding protein B in the acute diagnostics and severity assessment of traumatic brain injury (2021) (4)
- VALZ‐Pilot: High‐dose valacyclovir treatment in patients with early‐stage Alzheimer's disease (2022) (4)
- Serum‐neuroproteins, near‐infrared spectroscopy, and cognitive outcome after beach‐chair shoulder surgery: Observational cohort study analyses (2020) (4)
- Finding Correspondence between Metabolomic Features in Untargeted Liquid Chromatography–Mass Spectrometry Metabolomics Datasets (2022) (4)
- Long noncoding RNA MEG3 activates neuronal necroptosis in Alzheimer’s disease (2022) (4)
- A randomized, double-blind placebo-controlled trial of simvastatin on CSF, MRI, and cognitive biomarkers in middle-aged adults at risk for Alzheimer's disease: The ESPRIT Study (2010) (4)
- Author Correction: Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons (2020) (4)
- Combining biomarkers for prognostic modelling of Parkinson’s disease (2022) (4)
- Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis (2016) (4)
- Sleep Deprivation and CSF Biomarkers for Alzheimer Disease (2018) (4)
- Cross-Sectional and Longitudinal Validation of Serum Neurofilament Light Chain (NfL) as a Biomarker of Parkinson’s Disease Progression (2019) (4)
- Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study (2022) (4)
- Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity (2021) (4)
- Negligible influence of moderate to severe hyperthermia on blood-brain barrier permeability and neuronal-parenchymal integrity in healthy men. (2021) (4)
- Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age (2021) (4)
- Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences (2020) (4)
- Fluid biomarkers for disease activity in multiple sclerosis (2017) (4)
- Dissecting the Structural Organization of Multiprotein Amyloid Aggregates Using a Bottom-Up Approach (2020) (4)
- BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease (2010) (4)
- A genome-wide association study of plasma phosphorylated tau181 (2021) (4)
- Quality of life of ice hockey players after retirement due to concussions (2020) (4)
- The 12-Word Philadelphia Verbal Learning Test Performances in Older Adults: Brain MRI and Cerebrospinal Fluid Correlates and Regression-Based Normative Data (2018) (4)
- Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening (2022) (4)
- Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration (2021) (4)
- Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease (2016) (4)
- Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease (2017) (4)
- Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study (2021) (4)
- Molecular forms of neurogranin in cerebrospinal fluid (2020) (4)
- A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older. (2018) (4)
- Differential Stimulation of Pluripotent Stem Cell-Derived Human Microglia Leads to Exosomal Proteomic Changes Affecting Neurons (2021) (4)
- TH21. CEREBROSPINAL FLUID PROTEOMICS TARGETED FOR CENTRAL NERVOUS SYSTEM PROCESSES IN BIPOLAR DISORDER (2021) (4)
- Alzheimer´s disease related biomarkers in bipolar disorder - a longitudinal one-year case-control study. (2021) (4)
- Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset (2022) (4)
- Losing the identity of a hockey player: the long-term effects of concussions (2020) (4)
- Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults (2022) (4)
- Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays (2021) (4)
- Cardiac troponin T is elevated and increases longitudinally in ALS patients (2021) (4)
- Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers (2022) (4)
- Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models (2022) (4)
- Amyloid pathology and synaptic loss in pathological aging (2021) (4)
- CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects (2020) (4)
- Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. (2017) (4)
- A metabolite-based machine learning approach to diagnose Alzheimer’s-type dementia in blood: Results from the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort (2019) (4)
- Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community‐based sample of 70‐year‐olds (2022) (4)
- Plasma glial fibrillary acidic protein is an early marker of amyloid pathology in Alzheimer's disease (2021) (4)
- Prodromal frontotemporal dementia: clinical features and predictors of progression (2021) (4)
- Abstracts from HSG 2019 (2019) (4)
- Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease. (2022) (4)
- CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau (2018) (4)
- Biomarkers of neuronal damage in saturation diving—a controlled observational study (2020) (4)
- Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers (2021) (4)
- CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology (2022) (4)
- Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load (2020) (4)
- Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease (2022) (4)
- Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein (2019) (4)
- Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease (2022) (4)
- Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis (2019) (4)
- Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas (2023) (4)
- Plasma glial fi brillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer ’ s disease (2021) (4)
- Herpes Simplex Virus 1 and 2 Infections during Differentiation of Human Cortical Neurons (2021) (4)
- Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias (2021) (4)
- Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds (2021) (4)
- Association of neurogranin gene expression with Alzheimer's disease pathology in the perirhinal cortex (2021) (4)
- AMYLOID BIOMARKERS FOR AD: CURRENT STATUS AND NOVEL FINDINGS (2014) (4)
- N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases (2022) (4)
- Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease (2020) (4)
- Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile (2021) (4)
- The Szilard Hypothesis on the Nature of Aging Revisited (2009) (4)
- Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology (2020) (4)
- Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice (2012) (4)
- Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis (2022) (4)
- Amyloid β42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death (2019) (4)
- Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays (2020) (4)
- Association of brain network dynamics with plasma biomarkers in subjective memory complainers (2019) (4)
- Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles (2022) (4)
- The Epstein-Barr virus ZEBRA protein activates transcription from the early lytic F promoter by binding to a promoter-proximal AP-1-like site. (2002) (4)
- The relationship between white matter microstructure and self-perceived cognitive decline (2021) (4)
- A non-APOE polygenic risk score for Alzheimer ’ s disease is associated with CSF neurofilament light in a representative sample of cognitively unimpaired 70-year-olds (2021) (4)
- Increased immune activation and signs of neuronal injury in HIV-negative people on pre-exposure prophylaxis (PrEP). (2021) (4)
- Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint (2022) (4)
- Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study (2020) (4)
- Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest (2019) (4)
- Response to mitogen‐activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study (2021) (4)
- GFAp and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial (2021) (4)
- Cerebrospinal Fluid Secretory Ca 2 -Dependent Phospholipase A 2 Activity Is Increased in (2009) (4)
- CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER’S DISEASE: AN ASSAY COMPARISON STUDY (2017) (4)
- Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus (2022) (4)
- Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial (2022) (4)
- Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis (2021) (4)
- The Gothenburg population-based glioblastoma research database: Methodological aspects and potential impact (2019) (4)
- Plasma neurofilament light chain protein as a predictor of days in delirium and deep sedation, mortality and length of stay in critically ill patients (2022) (4)
- Temporal order of clinical and biomarker changes in familial frontotemporal dementia (2022) (4)
- Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease (2022) (4)
- Phospho‐tau217 and phospho‐tau181 in plasma and CSF as biomarkers for Alzheimer’s disease (2020) (3)
- Plasma amyloid-β in patients with Tangier disease. (2013) (3)
- Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration (2022) (3)
- Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults (2022) (3)
- Association of plasma Aβ40/Aβ42 ratio and brain Aβ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease (2021) (3)
- Correction: Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain (2021) (3)
- The phosphorylation cascade hypothesis of Alzheimer’s disease (2021) (3)
- Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in non‐demented adults (2021) (3)
- Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. (2020) (3)
- Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis (2020) (3)
- Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression (2017) (3)
- Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic (2021) (3)
- Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study (2022) (3)
- Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology (2022) (3)
- Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer’s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma (2021) (3)
- CSF alpha synuclein and late-life depression CSF alpha synuclein correlates with CSF neurogranin in late-life depression (2020) (3)
- Relevance of biomarkers across different neurodegenerative diseases (2020) (3)
- Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions (2015) (3)
- A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid (2015) (3)
- Concussion and long‐term cognitive function among rugby players—The BRAIN Study (2021) (3)
- Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum (2022) (3)
- MALDI Imaging Mass Spectrometry: Neurochemical Imaging of Proteins and Peptides (2019) (3)
- Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment (2022) (3)
- Differential chemokine alteration in the variants of primary progressive aphasia—a role for neuroinflammation (2021) (3)
- Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. (2019) (3)
- Effects of amyloid pathology and the APOE ε4 allele on the association between cerebrospinal fluid Aβ38 and Aβ40 and brain morphology in cognitively normal 70-years-olds (2021) (3)
- Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes (2022) (3)
- Corrigendum to “The amyloid-beta degradation pattern in plasma—A possible tool for clinical trials in Alzheimer’s disease” [Neurosci. Lett. 573 (2014) 7–12] (2015) (3)
- Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers (2022) (3)
- Brain injury markers in new-onset seizures in adults: A pilot study (2021) (3)
- Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease (2021) (3)
- Alzheimer Research Forum Live Discussion: sports concussions, dementia, and ApoE genotyping: what can scientists tell the public? What's up for research? (2009) (3)
- Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease (2022) (3)
- GUT MICROBIOME ALTERATIONS IN ALZHEIMER'S DISEASE AND THE RELATIONSHIP WITH CSF BIOMARKERS (2017) (3)
- Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study (2022) (3)
- Clinical Utility of β-Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms (2021) (3)
- Biomarkers for Alzheimer's disease (2013) (3)
- Fluid biomarkers for frontotemporal dementias (2018) (3)
- A longitudinal and cross‐sectional study of plasma neurofilament light chain concentration in Charcot‐Marie‐Tooth disease (2021) (3)
- A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. (2022) (3)
- Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. (2018) (3)
- A high‐performance biomarker panel for Alzheimer’s disease screening and staging identified by large‐scale plasma proteomic profiling (2021) (3)
- Cerebrospinal fluid and plasma lipopolysaccharide (LPS) levels in HIV-1 infection and associations with inflammation, blood-brain barrier permeability and neuronal injury. (2020) (3)
- Effect of bapineuzumab on CSF p-tau and t-tau in mild-to-moderate Alzheimer's disease: Results from two phase III trials in APOE-ε4 carriers and noncarriers (2013) (3)
- Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer’s disease biomarker? (2015) (3)
- Local Prefrontal Cortex TMS-Induced Reactivity Is Related to Working Memory and Reasoning in Middle-Aged Adults (2022) (3)
- No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab (2022) (3)
- Neurofilament light levels predict clinical progression and death in multiple system atrophy (2022) (3)
- Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis. (2022) (3)
- The transcobalamin 776C>G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease (2005) (3)
- Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis (2022) (3)
- Longitudinal measurements of cerebrospinal fluid biomarkers over four years in mild cognitive impairment (2012) (3)
- Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology (2020) (3)
- Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation (2021) (3)
- A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging (2022) (3)
- Principal components from untargeted cerebrospinal fluid metabolomics associated with Alzheimer's disease biomarkers (2022) (3)
- CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals (2021) (3)
- Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies. (2020) (3)
- Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke (2020) (3)
- Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. (2020) (3)
- Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. (2021) (3)
- Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis (2019) (3)
- Identification of a beta-amyloid-binding plasma protein, LRP1: implications for biomarker research and therapy in Alzheimer's disease. (2007) (3)
- Correction: Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia (2019) (3)
- CSF phosphorylated tau‐217 is increased in Alzheimer’s and Creutzfeldt‐Jakob diseases and correlates with amyloid pathology (2020) (3)
- The PPAR-alpha gene in Alzheimer's disease: lack of replication of earlier association. (2009) (3)
- Non-neurological surgery results in a neurochemical stress response (2008) (3)
- Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia (2021) (3)
- Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies (2023) (3)
- Correction: The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study (2019) (3)
- Structure-specific amyloid precipitation in biofluids (2022) (3)
- Head trauma in sports and risk for dementia (2019) (3)
- Comparing the effect of xenon and sevoflurane anesthesia on postoperative neural injury biomarkers: a randomized controlled trial (2021) (3)
- SerumNeurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest (2018) (3)
- ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease – Study Protocol and Baseline Characteristics (2022) (3)
- Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma (2022) (3)
- Unresolved questions in Alzheimer's research: will biomarkers help? (2014) (3)
- LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY (2017) (3)
- Neurofilament light plasma concentration positively associates with age and negatively associates with weight and height in the dog (2020) (3)
- Amyloid and Tau Biomarkers in CSF. (2015) (3)
- Genetic Variants and Related Biomarkers in Sporadic Alzheimer’s Disease (2014) (3)
- Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis (2021) (3)
- Serum IGF-1 is higher in patients with idiopathic normal pressure hydrocephalus than in the population. (2015) (3)
- Cerebral biomarkers in neurological complications of preeclampsia. (2022) (3)
- Characterization of Cerebrospinal Fluid BACE1 Species (2019) (3)
- Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers (2020) (3)
- β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage (2014) (3)
- Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure. (2017) (3)
- Cerebral Biomarkers and Blood-Brain Barrier Integrity in Preeclampsia (2022) (3)
- The relationship between CSF tau markers, hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. (2016) (3)
- Amyloid-β metabolism in Niemann-Pick C disease models and patients (2012) (3)
- A beta 40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer ' s Disease (2010) (3)
- Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms (2021) (3)
- Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. (2019) (3)
- A biorepository for the in‐depth validation of pre‐analytical sample handling effects on novel blood‐based biomarkers for Alzheimer’s disease: The first results (2020) (3)
- Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid (2019) (3)
- CSF α-synuclein correlates with CSF neurogranin in late-life depression (2020) (3)
- An extensive plasmid library to prepare tau protein variants and study their functional biochemistry. (2020) (3)
- Cerebrospinal fluid Aβ42/Aβ40 and Aβ42/Aβ38 as biomarkers of Alzheimer’s disease (2016) (3)
- Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement (2022) (2)
- Abstracts of 20th Annual ASENT Meeting (2018) (2)
- Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle loads (2022) (2)
- THE ROLE OF THE CENTRAL GHRELIN SYSTEM IN REWARD FROM ADDICTIVE DRUGS (2011) (2)
- Diabetes and Neuroaxonal Damage in Parkinson's Disease (2022) (2)
- The genetic regulation of protein expression in cerebrospinal fluid (2022) (2)
- Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal (2021) (2)
- A 9-year prospective population-based study on the association 1 between the APOE ε 4 allele and late-life depression in Sweden 2 Short Title : The APOE ε 4 allele and late-life depression (2015) (2)
- Serum neurofilament light concentration does not increase following exposure to low velocity football heading (2020) (2)
- Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie (2022) (2)
- Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup (2018) (2)
- Fluid biomarkers in Alzheimer’s disease – current concepts (2013) (2)
- SERUM NEUROFILAMENT LIGHT PROTEIN AND VISIN-LIKE PROTEIN-1 IN CONCUSSED PROFESSIONAL ICE HOCKEY PLAYERS (2014) (2)
- Small extracellular vesicles in plasma reveal molecular effects of modified Mediterranean-ketogenic diet in participants with mild cognitive impairment (2022) (2)
- Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers (2023) (2)
- Fatty Acid-Binding Protein 3 in Cerebrospinal Fluid of Hip Fracture Patients with Delirium. (2020) (2)
- TRANSFORMATION OF CSF BIOMARKER VALUES BETWEEN MEASUREMENT BATCHES (2018) (2)
- COMBINING CSF AB42 AND PET FLORBETAPIR TO PREDICT DIAGNOSIS, TAU, ATROPHY, AND COGNITION (2014) (2)
- The localization of amyloid precursor protein to ependymal cilia in vertebrates and its role in ciliogenesis and brain development in zebrafish (2021) (2)
- Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals (2016) (2)
- Psychosis and biological markers. (2017) (2)
- Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals (2022) (2)
- Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia (2018) (2)
- Association Between EEG Patterns and Serum Neurofilament Light After Cardiac Arrest (2022) (2)
- Power tools for Alzheimer’s disease – an electrochemical preamp for Aβ (2012) (2)
- Blood-based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider (2019) (2)
- Plasma pNfH differentiate SBMA from ALS (2019) (2)
- LONGITUDINAL CSF BIOMARKER CHANGES IN MIDDLE-AGED ADULTS AT RISK FOR AD: THE WISCONSIN REGISTRY FOR ALZHEIMER’S PREVENTION (WRAP) AND WISCONSIN ADRC COHORTS (2017) (2)
- Serum Neurofilament Light concentrations are not associated with renal function in Secondary Progressive Multiple Sclerosis (2021) (2)
- Sevoflurane dose and postoperative delirium: a prospective cohort analysis. (2022) (2)
- The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review (2022) (2)
- Truncating tau reveals different pathophysiological actions of oligomers in single neurons (2021) (2)
- Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy (2022) (2)
- Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer’s prevention (WRAP) (2015) (2)
- Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases (2021) (2)
- Reply to ‘MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis’ (2002) (2)
- Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78–94 (2022) (2)
- Brain disconnectome mapping and serum neurofilament light levels in multiple sclerosis (2021) (2)
- Cerebral amyloid burden and Alzheimer's disease subtypes – does localization information matter? (2016) (2)
- CHANGES IN ADIPOSITY AND CSF BIOMARKERS FOLLOWING A MODIFIED MEDITERRANEAN KETOGENIC DIET (2019) (2)
- Conserved YKL-40 changes in mice and humans after postoperative delirium (2022) (2)
- [Biomarkers in cerebrospinal fluid and blood in memory complaints]. (2009) (2)
- CSF sphingomyelin metabolites in Alzheimer’s disease, neurodegeneration, and neuroinflammation (2021) (2)
- Evolution of cerebrospinal fl uid total a-synuclein in Parkinson ' s disease (2018) (2)
- Cerebrospinal fluid quinolinic acid is strongly associated with delirium and mortality in hip-fracture patients (2022) (2)
- Screening with a high-precision blood-based assay for Alzheimer disease (2019) (2)
- Exposure to wireless phone emissions and serum ß-trace protein (2)
- Untangling the tau microtubule-binding region. (2021) (2)
- Zebrafish physiology: big interest in a small fish (2011) (2)
- Oligonucleotides Targeting DNA Repeats Downregulate Huntingtin Gene Expression in Huntington's Patient-Derived Neural Model System (2021) (2)
- Alzheimer's Disease-Related Dementias Summit 2019: National research priorities for the investigation of traumatic brain injury as a risk factor for Alzheimer's Disease and Related Dementias. (2021) (2)
- Pregnancy and a rare MTHFR haplotype (2012) (2)
- Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition (2022) (2)
- No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62) (2020) (2)
- Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage (2021) (2)
- Association of plasma proteins with rate of cognitive decline and dementia: 20-year follow-upof the Whitehall II and ARIC cohort studies (2020) (2)
- Acute sleep loss increases CNS health biomarkers and compromises the ability to stay awake in a sex-and weight-specific manner (2022) (2)
- Large-scale proteome analysis of CSF implicates altered glucose metabolism in Alzheimer's disease (2021) (2)
- The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020) (2)
- Evaluation of Factors of Importance for Clinical Dementia Diagnosis (2005) (2)
- Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk (2021) (2)
- Reliability of serum S100B measurement following mild traumatic brain injury: a comparison of assay measurements from two laboratories (2020) (2)
- The cerebrospinal fluid proteome in HIV infection: change associated with disease severity (2012) (2)
- Validity and Normative Data for the Biber Figure Learning Test: A Visual Supraspan Memory Measure (2018) (2)
- Evolution, exaptation, and stereopsis. (2005) (2)
- Functional brain activity constrained by structural connectivity reveals cohort-specific features for serum neurofilament light chain (2022) (2)
- Spitting image: can saliva biomarkers reflect Alzheimer's disease? (2021) (2)
- Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial (2021) (2)
- Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. (2017) (2)
- COMPARISON OF VARIABLES ASSOCIATED WITH CSF NEUROFILAMENT, TOTAL-TAU, AND NEUROGRANIN IN A COMMUNITY-BASED STUDY (2019) (2)
- Biomarker time out (2014) (2)
- Alzheimer’s disease biomarker roadmap 2020: Fluid biomarkers (2020) (2)
- PLASMA NEUROFILAMENT LIGHT MEASUREMENTS IN MORE THAN 2,100 PRESENILIN-1 E280A MUTATION CARRIERS AND NON-CARRIERS FROM THE WORLD’S LARGEST AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE KINDRED (2019) (2)
- Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis (2022) (2)
- Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome (2019) (2)
- Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation (2022) (2)
- Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy (2021) (2)
- Plasma biomarkers for neurodegenerative disorders: ready for prime time? (2023) (2)
- Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease (2016) (2)
- Author Correction: A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease (2022) (2)
- Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study (2017) (2)
- THE PREVALENCE OF PRECLINICAL ALZHEIMER’S DISEASE IN A POPULATION STUDY OF 70-YEAR-OLDS (2017) (2)
- CSF biomarkers for Alzheimer's pathology and the effect size of APOE-ε4 (2013) (2)
- Plasma biomarker profiles in autosomal dominant Alzheimer’s disease (2023) (2)
- Vascular risk burden is a key player in the early progression of Alzheimer's disease (2021) (2)
- Diagnostic comparison of regional amyloid PET and different CSF biomarker assays for identifying early Alzheimer's disease (2015) (2)
- Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes (2022) (2)
- Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress (2016) (2)
- The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer’s disease clinical trials (2017) (2)
- Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults (2022) (2)
- Intrathecal immunoreactivity in people with or without previous infectious mononucleosis (2020) (2)
- Disease signatures: Biomarkers/indicators of neurodegeneration (2019) (2)
- CSF IN THE DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE: CLINICAL UTILITY OF AN EXTENDED PANEL OF BIOMARKERS IN A SPECIALIST COGNITIVE CLINIC (2016) (2)
- A population‐based study of head injury, cognitive function and pathological markers (2021) (2)
- Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum (2021) (2)
- Cross-sectional associations of CSF tau levels with Rey's AVLT: A recency ratio study. (2022) (2)
- Brain injury markers in blood predict signs of hypoxic ischaemic encephalopathy on head computed tomography after cardiac arrest. (2022) (2)
- Alzheimer's disease diagnosis and management: Perspectives from around the world (2022) (2)
- Biological correlates of elevated soluble TREM2 in cerebrospinal fluid (2022) (2)
- Donanemab removes Alzheimer's plaques: what is special about its target? (2021) (2)
- NEIGHBORHOOD SOCIOECONOMIC CONTEXTUAL DISADVANTAGE, BASELINE COGNITION AND ALZHEIMER’S DISEASE BIOMARKERS IN THE WISCONSIN REGISTRY FOR ALZHEIMER’S PREVENTION (WRAP) STUDY (2017) (2)
- Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest (2022) (2)
- Lessons fromMulticenter Studies on CSF Biomarkers for Alzheimer ’ s Disease (2014) (2)
- High polygenic risk score for exceptional longevity is associated with a healthy metabolic profile (2022) (2)
- 22nd European Congress on Obesity (ECO2015), Prague, Czech Republic, May 6-9, 2015: Abstracts (2015) (2)
- Objectifying Subjective Cognitive Decline (2022) (1)
- Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease (2021) (1)
- MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study (2018) (1)
- Featured Article Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease (2015) (1)
- Detection and quantification of novel tau/phospho-tau epitopes in CSF using a multiplex assay approach (2013) (1)
- The prognostic significance of early blood neurofilament light chain concentration and magnetic resonance imaging variables in relapse‐onset multiple sclerosis (2022) (1)
- Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood (2023) (1)
- Interactions between dietary patterns and genetic factors in relation to incident dementia among 70‐year‐olds (2021) (1)
- Author Correction: Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17 (2022) (1)
- Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology (2020) (1)
- CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status (2021) (1)
- Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review (2019) (1)
- Commentary on Oeckl et al., “Serum Beta‐Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181” (2022) (1)
- EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER’S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY (2017) (1)
- Differences between plasma and CSF p-tau181 and p-tau231 in early Alzheimer s disease (2021) (1)
- Rare variants in IFFO1, DTNB and NLRC3 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation (2021) (1)
- TARGETING SYNAPTIC PATHOLOGY WITH A NOVEL AFFINITY MASS SPECTROMETRY APPROACH (2014) (1)
- Author Correction: A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease (2021) (1)
- CSF NFL levels and neuroimaging‐derived neurite density index improve prediction of MCI and dementia clinical diagnosis within the Alzheimer’s pathologic framework (2020) (1)
- A tear fluid proteome of Parkinson's disease. (2019) (1)
- All cognitive systems but speed and visuospatial functions reduce the effect of CSF pathology on other systems. (2012) (1)
- Alzheimer’s Disease and Other Neurodegenerative Disorders (2015) (1)
- Isotopic N,N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease. (2022) (1)
- Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic Aβ Peptides (2022) (1)
- Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex. (2021) (1)
- Cerebrospinal fl uid sphingolipids , b-amyloid , and tau in adults at risk for Alzheimer ’ s disease (2014) (1)
- CEREBROSPINAL FLUID LEVELS OF AMYLOID BETA AND TAU AS ENDOPHENOTYPES REVEAL NOVEL VARIANTS POTENTIALLY INFORMATIVE FOR ALZHEIMER'S DISEASE (2016) (1)
- Circulating brain injury biomarkers increase after endoscopic surgery for pituitary tumors (2021) (1)
- CSF metabolites associated with CSF NeuroToolKit biomarkers (2021) (1)
- ULTRASENSITIVE DETECTION OF NEURODEGENERATIVE BIOMARKERS IN BLOOD WITH THE FULLY AUTOMATED SIMOA ANALYZER: CLINICAL APPLICATIONS (2014) (1)
- IDENTIFYING MARKERS OF MICROGLIA ACTIVATION IN CSF FROM PATIENTS WITH ALZHEIMER'S DISEASE USING A NOVEL MASS SPECTROMETRY APPROACH (2014) (1)
- Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration (2013) (1)
- Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults (2022) (1)
- Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment (2020) (1)
- Cerebrospinal fluid total prion protein: a potential in vivo marker of cerebral prion pathology. (2015) (1)
- Laboratory testing for lyme neuroborreliosis. (2015) (1)
- Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer’s disease (2015) (1)
- FREE ORAL COMMUNICATIONS 4: ALCOHOL DEPENDENCE: TREATMENT APPROACHESO4.1EFFECTIVENESS OF STIMULANT MEDICATION IN FETAL ALCOHOL SPECTRUM DISORDERS (2011) (1)
- A β 1-15/16 as a marker for γ -secretase inhibition in Alzheimer’s disease (2013) (1)
- ELEVATED CEREBROSPINAL FLUID NEUROFILAMENT LIGHT LEVELS ARE ASSOCIATED WITH COMPROMISED WHITE MATTER INTEGRITY AMONG OLDER ADULTS (2017) (1)
- Genetic mapping of APP and amyloid-β biology modulation by trisomy 21 (2022) (1)
- Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein (2019) (1)
- Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels (2020) (1)
- Diagnostic Accuracy of ELISA and Luminex Technology (xMAP) for the Quantitation of CSF Amyloid Beta 40 and 42 Peptides to differentiate Patients with Probable Alzheimer Disease (AD) from Elderly Non-demented Controls (P1.094) (2017) (1)
- Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease (2020) (1)
- CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals (2022) (1)
- Correlation between cerebrospinal fluid and blood neurofilament light protein: A systematic review and meta‐analysis (2020) (1)
- Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer’s disease in the absence of AT(N) classification as the reference standard (2020) (1)
- Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study (2022) (1)
- Convergence of chromogranin and amyloid metabolism in the brain (2010) (1)
- An enzyme activity as a potential biomarker for Alzheimer's disease (2010) (1)
- Smartphone‐based long‐term delayed memory performance is associated with the Preclinical Alzheimer's Cognitive Composite and CSF levels of β‐amyloid (2022) (1)
- Combined tissue and fluid proteomics with Tandem Mass Tags to identify circulating biomarkers of microglial cell activation in CSF from patients with Alzheimer ’ s disease (2017) (1)
- Bioinformatics tools and data resources for assay development of fluid protein biomarkers (2022) (1)
- Longitudinal increase of CSF soluble TREM2 is driven by early aggregation of Aβ42 and associates with slower amyloid deposition and clinical decline in autosomal-dominant Alzheimer’s disease (2021) (1)
- Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study (2022) (1)
- Comparison of plasma and CSF Neurofilament light as outcome in a multiple sclerosis trial (2018) (1)
- CERTAIN PLASMA N-TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND AD-MCI COMPARED TO CONTROLS (2018) (1)
- VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER’S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED, LATE MIDDLE-AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER’S PREVENTION (2018) (1)
- CSF sphingolipids, β -amyloid, and tau in adults at risk for Alzheimer's disease (2014) (1)
- Mild behavioral impairment is associated with plasma p‐tau181 in a dementia‐free population (2022) (1)
- Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis (2022) (1)
- Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down’s Syndrome (2014) (1)
- Differences and similarities between familial and sporadic frontotemporal dementia: An Italian single‐center cohort study (2022) (1)
- APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment (2015) (1)
- Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice (2017) (1)
- CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER’S DISEASE (2019) (1)
- Plasma tau levels in Alzheimer's disease (2013) (1)
- Chitinase-3-like protein 1 (CH3L1) and Neurosecretory protein VGF (VGF) as two novel CSF biomarker candidates for improved diagnostics in Alzheimer’s disease (2017) (1)
- CSF proteomic profiling of mild cognitive impairment individuals with suspected non‐Alzheimer’s disease pathophysiology (2020) (1)
- Alcohol Attenuates Activation in the Bilateral Anterior Insula during an Emotional Processing Task: A Pilot Study (2016) (1)
- A novel ARC polymorphism is associated with reduced risk of Alzheimer's disease (2010) (1)
- Alzbiomarker database on established and novel CSF and plasma biomarkers for Alzheimer’s disease (2015) (1)
- A NEUROBIOLOGICAL MODEL OF MEMORY IMPAIRMENT IN LATE-LIFE MAJOR DEPRESSIVE DISORDER (2017) (1)
- PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON’S AND ALZHEIMER’S DISEASE (2017) (1)
- Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study (2022) (1)
- Abstract 1352: Serum neurofilament light (NfL), glial fibrillary acidic protein (GFAp) and tau protein are possible serum biomarkers for activity of brain metastases and gliomas (2019) (1)
- Diet and APOE as moderators of the relationship between trimethylamine N‐oxide and biomarkers of Alzheimer's disease and glial activation (2021) (1)
- Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys (2022) (1)
- Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis (2022) (1)
- ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER’S DISEASE (2019) (1)
- NOVEL ALZHEIMER’S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: Aβ1-42, TOTAL-TAU, PHOSPHORYLATED-TAU, NFL, NEUROGRANIN, AND YKL-40 (2018) (1)
- APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly (2023) (1)
- Human cerebrospinal fluid promotes spontaneous gamma oscillations in the hippocampus in vitro (2020) (1)
- Retraction notice to “Lower CSF interleukin-6 predicts future depression in a population-based sample of older women followed for 17 years” [Brain Behav. Immun. 32 (2013) 153–158] (2014) (1)
- ADDED DIAGNOSTIC VALUE OF CEREBROSPINAL FLUID NEUROGRANIN IN THE CLASSIFICATION OF PRODROMAL AND ALZHEIMER’S DISEASE DEMENTIA (2016) (1)
- Cerebrospinal fluid levels of SNAP‐25 and SYT1 in Alzheimer’s and Parkinson’s disease (2020) (1)
- Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real-world population-based cohort. (2023) (1)
- Plasma phospho-tau181 as a biomarker for Alzheimer’s disease: development and validation of a prediction model using data from four prospective cohorts (2020) (1)
- Neurochemical signs of astrocytic and neuronal injury in acute COVID‐19 normalizes during long‐term follow‐up (2021) (1)
- Distinct effects of amyloid and tau deposition on eigenvector centrality during hippocampal down-regulation: a real-time fMRI virtual reality closed-loop neurofeedback study with CSF biomarkers (2019) (1)
- Blood biomarkers indicate increased amyloid β production and mild neuroaxonal injury after transient hypoxia during breath-hold diving (2017) (1)
- Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy (2022) (1)
- Repetitive concussions — How dangerous are they? (2015) (1)
- VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER’S DISEASE CONTINUUM (2019) (1)
- Inhibiting the Ca 2 + Influx In duced by Human CSF Graphical (2017) (1)
- MODERATE INTENSITY PHYSICAL ACTIVITY ASSOCIATES WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER’S DISEASE (2017) (1)
- Associations between brain iron deposition and structural Alzheimer’s disease signature in cognitively unimpaired adults (2022) (1)
- Alzheimer’s disease biomarker roadmap 2020: [ 18 F]flortaucipir: Strategic roadmap for the translation of tau biomarkers in the clinic: An international task force (2020) (1)
- Nutritional Supplements for the Treatment and Prevention of Sports-Related Concussion - Omega 3 Fatty Acids: Evidence Still Lacking? (2018) (1)
- Monocyte chemo-attractant protein (MCP1) links microglia activation to predementia white matter (WM) tract integrity changes (2012) (1)
- Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study (2014) (1)
- Emerging beta‐amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences (2020) (1)
- Fluid biomarkers for Alzheimer's disease: standardization and recent developments. (2012) (1)
- ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE (2014) (1)
- Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease. (2022) (1)
- Improved concordance between [11C]PIB PET and CSF Aβ42 using Aβ42/Aβ40: findings from a multicentre European memory clinic population (2016) (1)
- Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks (2022) (1)
- Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound. (2023) (1)
- Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium. (2021) (1)
- Relationship Between Indices of CSF HPA AXIS Activity and AD Biomarkers in Late Life Depression (2017) (1)
- STATE-DEPENDENT ALTERATIONS IN CSF Aβ42 LEVELS IN COGNITIVELY-INTACT ELDERLY WITH LATE LIFE MAJOR DEPRESSION (2016) (1)
- Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders (2022) (1)
- Update on Alzheimer’s and Parkinson’s diseases (2007) (1)
- Genotypic effects of APOE-ε4 on resting-state connectivity in cognitively intact individuals support functional brain compensation (2022) (1)
- Plasma Levels of Phosphorylated Tau 181 Are Associated With Cerebral Metabolic Dysfunction in Cognitively Impaired Individuals (2020) (1)
- Neurodegenerative dementias: screening for major threats to healthy longevity with blood biomarkers. (2021) (1)
- GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY (2018) (1)
- CXCL13 in patients with facial palsy caused by varicella zoster virus and Borrelia burgdorferi: A comparative study (2016) (1)
- DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER’S DISEASE PROGRESSION (2018) (1)
- Association between polygenic risk score of Alzheimer’s disease and CSF amyloid beta 42 in a cohort of 70‐year‐olds from the general population (2020) (1)
- Plasma neurofilament light in progressive multiple sclerosis (2020) (1)
- Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy (2021) (1)
- Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non‐Alzheimer's disease pathophysiology (2022) (1)
- Comparison of brief cognitive tests and CSF analysis in predicting Alzheimer's disease in mild cognitive impairment: Six-year follow-up study (2012) (1)
- Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. (2021) (1)
- MOLECULAR FORMS OF NEUROGRANIN IN CEREBROSPINAL FLUID (2019) (1)
- Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline (2022) (1)
- Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis – a prospective follow-up study (2022) (1)
- No neurochemical evidence of neuronal injury or glial activation in children with Paediatric Acute-onset Neuropsychiatric Syndrome. An explorative pilot study (2020) (1)
- Truncating tau reveals different pathophysiological actions of oligomers in single neurons (2021) (1)
- Associations between brain iron deposition and structural Alzheimer’s disease signature in cognitively unimpaired adults (2022) (1)
- The CBI‐R detects early behavioural impairment in genetic frontotemporal dementia (2022) (1)
- Plasma glial fibrillary acidic protein is an early and specific marker of amyloid‐β pathology in Alzheimer’s disease (2021) (1)
- LONGITUDINAL COMPARISON OF CSF BIOMARKERS OF NEURODEGENERATION IN PATIENTS WITH PROBABLE IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (INPH) (2019) (1)
- Assessment of Plasma Neurofilament Light as a Biomarker of Neuronal Injury in Young Adults with Perinatal HIV Infection (2021) (1)
- Neurofilament light in serum for monitoring multiple sclerosis : A new quantitative tool for measuring disease activity and therapeutic response (2017) (1)
- Mild traumatic brain injury is associated with increased levels of axonal injury biomarkers in blood (2017) (1)
- Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. (2022) (1)
- Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients (2022) (1)
- Webinar | Unlocking the elusive mind: The role of protein biomarkers in understanding neurodegenerative disease (2017) (1)
- Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease (2019) (1)
- Protein tau concentration in blood increases after SCUBA diving: an observational study (2022) (1)
- Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic (2018) (1)
- Blood Test for Early Diagnosis of Alzheimer’s Disease (2013) (1)
- Sex-dependent effects of CYP46A1 overexpression on cognitive function during aging (2021) (1)
- Alzheimer's Disease-Related Dementias Summit 2022: National research priorities for the investigation of post-traumatic brain injury Alzheimer's Disease and Related Dementias. (2023) (1)
- Neuropathological validation of plasma GFAP (2022) (1)
- Association between serum urate and CSF markers of Alzheimer's disease pathology in a population‐based sample of 70‐year‐olds (2021) (1)
- Sample Collection and Measurement of Serum Neurofilament Light (NfL) v1 (2021) (1)
- Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer’s disease from healthy controls (2020) (1)
- Spatial Chemometrics and Comprehensive Chemical Imaging based Molecular Histopathology Delineates Anatomical Heterogeneity at Single Pixel Resolution (2020) (1)
- Plasma Aβ ratios in autosomal dominant Alzheimer’s disease: the influence of genotype (2021) (1)
- Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study (2022) (1)
- Plasma neurofilament light as a biomarker for neurodegeneration in Alzheimer’s disease (2017) (1)
- High sensitivity measurement of neurofilament-light levels in plasma demonstrates a significant reduction in multiple sclerosis patients starting fingolimod (2016) (1)
- Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk. (2009) (1)
- Serum Neurofilament Light in Neurosyphilis: A Pilot Study (2022) (1)
- Multicentre performance evaluation of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of Aβ(1–42) in human cerebrospinal fluid (2015) (1)
- Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients (2022) (1)
- Ion concentrations in cerebrospinal fluid in wakefulness, sleep and sleep deprivation in healthy humans (2021) (1)
- Methylenetetrahydrofolate Reductase Polymorphisms in Human Cataract (2005) (1)
- Author Correction: Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2021) (1)
- Animal Models for Concussion (2015) (1)
- ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHT-PREAD STUDY (2017) (1)
- A MEDIATION ANALYSIS OF THE RELATIONSHIP BETWEEN WHITE MATTER HYPERINTENSITIES, CSF BIOMARKERS, AND COGNITION IN COGNITIVELY UNIMPAIRED AND IMPAIRED ADULTS (2019) (1)
- Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics (2021) (1)
- Tau as a molecular biomarker in cerebrospinal fluid and plasma (2014) (1)
- Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study (2020) (1)
- Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. (2022) (1)
- International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease (2020) (1)
- Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values (2021) (1)
- Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment (2010) (1)
- Chitotriosidase: shucking the role of microglia in amyotrophic lateral sclerosis (2017) (1)
- Decreased ratio between β-amyloid 42 (Aβ42) and Aβ40 in cerebral spinal fluid is a better predictor of structural brain changes than Aβ42 alone in cognitively normal elderly people (2016) (1)
- Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations (2022) (1)
- PREVALENCE OF AMYLOID-β AND TAU PATHOLOGY IN MIDDLE-AGED COGNITIVELY UNIMPAIRED INDIVIDUALS: THE ALFA STUDY (2019) (1)
- Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer’s Disease (2021) (1)
- Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnestic Subtypes of Mild Cognitive Impairment (2022) (1)
- Plasma neurofilament light significantly decreases following treatment in Lyme neuroborreliosis and is not associated with persistent symptoms (2023) (1)
- An ultrasensitive immunoassay for detection of p‐tau181 in blood (2020) (1)
- Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer’s Disease (2022) (1)
- Principal components from untargeted CSF metabolomics associated with tau (2020) (1)
- Biomarkers of brain injury after cardiac arrest; a statistical analysis plan from the TTM2 trial biobank investigators (2022) (1)
- Fluid biomarkers in Alzheimer's disease. (2023) (1)
- Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP) (2015) (1)
- Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson’s Disease (2022) (1)
- NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression (2021) (1)
- CSFBiomarkersandIncipientAlzheimerDisease in Patients With Mild Cognitive Impairment (2009) (1)
- Characterization of EBV‐transformed B‐cells Established from an Individual Homozygously Mutated (G329A) in the FUT7α1,3‐fucosyltransferase Gene (2005) (1)
- Biomarkers of Alzheimer syndrome and related dementias: A&D author's guide (2022) (1)
- Impaired adult hippocampal neurogenesis in Alzheimer’s disease is mediated by microRNA-132 deficiency and can be restored by microRNA-132 replacement (2020) (1)
- Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease (2022) (1)
- The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease (2016) (1)
- CSF biomarkers for dementia (2022) (1)
- Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples (2013) (1)
- Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. (2021) (1)
- Serum neurofilament light and whole brain volume associate with machine‐learning derived brain‐predicted age in the British 1946 birth cohort (2020) (1)
- Commutability of candidate reference materials for the harmonization of Aβ1-42 measurements, on behalf of the ifcc working group on CSF proteins (2015) (1)
- Reference measurement procedure for CSF Aβ1-42 and the CSF Aβ1-42/Aβ1-40 ratio – a cross-validation study against Amyloid PET (2017) (1)
- Replication of an Association Between the RAGE G82S Polymorphism and Alzheimer's Disease (2010) (1)
- Best combination of CSF biomarkers for predicting cognitive decline and clinical progression: A multi‐cohort study (2022) (1)
- BIOMARKERS OF INFLAMMATION IN ALZHEIMER’S DISEASE (2017) (1)
- PROTEOMIC CHANGES IN ZEBRAFISH LACKING THE AMYLOID PRECURSOR HOMOLOG, APPB, USING A HIGH-THROUGHPUT DIFFERENTIAL PROTEOMIC APPROACH (2017) (1)
- [Automated cerebrospinal fluid cell count. A valuable contribution to diagnostics of brain diseases]. (2011) (1)
- Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer’s Disease Patients (2022) (1)
- Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease (2022) (1)
- A Longitudinal Study of Plasma pTau181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease (2022) (1)
- Cerebrospinal fluid neurofilament light improves accurate distinction between neurodegenerative and psychiatric disorders at a cognitive neuropsychiatry service (2022) (1)
- C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease (2017) (1)
- Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg (2020) (1)
- Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study (2022) (1)
- New diagnostic criteria for Alzheimer's disease. (2011) (1)
- Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer’s disease (2021) (1)
- [New investigations in suspected Creutzfeldt-Jakob disease. Analysis of 14-3-3 protein and T-tau in cerebrospinal fluid for safer diagnosis]. (2005) (1)
- Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease (2012) (1)
- Cerebrospinal fluid chemokine levels in healthy older adults: Relationship to beta-amyloid and tau indices (2013) (1)
- Metabolism of CSF beta-amyloid 42 is affected by vascular risk factors, memory and depressive symptoms differently in cognitively normal APOE-ε4 carriers (2012) (1)
- Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer’s Disease Cerebrospinal Fluid Biomarker Levels (2021) (1)
- CSF Alzheimer's disease-related biomarkers are higher in subjects with periodontal disease (2015) (1)
- Perioperative ischaemic brain injury and plasma neurofilament light: a secondary analysis of two prospective cohort studies. (2022) (1)
- A-4 Cerebrospinal Fluid and Plasma Neurofilament Light in Relation to Longitudinal Objective and Subjective Cognitive Decline in Older Adults (2021) (1)
- CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer’s disease (2021) (1)
- FIRST STEPS IN THE DEVELOPMENT AND PRODUCTION OF CLINICAL REFERENCE MATERIAL FOR AMYLOID-B1-42 IN HUMAN CEREBROSPINAL FLUID (2014) (1)
- Blood NfL as a potential axonal damage marker in different CIPN rat models. (2018) (1)
- Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimer’s disease continuum (2021) (1)
- CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia (2022) (1)
- Fluid biomarkers and risk of neurodegenerative disease in retired athletes with multiple concussions: results from the International Concussion and Head Injury Research Foundation Brain health in Retired athletes Study of Ageing and Impact-Related Neurodegenerative Disease (ICHIRF-BRAIN study) (2022) (1)
- Trisomy of human chromosome 21 enhances amyloid-beta 3 deposition independently of an extra copy of APP (vol 141, pg 2457, 2018) (2019) (1)
- CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: A systematic review and meta‐analysis (2021) (1)
- INCREASED LEVELS OF CHITOTRIOSIDASE AND YKL-40 IN CSF FROM PATIENTS WITH ALZHEIMER'S DISEASE (2014) (1)
- The interaction between sleep-disordered breathing and ApoE genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly (2014) (1)
- The performance of Aβ5-X isoforms as novel pharmacodynamic markers of BACE1 inhibition (2012) (1)
- Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic (2023) (1)
- Correlative chemical imaging identifies amyloid peptide signatures of neuritic plaques and dystrophy in human sporadic Alzheimer's disease. (2022) (1)
- The Gamma Secretase Inhibitor, BMS-708163 Increases Alpha Secretase Abeta Peptide Cleavage Fragments and Decreases the Gamma Secretase Abeta Peptide 1-34 Fragment in Cerebrospinal Fluid (2011) (1)
- Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis (2022) (1)
- Predictors of cognitive decline in elderly depressives (2015) (1)
- Title Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN 1 A 431 E-associated familial Alzheimer ' s disease Permalink (2010) (1)
- Amyloid-beta 42 adsorption following serial tube transfer (2014) (1)
- CSF biomarkers in patients with epilepsy in Alzheimer’s disease: a nation-wide study (2022) (1)
- Protective genetic variants in the MS4A gene cluster modulate microglial activity (2020) (1)
- Alpha-2-adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): protocol for a multicentre randomised controlled trial (2022) (1)
- Potential utility of plasma p-tau and NfL as surrogate biomarkers for preventive clinical trials (2022) (1)
- Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease (2014) (1)
- Neurodegenerative disease of the brain: a survey of interdisciplinary approaches (2023) (1)
- Multiomics profiling of human plasma and CSF reveals ATN derived networks and highlights causal links in Alzheimer's disease (2022) (1)
- Refining the risk of HTLV-1-associated myelopathy in people living with HTLV-1: identification of a HAM-like phenotype in a proportion of asymptomatic carriers (2022) (1)
- Exploring common genetic contributors to neuroprotection from amyloid pathology (2022) (1)
- PATTERNS OF [C-11]PIB AMYLOID BURDEN THAT ARE ASSOCIATED WITH CEREBROSPINAL FLUID AD BIOMARKERS IN PEOPLE AT RISK FOR ALZHEIMER'S DISEASE: FINDINGS FROM THE WRAP STUDY (2014) (1)
- Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes (2023) (1)
- VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER’S DISEASE CONTINUUM (2019) (1)
- INNOVATIVE BIOMARKER-GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER’S DISEASE DEMENTIA (2018) (0)
- Associations between sleep quality and biomarkers for neurodegeneration - A longitudinal one-year case-control study of patients with bipolar disorder and healthy control individuals (2022) (0)
- Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer’s continuum (2021) (0)
- The impact of pre-analytical variables on measuring CSF biomarkers for Alzheimer’s disease diagnosis: A review (2019) (0)
- MASS SPECTROMETRIC PROFILING OF ENDOGENOUS PEPTIDES DERIVED FROM THE POST-SYNAPTIC PROTEIN NEUROGRANIN IN CEREBROSPINAL FLUID (2014) (0)
- Blood‐brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein‐β in patients with subcortical small‐vessel disease (2022) (0)
- Microstructural alterations in medial temporal and frontal white matter tracts are associated with subjective cognitive decline (2021) (0)
- Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults puncture, blood draw and neuropsychological testing. CSF AD biomarkers (2016) (0)
- Transcriptional regulation of the Epstein-Barr virus nuclear antigen 1 gene in latent and lytic stages of infection (2003) (0)
- Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology (2021) (0)
- Synaptic proteins relate to memory scores in preclinical Alzheimer’s disease and cognitively healthy controls depending on amyloid (2020) (0)
- RACE MODIFIES THE RELATIONSHIP BETWEEN ALZHEIMER’S DISEASE (AD) BIOMARKERS AND COGNITION IN A COHORT OF MIDDLE-AGED INDIVIDUALS AT HIGH-RISK FOR AD (2019) (0)
- The role of LAMP-2 in AβPP processing and Aβ degradation; implications for Alzheimer’s Disease (2015) (0)
- Association of PlasmaNeurofilament Light With Neurodegeneration in PatientsWith Alzheimer Disease (2017) (0)
- Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest (2023) (0)
- Ex vivo18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway (2017) (0)
- SUBCELLULAR CO-LOCALIZATION OF APP AND APP-CLEAVING ENZYMES (2018) (0)
- Amyloid-related biomarkers for BACE1 inhibition in cell models of Alzheimer's disease (2010) (0)
- Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study (2023) (0)
- Author response to Dr. Beale (2018) (0)
- Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy (2012) (0)
- Author reply to the Letter to the Editor by Prof.Dr. Dr Mischak: “Re‐analysis of peptidomic analysis of cartilage and subchondral bone in OA patients” (2020) (0)
- PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER’S DISEASE: AN OBSERVATIONAL STUDY (2017) (0)
- Cerebrospinal fluid neurogranin in Alzheimer’s disease studies: are immunoassay results interchangeable? (2021) (0)
- ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER’S DISEASE (2019) (0)
- Cerebrospinal fluid stanniocalcin-1: no relation to Alzheimer’s disease but potentially to other dementia disorders (2017) (0)
- A novel proteomics assay allows parallel quantitation of a panel of synaptic proteins in human cerebrospinal fluid (2020) (0)
- Vitamin D supplementation and neurofilament light chain in patients with relapsing- remitting multiple sclerosis: A randomized placebo controlled trial (2018) (0)
- CSF amyloid‐beta, tau, and neurodegenerative and inflammatory biomarkers in cognitively unimpaired late middle‐aged and older adult APOE ε4 homozygotes, heterozygotes, and non‐carriers from the Arizona APOE Cohort (2021) (0)
- Plasma P‐tau181 and NfL are central nodes in a network of diagnostic, biomarker, and demographic data (2021) (0)
- Neuro‐COVID: Does severe COVID‐19 infection increase the risk for cognitive impairment? (2021) (0)
- Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders (2023) (0)
- Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration (2020) (0)
- Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study (2018) (0)
- Decorin is an early CSF biomarker of Alzheimer’s Aβ amyloidosis (2021) (0)
- [18F]RO‐948 Tau PET Retention and Correlation with Fluid Tau Biomarkers in the Early AD Continuum (2022) (0)
- Mid-life dementia risk scores as a predictor of CSF biomarker response to simvastatin therapy in asymptomatic adults at risk for Alzheimer's disease: The ESPRIT study (2010) (0)
- Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimer’s disease and related conditions (2012) (0)
- P3-097: Prediction of progressive mild cognitive impairment using cerebrospinal fluid biomarkers: Results from the Gothenburg mild cognitive impairment study (2008) (0)
- INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN IL1RAP AND ALZHEIMER’S-RELATED CSF-BIOMARKERS (2017) (0)
- Mass spectrometric measurement of six site‐specific tau phosphorylations in CSF and blood of Alzheimer's disease patients (2021) (0)
- Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer’s Disease and Other Neurodegenerative Disorders (2016) (0)
- P.2.d.038 Cerebrospinal fluid cytokine concentrations in bipolar disorder patients and healthy controls (2013) (0)
- Cerebrospinal fluid neurogranin concentrations in Alzheimer’s disease and major depressive disorder (2017) (0)
- APOE and immunity: Research highlights. (2023) (0)
- Exploring biomarkers for neurodegenerative processes in the cerebrospinal fluid from bipolar patients (2012) (0)
- Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest (2023) (0)
- IMMUNOHISTOCHEMICAL PROFILING OF PRIMARY TAUOPATHIES (2019) (0)
- Levels of amyloid β in cerebrospinal fluid predicts cognition five years later: A population‐based study of 70‐year‐olds (2020) (0)
- Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults (2021) (0)
- Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease (2020) (0)
- Endo‐lysosomal protein concentrations in CSF from patients with frontotemporal dementia caused by CHMP2B mutation (2023) (0)
- Multimodal genome‐wide meta‐analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures (2020) (0)
- Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routine‐use protocol for CSF collection (2020) (0)
- Examining four blood biomarkers for the detection of acute intracranial abnormalities following mild traumatic brain injury in older adults (2022) (0)
- Combined Effects of Synaptic and Axonal Integrity on Longitudinal Gray Matter Atrophy in Cognitively Unimpaired Adults (2022) (0)
- Patients With Mild Cognitive Impairment CSF Biomarkers and Incipient Alzheimer Disease in Supplementary material (2009) (0)
- Higher CSF Ab38 levels protect against cognitive decline in high‐functioning individuals (2022) (0)
- Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in CSF by Mass Spectrometry Provides New Biomarker Candidates (2017) (0)
- Blood-based molecular biomarkers for Alzheimer’s disease (2019) (0)
- Fluid Biomarkers and Diagnostics (2016) (0)
- Author response: Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy (2021) (0)
- Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. (2023) (0)
- DNA methylation differences associated with peripheral biomarkers in the EMIF‐AD cohort (2020) (0)
- A POPULATION-BASED STUDY ON THE RELATION BETWEEN SLEEP DISTURBANCE AND BETA-AMYLOID 42 IN CEREBROSPINAL FLUID IN 70-YEAR-OLDS (2016) (0)
- Plasma tau-protein analysis after resuscitation from cardiac arrest and hypothermia treatment : a pilot study (2010) (0)
- Polygenic determinants of White Matter Hyperintensities and sex‐specific genetic profiles in the Alzheimer’s continuum (2022) (0)
- Novel CSF biomarkers associated with rates of brain atrophy in Alzheimer's disease (2013) (0)
- White matter microstructure and cerebrospinal fluid biomarkers of Alzheimer’s disease in middle‐aged cognitively unimpaired participants (the ALFA study) (2020) (0)
- P4-344 Cholinesterase inhibitor treatment affects acetylcholinesterase activity in CSF (2006) (0)
- Genome‐wide association study on Alzheimer’s disease CSF profiles in the EMIF‐AD MBD and ADNI datasets (2022) (0)
- Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration? (2020) (0)
- The recency ratio assessed by story recall is associated with cerebrospinal fluid levels of neurodegeneration biomarkers (2022) (0)
- PHOSPHO-TAU 181 IN PLASMA AND SERUM IS INCREASED IN ALZHEIMER’S DISEASE PATIENTS COMPARED WITH NON-AD CONTROLS (2019) (0)
- AMYLOID-β42 (Aβ42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID-POSITIVE VERSUS AMYLOID-NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK FOR AD POPULATION (2017) (0)
- Brain energy metabolism is optimized to minimize the cost of enzyme synthesis and transport (2022) (0)
- A b 40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer ’ s Disease (2011) (0)
- PLASMA NEUROFILAMENT LIGHT CONCENTRATION PREDICTS LONG-TERM OUTCOME IN ACUTE STROKE (2016) (0)
- Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum (2020) (0)
- Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies (2023) (0)
- Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals (2022) (0)
- Inflammatory biomarkers are associated with changes in cerebral large artery thickness and lumen diameter in older adults (2022) (0)
- Strong evidence that professional boxing leads to chronic brain damage (2005) (0)
- Neurofilament light concentrations in serum following experimental rotational traumatic brain injury in rats (2017) (0)
- PATTERNS OF [C-11]PIB AMYLOID BURDEN THAT ARE ASSOCIATED WITH CEREBROSPINAL FLUID AD BIOMARKERS IN PEOPLE AT RISK FOR ALZHEIMER'S DISEASE: FINDINGS FROM THE WRAP STUDY (2014) (0)
- Aβ1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases (2012) (0)
- 2348. Distinct cerebrospinal fluid immune proteins mark neurosyphilis (2022) (0)
- Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes. (2023) (0)
- Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings (2020) (0)
- FROM BLOOD-BASED REDOX PROFILE TO THE IDENTIFICATION OF A LEAD BIOMARKER FOR THE TIMELY DIAGNOSIS OF ALZHEIMER’S DISEASE (2018) (0)
- P1-344 POOR SLEEP QUALITY IS ASSOCIATEDWITH CSF MARKERS OFAMYLOID DEPOSITION IN COGNITIVELY HEALTHYADULTS AT RISK FOR ALZHEIMER’S DISEASE (2019) (0)
- Cerebrospinal Fluid and Serum Concentrations of Insulin, Leptin, and Agouti-Related Protein in Relation to Weight Change after Pregnancy- A Follow-up Study (2018) (0)
- 0282 WHITE MATTER DAMAGE AND AXONAL DEGENERATION ARE RELATED TO HYPOXIA IN UNTREATED OBSTRUCTIVE SLEEP APNEA (2017) (0)
- SERUM FERRITIN IS INCREASED IN A SUBSET OF PATIENTS WITH FRONTOTEMPORAL DEMENTIA (2017) (0)
- EFFECTS OF APOE E4 IN PRODROMAL ALZHEIMER’S DISEASE (2017) (0)
- Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry (2016) (0)
- The accuracy and robustness of plasma biomarker models for amyloid PET positivity (2022) (0)
- CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD (2021) (0)
- PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS (2016) (0)
- BIOMARKER-GUIDED STRATIFICATION APPROACH OF THE CLINICAL CONTINUUM OF ALZHEIMER’S DISEASE USING UNSUPERVISED CLUSTERING METHODS (2019) (0)
- Apolipoprotein ε genotype modifies the association between blood‐brain barrier permeability and both grey and white matter integrity in older adults (2021) (0)
- Tetramodal Chemical Imaging Delineates the Lipid–Amyloid Peptide Interplay at Single Plaques in Transgenic Alzheimer’s Disease Models (2023) (0)
- Age-related differences in the functional topography of the locus coeruleus: implications for cognitive and affective functions (2023) (0)
- No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach (2021) (0)
- Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community‐based population of 70‐year‐olds (2021) (0)
- Longitudinal changes in plasma p‐tau181 as a surrogate variable to populational interventions (2022) (0)
- Head‐to‐Head Comparison of Four Plasma Phospho‐Tau Immunoassays in the Neuropathological Diagnosis of Alzheimer’s Disease (2022) (0)
- Selective association of neurogranin gene expression with amyloid and tau pathology in the parahippocampal gyrus in Alzheimer’s disease (2020) (0)
- P.2.d.023 Associations between cerebrospinal fluid markers and on-going medical treatment in patients with bipolar disorder (2013) (0)
- Longitudinal reduction in blood pressure in hypertensive individuals is associated with increased levels of biomarkers for Alzheimer's disease (2012) (0)
- Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE4 carriers (2015) (0)
- Tau as a fluid biomarker of concussion and neurodegeneration (2022) (0)
- Assessing the significance of insulin resistance on cerebrospinal fluid Alzheimer's disease biomarkers and memory function in people at risk for Alzheimer’s disease: Findings from the wisconsin adrc impact cohort (2015) (0)
- Tau protein profiling across brain of different tauopathies using high‐resolution mass spectrometry: quantification of isoforms and phosphorylations (2022) (0)
- White matter lesions but not lacunes are associated with the CSF levels of Aβ38 and Aβ40, and to a lesser degree with CSF Aβ42 (2015) (0)
- Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife (2020) (0)
- Brain Communications The influence of the R47H TREM2 variant on microglial exosome profiles Running title: TREM2 variant microglial exosomes (2021) (0)
- Baseline cerebrospinal fluid biomarkers of amyloidosis, phosphorylated tau, and total tau relate to greater longitudinal atrophy in regions susceptible to Alzheimer’s disease‐related neurodegeneration (2020) (0)
- Biomarkers of brain injury in patients with stress-related exhaustion: A longitudinal study (2022) (0)
- Associations between obstructive sleep apnea, Alzheimer’s disease pathology, and objective daytime sleepiness measured by the psychomotor vigilance task in cognitively unimpaired adults (2021) (0)
- Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant 1 carriers 2 (2019) (0)
- Mutations in the juxtamembrane segment of the cholesterol-binding site of APP alter its processing and promotes production of shorter, less toxic Aβ peptides (2020) (0)
- Brain TSPO expression is associated with plasma pTau181 & pTau231 across the AD spectrum (2022) (0)
- Special issue on blood biomarkers in neurology (2022) (0)
- The Lancet Neurology Amyloid and FDG-PET in the diagnostic work-up of Alzheimer’s disease and other dementias (2020) (0)
- O-005. Circulating biomarkers for neurological complications in preeclampsia (2021) (0)
- Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease (2023) (0)
- N-TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH IN-HOUSE CLEAVAGE-SPECIFIC ANTIBODY (2017) (0)
- O-53 Transcranial Doppler microembolic signals and serum S100β during transcatheter aortic valve implantation (2011) (0)
- No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial (2019) (0)
- Synaptic dysfunction reflected in CSF: serial CSF sampling reveals trajectories of potential synaptic biomarkers in early AD stages (2022) (0)
- Does neuroinflammation impact on amyloid beta pathways? Evidences from a consecutive series of encephalitis (2021) (0)
- Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease (2019) (0)
- NEUROGRANIN: A SPECIFIC SYNAPTIC BIOMARKER FOR AMNESTIC ALZHEIMER’S DISEASE? (2016) (0)
- Comparison of the prognostic value of cerebrospinal fluid and plasma neurofilament light in predicting longitudinal decline in white matter integrity among older adults (2021) (0)
- Title ( 82 / 100 characters ) : Neurogranin as cerebrospinal fluid biomarker for dementia-assay comparison study (2018) (0)
- DT-02-04 DETECTING BRAIN AMYLOID STATUS USING FULLYAUTOMATED PLASMA Ab BIOMARKER ASSAYS (2018) (0)
- Circulating Aβ40 influences plasma BDNF levels and white matter integrity (2012) (0)
- The ‘CSF Alzheimer’s profile’: Easily said, but what do we mean? (2013) (0)
- ACUTE, TRANSIENT INCREASE IN SECRETION OF NEURODEGENERATION BIOMARKERS AFTER IRRADIATION OF HUMAN CORTICAL NEURONS (2017) (0)
- P3-082: Multiplex analysis of Alzheimer-associated amyloid-β isoforms in cerebrospinal fluid - diagnostic performance in a case-control setting (2008) (0)
- Microglial-derived proteins in CSF are candidate biomarkers for early diagnosis of Alzheimer’s disease (2015) (0)
- Plasma biomarkers associations with cognitive change in preclinical Alzheimer’s disease (2022) (0)
- The relationship of cerebral perfusion with age and CSF measures in middle-aged adults at risk for Alzheimer's disease (2013) (0)
- PLASMA AMYLOID-BETA AND TAU AND VISUAL CONTRAST SENSITIVITY SYNERGISTICALLY PREDICT CEREBRAL AMYLOID AND TAU DEPOSITION ON PET IN PRECLINICAL AND PRODROMAL AD (2019) (0)
- P2-220: Patients with dementia with Lewy bodies have increased calcium and magnesium levels in CSF (2008) (0)
- Cerebral biomarkers in neurologic complications of preeclampsia (2022) (0)
- EFFECTS OF THE EPIGENETIC BET-INHIBITOR SMALL MOLECULE APABETALONE ON COGNITION IN PATIENTS WITH DIABETES AND CARDIOVASCULAR DISEASE (2019) (0)
- Parkinson’s disease with restless legs syndrome—an in vivo corneal confocal microscopy study (2021) (0)
- DISTINCT Aβ PRODUCTION IN STEM CELL-DERIVED CORTICAL NEURONS FROM PATIENTS WITH FAD MUTATION (2017) (0)
- NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD (2018) (0)
- P.2.d.042 Identification and semi-quantification of potential biomarkers for bipolar disorder with a novel mass spectrometric methodology (2014) (0)
- Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinson’s disease (2021) (0)
- Amyloid status is associated with deficits in connected speech language (2021) (0)
- Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus (2021) (0)
- Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit (2023) (0)
- VALIDATING PLASMA NEUROFILAMENT LIGHT AS A BLOOD BIOMARKER FOR NEURODEGENERATION USING NEUROIMAGING (2017) (0)
- A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX Aβ PEPTIDES IN HUMAN CEREBROSPINAL FLUID (2019) (0)
- CEREBROSPINAL FLUID BIOMARKERS OF NEURONAL INJURY IN CHRONIC TRAUMATIC BRAIN INJURY (2016) (0)
- Amyloid‐β, tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer’s continuum (2020) (0)
- The App NL‐F mouse model of Alzheimer’s Disease demonstrates reduced serum Aß42 levels and Aß42/Aß40 ratio, changes that correlate with CSF Aß levels and cerebral Aß42 plaque load (2022) (0)
- Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias (2022) (0)
- Alzheimer’s disease in primary care: new tools for improved and simplified diagnostics (2021) (0)
- Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE ε4 carriers (2015) (0)
- Effect of APOE4 on Plasma Phospho‐tau 217 and Neurofilament Light in the PSEN1 E280A Autosomal Dominant Alzheimer’s Disease Colombian Kindred (2022) (0)
- LIFETIME RECREATIONAL PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC ADULTS (2016) (0)
- sAPP-α and sApp-β levels in Alzheimer's disease, Lewy body and Parkinson's disease dementia patients and their correlation with clinical diagnosis (2011) (0)
- Concordance of Alzheimer’s Disease-Related Biomarkers Between Intraventricular and Lumbar Cerebrospinal Fluid in Idiopathic Normal Pressure Hydrocephalus (2022) (0)
- Exploring semantic verbal fluency patterns and their relationship to age and Alzheimer's disease in adults with Down syndrome. (2023) (0)
- LAMP-2 changes Aβ generation, uptake, and degradation (2015) (0)
- Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits. (2022) (0)
- Neurofilament Light and Tau in the Aftermath of Human Repetitive Concussive Traumatic Brain Injury (S49.002) (2018) (0)
- HIGH RESOLUTION MASS SPECTROMETRY PARALLEL REACTION MONITORING MULTIPLEX ASSAYS OF HUMAN CSF PROTEINS USING MINIMUM SAMPLE PREPARATION (2014) (0)
- Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer’s disease (2021) (0)
- Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2020) (0)
- Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders (2023) (0)
- Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau (2023) (0)
- The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease (2022) (0)
- Cerebrospinal fluid proteomic study of two bipolar disorder cohorts (2022) (0)
- Reduction of neurogranin immunostaining in the hippocampus of post‐mortem brain of Alzheimer’s disease (2020) (0)
- Tau is a microtubule-binding axonal protein that promotes microtubule assembly and stability [4]. Abnormal phosphorylation and truncation of tau may lead to disassembly of microtubules and impaired axonal transport with compromised neuronal function and tau aggregation into paired helical filaments (2017) (0)
- Axonal Injury Partially Mediates Associations Between Increased Left Ventricular Mass Index and White Matter Damage (2021) (0)
- Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics. (2022) (0)
- Neuropathology-based APOE genetic risk score better quantifies Alzheimer's risk (2022) (0)
- Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease (2019) (0)
- O5-04-05 A NEW THERAPEUTIC STRATEGY FOR TAUOPATHIES: DISCOVERY OF HIGHLY POTENT BRAIN PENETRANT PROTAC DEGRADER MOLECULES THAT TARGET PATHOLOGIC TAU PROTEIN SPECIES (2019) (0)
- COMPARISON OF CEREBROSPINAL FLUID NEUROFILAMENT LIGHT CHAIN PROTEIN AND THREE MRI-BASED MORPHOMETRIC ESTIMATES FOR DEFINING NEURODEGENERATION (N) ACROSS THE ALZHEIMER’S DISEASE CONTINUUM (2019) (0)
- Insulin resistance is related to cognitive decline but not biomarkers of Alzheimer’s pathology in adults without dementia (2020) (0)
- Brain TSPO expression is associated with plasma pTau181 & pTau231 across the AD spectrum (2022) (0)
- Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations (2017) (0)
- A Population Study of Cognitively Healthy Individuals: The Associations between Cerebrospinal Fluid Biomarkers and MRI Brain Changes of Alzheimer's Disease (2023) (0)
- Becoming physically active or maintaining physical activity during midlife is associated with biomarkers of amyloid‐beta, microglia, and temporal lobe integrity (2022) (0)
- Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease (2022) (0)
- PLASMA NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH THE KYNURENINE PATHWAY METABOLITES (2019) (0)
- 1 Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease (2020) (0)
- Synergistic effects of CSF Aβ42 and p‐Tau on functional resting‐state connectivity in cognitively unimpaired individuals (2021) (0)
- P3-076: CSF Tau levels and APOEϵ4 carriership predict the progression of mild cognitive impairment to Alzheimer's disease (2008) (0)
- Amyloid precipitation in biofluids using a structure-specific chemical antibody (2020) (0)
- CSF Proteome Changes Depend on APOE Genotype in Prodromal AD (2022) (0)
- Biomarkers in dementia (2019) (0)
- The Importance Of Measuring Cerebrospinal Fluid Biomarkers In Cardiac Arrest Survivors (P1.101) (2014) (0)
- The certification of Amyloid β 1-42 in CSF in ERM ®-DA 480 / IFCC , ERM ®-DA 481 / IFCC and ERM ®-DA 482 / IFCC (2017) (0)
- Plasma metabolomics of presymptomatic PSEN1-H163Y mutation carriers: A pilot study (2020) (0)
- APOE ε4 gene dose effect on imaging and blood biomarkers of glial reactivity and β-amyloid pathology (2022) (0)
- Repeated lumbar punctures within 3 days may affect CSF biomarker levels (2019) (0)
- INTERACTIVE EFFECT OF CSF ABETA42 AND P-TAU ON HIPPOCAMPAL SUBFIELD VOLUMETRY IN COGNITIVELY UNIMPAIRED SUBJECTS (2019) (0)
- Author Correction: Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons (2020) (0)
- Multiomics machine learning identifies sleep and inflammation molecular pathways in prodromal Alzheimer's Disease (2023) (0)
- NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER’S DISEASE AND TAUOPATHIES (2017) (0)
- Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis (2019) (0)
- The CSF levels of Aβ42, but not tau, are fully changed already 5-10 years before onset of Alzheimer's dementia (2011) (0)
- APOE‐ε4 shapes temporo‐parietal network properties in middle‐aged, cognitively unimpaired individuals: A graph theory analysis (2020) (0)
- A-4 Amyloid Status Modifies the Association between Subjective Cognitive Decline and Brain MRI Metrics (2021) (0)
- DIFFERENCES IN PSYCHIATRIC AND SOMATIC DIAGNOSES BETWEEN THE TaqI A1/A2 DRD2 GENOTYPES IN ALCOHOL-DEPENDENT SUBJECTS. (2004) (0)
- Dementia and neurodegeneration : Challenges and opportunities Fundamental research : From molecules to neural circuitry (2013) (0)
- Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease (2020) (0)
- Two year cognitive and biomarker change in a racially diverse, middle‐aged, cohort at risk for Alzheimer’s disease (2022) (0)
- CHARACTERIZATION OF THE POSTSYNAPTIC PROTEIN NEUROGRANIN IN DIFFERENT BRAIN REGIONS IN PATIENTS WITH FAMILIAL ALZHEIMER’S DISEASE, ALZHEIMER'S DISEASE, PATHOLOGICAL AGING AND HEALTHY CONTROLS (2016) (0)
- CROSS-TALK BETWEEN WNT SIGNALLING AND AMYLOID PRECURSOR PROTEIN IN NEURONS (2018) (0)
- α‐Synuclein in Neurodegeneration—A Good Protein that may go Bad (2016) (0)
- The zebrafish brain proteome project (2009) (0)
- REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLE-AGED ADULTS (2017) (0)
- Long-term effect of phenserine treatment in Alzheimer patients as assessed by PET and CSF biomarkers (2009) (0)
- Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers (2021) (0)
- LONGITUDINAL ASSOCIATIONS OF PLASMA NEUROFILAMENT LEVELS WITH AMYLOID-PET, FDG-PET, AND COGNITION AMONG NON-DEMENTED PARTICIPANTS IN THE MAYO CLINIC STUDY ON AGING (2018) (0)
- Identification of an important potential confound in CSF Alzheimer's disease studies: Aliquot volume (2013) (0)
- The Mechanism of Antioxidant Actions by NSAIDs/ASA in Cultured Human Lens Epithelial Cells (2005) (0)
- Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. (2023) (0)
- UNBIASED BIOMARKER-BASED CATEGORIZATION OF A MULTICENTER COHORT OF ADD, MCI AND FTD PATIENTS (2017) (0)
- Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease (2023) (0)
- Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders. (2023) (0)
- INSULIN RESISTANCE AND CENTRAL OBESITY IN APOE4 CARRIERS ARE ASSOCIATED WITH INCREASES IN CEREBRAL SPINAL FLUID PHOSPHORYLATED TAU (2014) (0)
- Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission (2020) (0)
- Validation of an electrochemiluminescent-based assay for α-Synuclein detection in cerebrospinal fluid (2017) (0)
- Chronic Traumatic Encephalopathy (2015) (0)
- Investigating changes in fluid biomarkers in early Alzheimer’s disease: design of plasma biomarker analyses and a cerebrospinal fluid sub‐study in the evoke and evoke+ trials of semaglutide versus placebo (2022) (0)
- Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease. (2023) (0)
- ALTERATIONS IN ALZHEIMER-ASSOCIATED SYNAPTIC MARKERS FOLLOWING IRRADIATION OF STEM CELL-DERIVED CORTICAL NEURONS (2018) (0)
- Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease (2021) (0)
- CEREBROSPINAL FLUID Aβ42 ANALYZED AS PART OF CLINICAL ROUTINE CAN ACCURATELY DISTINGUISH AMYLOID-POSITIVE FROM AMYLOID-NEGATIVE INDIVIDUALS (2014) (0)
- A EUROPEAN BIOBANK FOR THE VALIDATION OF NEW MARKERS FOR ALZHEIMER'S AND PARKINSON’S DISEASE: THE BIOMARKAPD PROJECT (2014) (0)
- FP-CIT SPECT and neuropathologic findings amongpatients with neurodegenerative syndromes from the Mayo Alzheimer’s Disease (2019) (0)
- Development of ultra-sensitive assay for detection of aggregated beta amyloid in human CSF (2011) (0)
- A novel antibody‐free mass spectrometry panel of CSF biomarkers for synaptic dysfunction (2021) (0)
- Air pollution has a more deleterious effect on Alzheimer’s disease biomarkers in genetic predisposition to larger hippocampal volumes (2022) (0)
- Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons (2020) (0)
- Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy (2018) (0)
- Amyloid aggregation in temporal regions is associated with longitudinal memory decline in cognitively unimpaired Apoe‐ε4 carriers (2021) (0)
- ALCOHOLISM: TRANSCRIPTIONAL/EPIGENETIC ADAPTATIONS IN ANIMAL AND HUMAN BRAIN (2011) (0)
- Featured Article Round robin test on quantification of amyloid-b 1-42 in cerebrospinal fluid by mass spectrometry (2016) (0)
- ARE PLASMA AMYLOID-β LEVELS IN LATE-LIFE MAJOR DEPRESSION A MARKER OF HEIGHTENED AD RISK? (2019) (0)
- Inflammatory biomarkers are associated with cerebral large artery thickening and dilatation in older adults (2021) (0)
- Association of Retinal Nerve Fiber Layer Thickness with Plasma pTau181 and Aβ42/Aβ40 ratio (2022) (0)
- CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer’s disease patients from the SPARC clinical trial (2022) (0)
- Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls (2015) (0)
- Metabolic and muscle-derived serum biomarkers define CHCHD10-linked late-onset spinal muscular atrophy (2021) (0)
- F05 Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis (2021) (0)
- DISSECTION OF SYNAPTIC PATHWAYS THROUGH THE ANALYSIS OF BIOMARKERS IN THE CSF: A COMBINING TOOL FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (2018) (0)
- 1 Title : Time course and diagnostic utility of NfL , tau , GFAP , and UCH-L 1 in subacute and chronic TBI (2020) (0)
- Blood‐brain barrier permeability measured by 7α‐hydroxy‐3‐oxo‐4‐cholestenoic acid in CSF associates with Alzheimer’s pathology biomarkers in cerebrospinal fluid (2020) (0)
- Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients (2021) (0)
- Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
- The Alzheimer's association global quality control program for CSF biomarkers (2010) (0)
- Microglial activation indexed by [11C]PBR28 is associated with synaptic depletion in the Alzheimer’s disease spectrum (2020) (0)
- Effect of spinal manometers on CSF amyloid beta concentration (2017) (0)
- Author ' s response to reviews Title : Cerebrospinal fluid CXCL 13 in Lyme neuroborreliosis and asymptomatic HIV infection (2012) (0)
- PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR AB1-42 (2016) (0)
- The iterative process of fluid biomarker development and validation in Alzheimer's disease (2022) (0)
- REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLE-AGED ADULTS (2017) (0)
- Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2023) (0)
- Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation. (2022) (0)
- Score predicts cognitive and neuroimaging progression in mild cognitive impairment stage of Alzheimer ' s disease (2019) (0)
- Using florbetapir F18 PET to validate CSF cut-points and increase diagnostic certainty in atypical dementias (2015) (0)
- Molar DNA in Maternal Serum in a Case of 46,XY Heterozygous Complete Hydatidiform Mole Coexisting with a 46,XX Twin Live Fetus To the Editor: Cell-free fetal DNA in maternal cir- (2005) (0)
- Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus (2016) (0)
- CEREBROSPINAL FLUID MICROGLIAL MARKERS IN ALZHEIMER'S DISEASE, MCI, AND ASYMPTOMATIC ADULTS (2014) (0)
- Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer’s disease (2015) (0)
- MODELLING AMYLOID BETA PROFILES IN IPSC-DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER’S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE (2018) (0)
- Polygenic risk score for Alzheimer’s disease and APOE ε4 status in relation to cognitive decline: a population‐based study of individuals followed over 16 years. (2022) (0)
- ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER’S DISEASE (2019) (0)
- Data‐driven approach for early detection of pathological pathways in middle‐aged adults with family history of sporadic Alzheimer’s disease (2021) (0)
- Relationship between platelet derived growth factor receptor‐β and Alzheimer’s biomarkers in a racially diverse, high‐risk cohort (2021) (0)
- ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER’S DISEASE (2019) (0)
- Amyloid precursor like protein 1 in Idiopathic Normal Pressure hydrocephalus; expanding the knowledge of an altered amyloid metabolism (2015) (0)
- An extensive plasmid library for preparing tau variants and studying their functional biochemistry (2020) (0)
- Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching β‐amyloid biomarkers (2021) (0)
- PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY (2018) (0)
- Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease (2019) (0)
- Lovestone S, Rochester L. Gait in Mild Alzheimer’s Disease: Feasibility of Multi- Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot (2018) (0)
- TREM2 is downregulated by HSV1 in microglia and involved in antiviral defense in the brain (2023) (0)
- Contents Vol. 19, 2005 (2005) (0)
- Cerebrospinal fluid biomarker standardization efforts (2012) (0)
- VERBAL EPISODIC MEMORY IS PREFERENTIALLY RELATED TO WHITE MATTER INTEGRITY IN COGNITIVELY NORMAL OLDER ADULTS: THE VANDERBILT MEMORY & AGING PROJECT (2018) (0)
- Gut microbe‐modulated metabolites are longitudinally associated with higher neurodegeneration biomarkers in cerebrospinal fluid (CSF) (2022) (0)
- RELATIONSHIPS BETWEEN P-TAU AND CHANGES IN MYELIN CONTENT AND COGNITIVE PERFORMANCE (2019) (0)
- ABCA1 ACTIVATION BY CS6253 AS A THERAPEUTIC FOR APOE4-ASSOCIATED ALZHEIMER’S DISEASE (2019) (0)
- Brain structural alterations in cognitively unimpaired individuals with discordant amyloid‐β PET and CSF Aβ42 status: Findings using machine learning (2021) (0)
- Could the parvopyramidal layer hold clues to protecting neurons from degeneration (2015) (0)
- Characterization of the postsynaptic protein neurogranin in brain tissue of Alzheimer's disease patients and healthy controls (2015) (0)
- Stress in relation to biomarkers of Alzheimer’s disease Title: Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study Running head: Stress in relation to biomarkers of Alzheimer’s disease (2018) (0)
- THE PROTEIN-TO-PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULE-ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER (2018) (0)
- Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. (2023) (0)
- The influence of the R47H triggering receptor expressed on myeloid cells 2 variant on microglial exosome profiles (2021) (0)
- D08 Neurofilament light protein in blood as a potential biomarker of neurodegeneration in hungtington’s disease: a retrospective cohort analysis (2018) (0)
- CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO β-AMYLOID POSITIVITY (2019) (0)
- Premature neuronal differentiation in familial Alzheimer’s disease human stem cells in vitro and in postmortem brain tissue (2020) (0)
- DIFFERENT CSF TOTAL AND PHOSPHORYLATED TAU, BUT NOT Aβ, IN OLDER AND YOUNGER AFRICAN AMERICANS AND WHITES (2019) (0)
- EVIDENCE FOR EARLY DETECTION OF CSF BETA-AMYLOID AND TAU AND EFFECT ON LONGITUDINAL COGNITIVE PERFORMANCE IN INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE (2017) (0)
- IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION (2017) (0)
- EFFECT OF PHYSICAL EXERCISE ON MARKERS OF NEURONAL DYSFUNCTION IN CEREBROSPINAL FLUID IN PATIENTS WITH ALZHEIMER’S DISEASE (2017) (0)
- CSF and blood biomarkers: How strongly do they reflect Alzheimer's pathophysiology and are they dynamic? (2021) (0)
- CSF sphingomyelin metabolites in Alzheimer's disease, neurodegeneration, and neuroinflammation (2022) (0)
- CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer’s disease (2020) (0)
- Biomarkers for Acute Brain Injury in Cord Blood [23E] (2018) (0)
- CHANGES IN AGE-RELATED AND NEURODEGENERATION HUMAN BLOOD FACTORS THROUGHOUT AGEING: FROM UMBILICAL CORD TO ELDERLY (2019) (0)
- Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum (2020) (0)
- Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study (2020) (0)
- The effects of gene mutations on the cerebrospinal fluid levels of soluble amyloid precursor proteins in familial Alzheimer's disease (2013) (0)
- LATENT PROFILES DERIVED FROM ATN RELATED CSF BIOMARKERS (2018) (0)
- ANALYSIS OF NEW POTENTIAL CSF BIOMARKERS FOR ALZHEIMER’S DISEASE BY PARALLEL REACTION MONITORING MASS SPECTROMETRY (2017) (0)
- Title: Cerebrospinal Fluid Interferon alpha Levels Correlate with Neurocognitive Impairment in Ambulatory HIV-infected Individuals (2017) (0)
- Changes in cerebrospinal fluid insulin during non-neurological surgery (2009) (0)
- Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes. (2023) (0)
- The role of neurofilament light in genetic frontotemporal lobar degeneration (2022) (0)
- Biomarkers for Concussion: The Need and the Prospects for the Near Future (2019) (0)
- Author Correction: A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease (2021) (0)
- Glymphatic clearance estimated using diffusion tensor imaging along perivascular spaces (DTI-ALPS) is reduced after traumatic brain injury and correlates with plasma neurofilament light, a biomarker of injury severity (2023) (0)
- Discovery of Alzheimer's disease biomarkers associated with inflammation using a novel validated cytokine screening panel (2013) (0)
- The Nairobi Declaration—Reducing the burden of dementia in low‐ and middle‐income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs (2023) (0)
- Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression (2019) (0)
- CSF MARKERS OF NEURODEGENERATION ARE ASSOCIATED WITH QUANTITATIVE T1 (2019) (0)
- A new member in the biomarker discovery toolbox. (2011) (0)
- Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays (2020) (0)
- Subject Index Vol. 20, 2005 (2005) (0)
- [Exercise and weight loss does not reduce cardiovascular risk in type 2 diabetes]. (2014) (0)
- PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER’S DISEASE: AN OBSERVATIONAL STUDY (2017) (0)
- Author response: Calcium supplementation and risk of dementia in women with cerebrovascular disease (2017) (0)
- CENTILOID CUT-OFF VALUES FOR OPTIMAL AGREEMENT BETWEEN AMYLOID PET AND CSF CORE AD BIOMARKERS (2019) (0)
- Associations between diffusion MRI microstructure and cerebrospinal fluid markers of Alzheimer's disease pathology and neurodegeneration along the Alzheimer's disease continuum (2022) (0)
- DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION (2017) (0)
- Incidence of subjective cognitive decline is associated with amyloid‐β pathology, whereas stability relates to neurodegeneration (2020) (0)
- SECRETION OF ABETA, SAPP, AND TAU DURING DEVELOPMENT OF CORTICAL NEURONS (2014) (0)
- Molecules of senescent glial cells differentiate Alzheimer’s disease from ageing (2023) (0)
- Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia (2022) (0)
- Editorial: Blood Biomarkers of Neurodegenerative Diseases (2022) (0)
- CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE (2017) (0)
- Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimer’s disease (2020) (0)
- Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome. (2023) (0)
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease implicates mediation through GPX3 (2022) (0)
- Neurocognitive Impairment of HIV Elite Controllers: Feature of Viral Suppression and Inflammation? (S53.004) (2016) (0)
- Neuroinflammation in preclinical Alzheimer’s disease is associated with parahippocampal pathology and memory deficits (2015) (0)
- RELATIONSHIP BETWEEN ALZHEIMER’S DISEASE BIOMARKERS AND CHANGE IN MYELIN AMONG COGNITIVELY UNIMPAIRED ADULTS (2018) (0)
- TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/Aβ PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP (2017) (0)
- Neuroimaging Intracranial arterial four-dimensional flow is associated with metrics of brain health and Alzheimer's disease (2015) (0)
- IC‐P‐087: WITHDRAWN (2018) (0)
- PYROGLUTAMATION OF AβX-42 AND Aβ1-40 DEPOSITION UNDERLIE AMYLOID PLAQUE POLYMORPHISM IN PROGRESSING ALZHEIMER’S DISEASE PATHOLOGY (2019) (0)
- Increased cerebrospinal fluid amyloid β levels in Niemann-Pick disease patients: Implications for Alzheimer's disease (2010) (0)
- Moderate-to-high intensity physical training does not alter cerebrospinal amyloid-β1-42 levels in patients with Alzheimer’s disease (2015) (0)
- A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging (2022) (0)
- Concordance of CSF AD biomarkers between intraventricular and lumbar CSF in iNPH (2022) (0)
- CSF biomarkers and blood pressure trajectories in normotensive individuals and subjects with controlled and uncontrolled hypertension (2021) (0)
- Diagnostic tools: Fluid biomarkers for Alzheimer's disease (2012) (0)
- PSYCHOLOGICAL STRESS IN MIDLIFE ASSOCIATED WITH HIGHER LEVELS OF CSF T-TAU AND AB40 IN LATE-LIFE: A 25-YEAR LONGITUDINAL POPULATION STUDY OF WOMEN (2016) (0)
- Modifying effect of AD pathology in the association between CSF synaptic biomarkers and brain function and structure in preclinical Alzheimer (2022) (0)
- Pathological differences observed in the presubiculum and entorhinal cortex in post-mortem Alzheimer's disease brain tissue (2016) (0)
- SEX-SPECIFIC ASSOCIATIONS OF CEREBROSPINAL FLUID TAU AND NEUROGRANIN CONCENTRATIONS WITH ALZHEIMER’S NEUROIMAGING SIGNATURES (2019) (0)
- No support for premature CNS aging in HIV when measured by cerebrospinal fluid hyperphosphorylated tau (p-tau) (2017) (0)
- The effects of different familial Alzheimer’s disease mutations on APP processing in vivo (2017) (0)
- A role for inflammaging in α‐synuclein‐associated breakdown of local sleep in the elderly (2021) (0)
- FOUR-DIMENSIONAL ARTERIAL BLOOD FLOW METRICS IN THE INTERNAL CAROTID ARTERY PREDICT COGNITIVE PERFORMANCE AND ARE ASSOCIATED WITH CSF BIOMARKERS IN PATIENTS WITH MCI (2016) (0)
- INTERNATIONAL ROUND ROBIN ON SRM TRIPLE QUAD MASS SPECTROMETRIC ANALYSIS OF Aβ42 IN CEREBROSPINAL FLUID (2014) (0)
- Aβ40 and Aβ42 levels in plasma: Comparison of enzyme-linked immunosorbent assay (ELISA) with multiplex technology (2015) (0)
- Plasma‐based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease (2020) (0)
- Subject Index Vol. 6, 2009 (2010) (0)
- Higher CSF/serum free-T4 ratio is associated with improvement of quality of life during treatment with L-thyroxine. (2023) (0)
- Amyloid precursor protein localises to ependymal cilia in vertebrates and is required for ciliogenesis and brain development in zebrafish (2021) (0)
- P2-273 CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OFAGING (2018) (0)
- A-8 Sex Modifies the Association between CSF Neurogranin and Cognitive Decline in Older Adults (2021) (0)
- ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LC-MS-MS REFERENCE METHOD (2018) (0)
- P2-160 Csf Aβ and tau levels in Alzheimer’s disease and mild cognitive impairment (2006) (0)
- Prevalence and Characteristics Associated With Post–COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults (2023) (0)
- The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology (2017) (0)
- COMBINED ADDED VALUE OF CEREBROSPINAL FLUID NEUROGRANIN AND NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE DIAGNOSIS AND CLASSIFICATION OF PRODROMAL AND ALZHEIMER’S DISEASE DEMENTIA (2016) (0)
- Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome (2023) (0)
- USE FOR CALIBRATION OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42 (2017) (0)
- Human iPSC-derived endothelial cells can develop in to brain-like endothelial cells after coculture with primary human brain cells (2017) (0)
- Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid (2023) (0)
- Erratum: Gait in mild Alzheimer's disease: Feasibility of multi-center measurement in the clinic and home with body-worn sensors: A pilot study (Journal of Alzheimer's Disease (2018) 63:1 (331-341) DOI: 10.3233/JAD-171116) (2018) (0)
- Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s disease (2021) (0)
- Huntington Study Group Abstracts 2020 (2020) (0)
- Cerebrospinal Fluid Neurofilament Levels in Neuropathological Subtypes of Frontotemporal Dementia - a Pilot Study (2012) (0)
- ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER’S DISEASE (2019) (0)
- P.621 Exploring the cerebrospinal fluid proteome in bipolar disorder (2019) (0)
- Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling (2021) (0)
- Impact of CSF pTau/Aβ42 ratio on brain structure and metabolism in middle‐aged cognitively unimpaired individuals (2022) (0)
- SUBCLINICAL CARDIOVASCULAR DYSFUNCTION IS ASSOCIATED WITH INCREASED CEREBROSPINAL FLUID EVIDENCE OF NEURODEGENERATION IN OLDER ADULTS (2019) (0)
- Fluid‐based biomarkers to facilitate clinical trial execution and interpretation (2020) (0)
- P-021. Correlation between cognitive assessment scores and circulating cerebral biomarkers in women with preeclampsia and eclampsia (2021) (0)
- Trajectories of neurodegeneration and seed amplification biomarkers prior to disease onset in individuals at risk of prion disease (2022) (0)
- P4-127 CSF neurofilament light as a diagnostic and prognostic biomarker for amyotrophic lateral sclerosis (2006) (0)
- COMPARING THE DIAGNOSTIC ACCURACIES OF CSF Aβ42 AND PET FLORBETAPIR (2014) (0)
- Detection of subarachnoid haemorrhage with spectrophotometry of cerebrospinal fluid – a comparison of two methods (2022) (0)
- Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease (2015) (0)
- THE DISTRIBUTION OF APOLIPOPROTEIN E GENOTYPE OVER THE ADULT LIFESPAN AND IN RELATION TO BIRTH ORIGIN (2014) (0)
- P.1.i.002 Changes in cerebrospinal fluid insulin during non-neurological surgery (2010) (0)
- NEUROFILAMENTS ACROSS THE SPECTRUM OF NEURODEGENERATIVE AND NEUROINFLAMMATORY DISEASES F2-02-01 NEUROFILAMENT LIGHT CHAIN IN AD IN CSFAND BLOOD (2018) (0)
- Translational potential of mouse CSF biomarkers in Alzheimer’s disease: Association of CSF neurogranin with tau, NFL and amyloid pathology in APP knock‐in mouse models (2020) (0)
- Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease (2023) (0)
- NOVEL ASSAYS TO MONITOR Aβ PEPTIDES GENERATED BY THE ASPARAGATE ENDOPEPTIDASE AFTER INHIBITION OF BACE (2017) (0)
- ASTROGLIAL ACTIVATION AND ALTERED AMYLOID METABOLISM IN HUMAN REPETITIVE CONCUSSIVE TRAUMATIC BRAIN INJURY (2017) (0)
- PLASMA A b AND CEREBRAL AND DEPOSITION THE GUT MICROBIOTA-DERIVED METABOLITE TRIMETHYLAMINE N-OXIDE (TMAO) IS ELEVATED IN ALZHEIMER’S (0)
- Contrasting alterations between cortical and subcortical myelin across age, AD diagnosis, and amyloid and tau pathology as assessed by quantitative R1 mapping (2020) (0)
- Multi‐modal Analysis and Modeling of Human Neurodegenerative Disease to Reveal Disease Mechanisms and Biomarkers (2022) (0)
- Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies (2021) (0)
- CSF biomarkers are differentially related to structural and functional changes in dementia of the Alzheimer’s type (2018) (0)
- P.4.033 Cerebrospinal fluid biomarkers of brain injury in bipolar disorder (2013) (0)
- LIFETIME PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC APOE ɛ4+ ADULTS (2017) (0)
- Amyloid precursor protein localises to ependymal cilia in vertebrates and is required for ciliogenesis and brain development in zebra sh (2021) (0)
- Passive and active suicidal ideation in a population-based sample of older adults: Associations with polygenic risk scores of relevance for suicidal behavior (2023) (0)
- Functional Applications of Stable Tau Oligomers in Cell Biology and Electrophysiology Studies. (2023) (0)
- Cerebrospinal fluid levels of growth associated protein 43 (GAP‐43) are associated with Alzheimer’s disease biomarkers, cognition, and functional changes (2022) (0)
- Investigating New Applications of a Photoswitchable Fluorescent Norbornadiene as a Multifunctional Probe for Delineation of Amyloid Plaque Polymorphism (2023) (0)
- Circulating granulocyte colony-stimulating factor and functional outcome after ischemic stroke: an observational study (2021) (0)
- ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER’S DISEASE BIOMARKERS (2018) (0)
- CSF sphingolipid levels correlate with CSF beta-amyloid and tau (2013) (0)
- Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study (2017) (0)
- P 2117 MICRORNAS AS NOVEL BIOMARKERS IN AD : DIFFERENTIAL EXPRESSION IN HIPPOCAMPUS AND IN CELL-FREE CEREBROSPINAL FLUID (2014) (0)
- PrognosticationS-100B is superior to NSE, BDNF and GFAP in predicting outcome of resuscitation from cardiac arrest with hypothermia treatment (2010) (0)
- The association of Alzheimer’s disease and cerebrovascular disease biomarkers towards the neurodegeneration of the cholinergic pathways (2021) (0)
- THE NEURAL CELL ADHESION PROTEIN NEUROLIGIN 1 IN ALZHEIMER’S DISEASE (2019) (0)
- P2-170 The prediction of Alzheimer’s disease in patients with mild cognitive impairment using a disease specific pattern of C-terminally truncated β-amyloid peptides (2006) (0)
- Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis (2023) (0)
- Subacute plasma neurofilament light predicts neurodegeneration after moderate‐severe traumatic brain injury (2021) (0)
- PROTEOLYTIC PROCESSING OF THE SYNAPTIC ALZHEIMER BIOMARKER NEUROGRANIN BY CALPAIN I AND PROLYL ENDOPEPTIDASE (2018) (0)
- Altered amyloid metabolism in neuroinflammation (2009) (0)
- A Selected Reaction Monitoring Protocol for the Measurement of sTREM2 in Cerebrospinal Fluid (2018) (0)
- Alzheimer’s pathologic change indexed by CSF B‐amyloid42 associates with longitudinal alterations in myelin content (2020) (0)
- PLASMA AMYLOID-BETA AND TAU AND VISUAL CONTRAST SENSITIVITY SYNERGISTICALLY PREDICT CEREBRAL AMYLOID AND TAU DEPOSITION ON PET IN PRECLINICAL AND PRODROMAL AD (2019) (0)
- Stress and Alzheimer’s disease: Linking salivary cortisol to biomarkers of neurodegeneration and cognitive decline in a memory clinic cohort (2021) (0)
- MODIFIDED KETOGENIC DIET IS ASSOCIATED WITH IMPROVED CSF BIOMARKER PROFILE, CEREBRAL PERFUSION, AND CEREBRAL KETONE BODY UPTAKE IN OLDER ADULTS AT-RISK FOR ALZHEIMER’S DISEASE: A PILOT STUDY (2019) (0)
- Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer’s Disease Neuropathology (S15.005) (2023) (0)
- Prospective analysis of plasma amyloid beta and postoperative delirium in the Interventions for Postoperative Delirium: Biomarker-3 study. (2023) (0)
- CSF 7‐ketocholesterol is related to β‐amyloid and white matter microstructure in healthy adults (2020) (0)
- Positive clinical outcomes in two phase 2a studies: ADAS‐COG in Alzheimer’s and MDS‐UPDRS in Parkinson’s patients plus markers of toxic cascade that leads to nerve cell death (2021) (0)
- CSF Aβ42 and Aβ40 and their relation to brain soluble and insoluble Aβ in the 5xFAD mouse model of Alzheimer’s disease (2021) (0)
- CSF MARKERS OF NEURODEGENERATION ARE ASSOCIATED WITH QUANTITATIVE T1 (2019) (0)
- Tau phosphorylation is more closely associated with amyloid‐β plaques than with tau neurofibrillary tangles (2022) (0)
- Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models (2018) (0)
- Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases (2020) (0)
- Interim results from an international , open-label study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson ’ s disease : efficacy results by country (2012) (0)
- The effect of physical activity on CSF biomarkers of Alzheimer’s disease differs between men and women (2020) (0)
- POOR SLEEP IS ASSOCIATED WITH CSF-MARKERS OF ALZHEIMER’S DISEASE IN 70-YEAR-OLDS WITHOUT DEMENTIA (2018) (0)
- Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) (0)
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia (2020) (0)
- Favorable cognitive effects of the BET protein inhibitor apabetalone in patients 70 and older (2021) (0)
- Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease (2023) (0)
- Identification of a sex-specific genetic signature in dementia with Lewy bodies: a meta-analysis of genome-wide association studies (2022) (0)
- Characterization of cerebrospinal fluid BACE1 as a biomarker for Alzheimer’s disease (2019) (0)
- The relationship between intracranial vascular health and metrics of Alzheimer's disease (2015) (0)
- DOES CALCIUM SUPPLEMENTATION INCREASE THE RISK OF DEMENTIA IN WOMEN WITH CEREBROVASCULAR DISEASE? A FIVE YEAR FOLLOW-UP OF OLDER SWEDISH WOMEN (2016) (0)
- Cerebrospinal fluid biomarkers for preclinical Alzheimer’s disease: Results from an 18-year follow-up of women in Gothenburg (2013) (0)
- Discovery of multiple phosphorylated tau biomarkers in CSF using a novel mass spectrometry method (2015) (0)
- CSF biomarkers (2005) (0)
- PROXIMITY TO PARENTAL ONSET AND APOE ε4 INDEPENDENTLY CONTRIBUTE TO AMYLOID BURDEN IN MIDDLE-AGED ADULTS WITH A FAMILY HISTORY OF SPORADIC ALZHEIMER’S DISEASE (2019) (0)
- SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease (2014) (0)
- The effect of vitamin B supplementation on neuronal injury in people living with HIV: a randomized controlled trial (2022) (0)
- Plasma phospho‐tau181 in over 400 cognitively healthy 69‐ to 71‐year‐olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study (2020) (0)
- A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans (2016) (0)
- Subjective Cognitive Decline Interacts with Sex and Education on CSF β‐Amyloid. (2022) (0)
- Plasma measurements in mutation carriers and non-carriers from the world’s largest autosomal dominant Alzheimer’s disease kindred: a cross-sectional and longitudinal cohort study (2020) (0)
- Cerebrospinal fluid markers of microglial activation and neuroinflammation in Alzheimer's disease (2011) (0)
- APOE-ε4 ALLELIC LOAD MODULATES THE ASSOCIATION BETWEEN CSF BETA-AMYLOID AND GRAY MATTER VOLUME IN COGNITIVELY UNIMPAIRED INDIVIDUALS (2019) (0)
- Smartphone‐based long‐term delayed memory performance is associated with the Preclinical Alzheimer’s Cognitive Composite and CSF levels of β‐amyloid (2022) (0)
- Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid- (cid:2) in Cerebrospinal Fluid (2014) (0)
- ASSOCIATION BETWEEN BRAIN NETWORK DYNAMICS AND PLASMA BIOMARKERS IN COGNITIVELY INTACT INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE (2019) (0)
- 776C>G, not 775G>C The transcobalamin codon 259 polymorphism should be designated (2013) (0)
- The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease (2018) (0)
- CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER’S DISEASE (2017) (0)
- ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER’S DISEASE (2017) (0)
- Neurofilament light chain: defining the analyte (2022) (0)
- ADSoluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression (2019) (0)
- It is all about clearance. (2011) (0)
- Characterization of the contactin 5 protein and its risk-associated polymorphic variant throughout the Alzheimer's disease spectrum. (2022) (0)
- Machine learning on combined neuroimaging and plasma biomarkers for triaging participants of secondary prevention trials in Alzheimer’s disease (2021) (0)
- No association of salivary tau concentration with Alzheimer’s disease (2019) (0)
- Additional file 1: Figure S1. of Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway (2017) (0)
- Mild behavioral impairment symptom severity predicts tau hyperphosphorylation assessed by plasma p‐tau181 across the Alzheimer’s disease spectrum (2022) (0)
- The Abeta Oligomer Selective Antibody Nab61 Recognizes Abeta Oligomers In The AD And APP Transgenic Mouse Brains And Neutralizes Abeta Mediated Synaptic Dysfunction (2009) (0)
- THE 1946 COHORT: RELATIONSHIPS BETWEEN CEREBRAL AMYLOID PATHOLOGY USING TWO INDEPENDENT METHODS FOR PLASMA AMYLOID BETA MEASUREMENT (2019) (0)
- HOW DO WE DEFINE N+? COMPARISON OF DIFFERENT MRI-BASED MORPHOMETRIC ESTIMATES FOR DEFINING NEURODEGENERATION IN CSF AMYLOID-POSITIVE INDIVIDUALS ACROSS THE ALZHEIMER’S DISEASE SPECTRUM (2018) (0)
- OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH LOWER MEMORY FUNCTION IN MIDDLE-AGED ADULTS (2018) (0)
- THE CONTRIBUTION OF SEX-SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER’S DISEASE PATHOLOGY (2018) (0)
- Immediate andDelayed Recall 10 ) and executive functioning ( Trail Making Test Part B [ TMT-B ] , 11 Animal Fluency (0)
- P1-306 The kinesin gene KNS2 interacts with APOE and influences the risk of Sporadic Alzheimer’s disease (2006) (0)
- Higher fronto‐parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men (2020) (0)
- Correction: Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection (2022) (0)
- E05 Longitudinal evaluation of magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease (2022) (0)
- Agarwal, Yasha; Matt, Stephaniea; Mompho, Krisnaa; Runner, Kaitlyna; Gaskill, Peter Ja (1) Mediators of inflammation alter HIV latency and re-activation in a human microglial cell line (2022) (0)
- Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (0)
- Differential proteomic profile of lumbar and ventricular cerebrospinal fluid (2023) (0)
- Active elite rugby participation predicts alterations in cortical thickness (2022) (0)
- Blood plasma biomarkers improve prediction accuracy over and above genetic predictors of Alzheimer’s disease (2022) (0)
- Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial. (2023) (0)
- Strong effects of the ABCA1 agonist CS6253 on Amyloidβ42/40 ratio and lipoproteins in cynomolgus monkeys (2022) (0)
- ADVANCE-TBI study protocol: traumatic brain injury outcomes in UK military personnel serving in Afghanistan between 2003 and 2014 – a longitudinal cohort study (2023) (0)
- The Influence of Orthopedic Surgery on Circulating Metabolite Levels, and their Associations with the Incidence of Postoperative Delirium (2022) (0)
- Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials. (2023) (0)
- Plasma neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot study (2023) (0)
- Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay (2016) (0)
- Longitudinal decline of plasma neurofilament light levels after antiretroviral initiation in people living with HIV (2022) (0)
- Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus (2023) (0)
- All Players including Goalies: goal = 1 point, assist = 1 point, shootout goal = 1 point (2015) (0)
- Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study (2022) (0)
- Amplification of neuropathology and acceleration of cognitive decline in asthma (2022) (0)
- Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection (2022) (0)
- Genome-wide association study of Alzheimer's disease brain imaging biomarkers and neuropsychological phenotypes in the EMIF-AD Multimodal Biomarker Discovery dataset (2021) (0)
- Author Correction: Seven day pre-analytical stability of serum and plasma neurofilament light chain (2022) (0)
- Assessment of Protein as a in Rodent Models of Toxic-Induced Peripheral (2021) (0)
- Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study (2022) (0)
- The Neuroimmune Response to Surgery – An Exploratory Study of Trauma-Induced Changes in Innate Immunity and Heart Rate Variability (2022) (0)
- Plasma Markers of Neurodegeneration Associated with Postoperative Delirium in an Older Elective Arthroplasty Population (2022) (0)
- The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort (2021) (0)
- NMDA Receptor Antibodies and Neuropsychiatric Symptoms in Parkinson's Disease. (2023) (0)
- Factors influencing resilience to postoperative delirium in adults undergoing elective orthopaedic surgery. (2022) (0)
- Predictive blood biomarkers and brain changes associated with age-related cognitive decline (2023) (0)
- The Effects of Stressful Life Events on Alzheimer’s Disease Biomarkers, Neuroinflammation and Brain Integrity in Later Life: A Life Course Perspective (2022) (0)
- A synergistic association of diabetes and AD biomarkers on cognitive decline in persons without dementia? (2022) (0)
- Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease (2022) (0)
- Mild cognitive impairment is associated with passive suicidal ideation in older adults: a population-based study. (2023) (0)
- Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery (2019) (0)
- Structural MRI predicts clinical progression in presymptomatic genetic frontotemporal dementia: findings from the GENetic Frontotemporal dementia Initiative cohort (2023) (0)
- The PSEN1 E280G mutation leads to increased amyloid-β43 production in induced pluripotent stem cell neurons and deposition in brain tissue (2022) (0)
- Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice? (2023) (0)
- P3-067: MRI brain atrophy and CSF biomarkers predict decline to Alzheimer's disease in mild cognitive impairment (2008) (0)
- Capturing protein production and clearance in neurodegeneration with SILK (2019) (0)
- D08 Elevated GFAP and UCHL-1 in plasma and CSF in HD (2022) (0)
- 263 Neurofilament light chain is a predictor of outcome after aneurysmal subarach- noid haemorrhage (2022) (0)
- Neuroinflammation in asthma: Evidence from brain structural alterations (2022) (0)
- Reply to Dr. Arieli regarding our article protein tau concentration in blood increases after SCUBA diving: an observational study published in European journal of applied physiology 2022;122:993-1005 (2022) (0)
- Correction to: Relevance of biomarkers across different neurodegenerative diseases (2020) (0)
- Gut inflammation associated with age and Alzheimer's disease pathology (2022) (0)
- Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome (2020) (0)
- S.01.01 Developing biomarkers for Alzheimer’s disease (2017) (0)
- Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease (2018) (0)
- Blood biomarkers for HIV infection with focus on neurologic complications—A review (2022) (0)
- 1261 Increased concentrations of S100B and neurofilament light chain in serum indicate checkpoint inhibitor-induced CNS inflammation (2022) (0)
- Differential chemokine alteration in the variants of primary progressive aphasia—a role for neuroinflammation (2021) (0)
- Cerebral metabolic dysfunction at the acute phase of traumatic brain injury correlates with long-term tissue loss. (2022) (0)
- A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study (2021) (0)
- Reduced glymphatic function after traumatic brain injury measured using diffusion MRI (2022) (0)
- Acceptability and feasibility of plasma phosphorylated‐tau181 in two memory services (2023) (0)
- Cerebrospinal Fluid Markers of Neurodegeneration Associated with Postoperative Delirium in an Older Elective Arthroplasty Population (2022) (0)
- Preoperative Cerebrospinal Fluid and Plasma Markers of Inflammation and Neurodegeneration Predict Mortality Eight Years Later in an Observational Cohort Study of Postoperative delirium in an Older Elective Arthroplasty Populatio (2022) (0)
- Recency ratio and ABeta42 The recency ratio is related to CSF Amyloid Beta 1-42 levels in MCI (2018) (0)
- Combinatorial Diagnostics of Sports-Related Concussion. (2022) (0)
- 2015 NHL Playoff Pool Sheet Choose 1 player from each of the 21 groups All Players including Goalies: Goal=1 point, Assist=1 point, OT goal=+1 point (2 total) (2015) (0)
- Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. (2023) (0)
- The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. (2022) (0)
- IDENTIFICATION OF LAMP2 AS A CANDIDATE BIOMARKER FOR ALZHEIMER'S DISEASE IN CEREBROSPINAL FLUID USING MASS SPECTROMETRY (2014) (0)
- USING FLORBETAPIR PET TO INCREASE DIAGNOSTIC CERTAINTY IN ATYPICAL DEMENTIAS (2015) (0)
- GMNC risk alleles in individuals with Alzheimer’s disease are associated with cerebrospinal fluid concentrations of proteins involved in neuronal plasticity and blood brain barrier function (2022) (0)
- DIAGNOSTIC PERFORMANCE USING CSF YKL-40 IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA (2017) (0)
- IMPACT OF READY TO USE CALIBRATORS AND THE USE OF UNIFIED STANDARD OPERATING PROCEDURES ON THE VARIABILITY IN ASSAY PERFORMANCE (2014) (0)
- P1-472: New N-terminal APP isoforms in human cerebrospinal fluid (2008) (0)
- Plasma ptau231 predicts locus coeruleus integrity earlier in life than other Alzheimer’s disease plasma markers: a 7T MRI study across the adult lifespan (2022) (0)
- Serum NFL as a predictor of disease progression in dementia with Lewy bodies (2020) (0)
- Blood-based high sensitivity measurements of amyloid beta and phosphorylated tau as biomarkers of Alzheimer's disease: A focused review on recent advances (2021) (0)
- 1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France (2008) (0)
- DIAGNOSTIC ACCURACY OF CSF Aβ1-42, P-TAU, T-TAU, NEUROFILAMENT LIGHT CHAIN, NEUROGRANIN, YKL-40 COMBINED BIOMARKERS IN A MULTICENTER COHORT OF COGNITIVELY IMPAIRED PATIENTS (2017) (0)
- S18Y polymorphism in Alzheimer's disease (2010) (0)
- 0637 Associations between Alzheimer’s Disease Pathology and the Psychomotor Vigilance Task in Cognitively Unimpaired Adults with and without Obstructive Sleep Apnea (2022) (0)
- Investigating the use of plasma pTau181 in retired contact sports athletes (2022) (0)
- HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α-SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH (2018) (0)
- PRESYNAPTIC DEGRADATION IN ALZHEIMER’S DISEASE MEASURED BY NOVEL GAP-43 ELISA IN CSF (2017) (0)
- Identification of Biomarkers During Investigational Therapy for Niemann-Pick Type C Disease (2012) (0)
- Markers of neutrophil mediated inflammation associate with disturbed continuous electroencephalogram after out of hospital cardiac arrest (2022) (0)
- PLASMA BIOMARKER PROFILE OF AMYLOID, TAU, AND NEURONAL PATHOPHYSIOLOGY IN COGNITIVELY NORMAL PRECLINICAL INDIVIDUALS STRATIFIED BY AMYLOID-PET STATUS (2016) (0)
- caused by heading in soccer No neurochemical evidence for brain injury (2007) (0)
- Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimerâ•Žs disease: Neuroimaging / multiâ•’modal comparisons (2020) (0)
- Central inflammatory markers correlate with personality traits and increase in response to surgical stress (2011) (0)
- D4 Prediction of huntington’s disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death (2016) (0)
- FOUR DIMENSIONAL ARTERIAL BLOOD FLOW METRICS IN THE INTERNAL CAROTID ARTERY PREDICT COGNITIVE PERFORMANCE AND ARE ASSOCIATED WITH CSF BIOMARKERS IN PATIENTS WITH MCI (2016) (0)
- D02 Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in huntington’s disease (2021) (0)
- Microglia activation in the Alzheimer's brain: Normalization by Posiphen® (2012) (0)
- RELATIONSHIP BETWEEN THE RENIN ANGIOTENSIN SYSTEM AND ALZHEIMER'S BIOMARKERS: RESULTS FROM THE EMBARK STUDY (2014) (0)
- Plasma metabolomics of presymptomatic PSEN1‐H163Y mutation carriers: a pilot study (2021) (0)
- Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels in Down Syndrome and Sporadic Alzheimer´S Disease: A Cross-Sectional Study (2022) (0)
- POLYSOMNOGRAPHIC EVIDENCE OF SLEEP FRAGMENTATION AND POOR SLEEP EFFICIENCY IN DEMENTIA WITH LEWY BODIES (2008) (0)
- Association of deep‐learning–derived brain computed tomography measures with cognition and blood‐based biomarkers of neurodegenerative diseases (2021) (0)
- MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (2016) (0)
- ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN WITH COGNITIVE PERFORMANCE IN COGNITIVELY NORMAL ELDERLY PARTICIPANTS (2018) (0)
- Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease (2018) (0)
- The interaction of amyloid and tau on decreased cortical neurite density in preclinical Alzheimer’s disease (2020) (0)
- MTHFR C677???T polymorphism, plasma homocysteine, smoking, coffee consumption and risk of coronary heart disease in a population based case???cohort study ??? the intergene research programme (2006) (0)
- Should the MTHFR 1298A>C polymorphism be considered in the clinical evaluation of patients at risk for thrombotic disease? (2005) (0)
- Freeze-drying as a novel cerebrospinal fluid processing method for biomarker measurements (2018) (0)
- OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH LOWER MEMORY FUNCTION IN MIDDLE-AGED ADULTS (2018) (0)
- DIFFERENTIAL REGIONAL MRI VOLUME CHANGE AS A MARKER OF NEURODEGENERATIVE DISEASE IN THOSE EXPOSED TO REPETITIVE HEAD TRAUMA (2019) (0)
- Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimers disease (2019) (0)
- DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKER-GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER’S DISEASE (2017) (0)
- Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology. (2023) (0)
- Withdrawn: Plasma concentrations of free amyloid-β cannot predict the development of Alzheimer's disease. (2016) (0)
- Plasma Amyloid (A42) Correlates with CSF A42 in Alzheimer’s Disease (2018) (0)
- DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER\textquotesingleS DISEASE PATHOLOGY AND PROGRESSION (2017) (0)
- Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile (2021) (0)
- Sex, age, and regional differences in CHRM1 and CHRM3 genes expression levels in the human brain biopsies: potential targets for Alzheimer's disease-related sleep disturbances. (2022) (0)
- Liver-Specific Polygenic Risk Score Is Associated with Alzheimer's Disease Diagnosis. (2023) (0)
- Aß42 and T-tau levels in cerebrospinal fluid associate with survival in an 85- year old population-based cohort followed until death (2019) (0)
- CSF AND PET MEASURES FOR TAU IN DIFFERENT STAGES OF ALZHEIMER’S DISEASE (2019) (0)
- PATIENT-RELATED PRE-ANALYTICAL FACTORS INFLUENCING PLASMA AMYLOID BETA CONCENTRATIONS (2019) (0)
- The use of AlphaLISA in measurement of Aβ1-15/16 as a potential biomarker in neurodegenerative diseases (2012) (0)
- Structural and metabolic brain correlates of excess Aβ accumulation at the earliest AD continuum (2022) (0)
- Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by PTAU/AΒ42 status in cognitively unimpaired adults (2020) (0)
- S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus (iNPH) in Relation to Confirmed Amyloi (2018) (0)
- PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS (2017) (0)
- Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias (2021) (0)
- PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42 (2017) (0)
- Associations between plasma p‐tau217, in vivo brain pathology and cognition in individuals with autosomal‐dominant Alzheimer’s disease: Findings from the Colombia‐Boston (COLBOS) biomarker study (2021) (0)
- PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER’S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT (2018) (0)
- NOVEL METHOD FOR OLIGOMERIC Aβ DETECTION REVEALS INTRACELLULAR ACCUMULATION OF Aβ UPON LOW-DOSE TREATMENT WITH A GAMMA-SECRETASE INHIBITOR (2017) (0)
- Genomic Variation Within the C4 Locus and Cerebrospinal Fluid Levels of C4 Isotype Proteins in Acute and Chronic Schizophrenia (2021) (0)
- 0422 Apocalypse Tau: The Relationship Between Inflammaging and Local Sleep Disruption in Older Adults is Mediated by Tau Burden (2020) (0)
- SUBJECTIVE COGNITIVE DECLINE AND NEUROIMAGING AND CEREBROSPINAL FLUID MARKERS OF CEREBROVASCULAR HEALTH: THE VANDERBILT MEMORY AND AGING PROJECT (2017) (0)
- GUT MICROBIAL METABOLITES IN CEREBROSPINAL FLUID ARE ASSOCIATED WITH BIOMARKERS OF ALZHEIMER’S DISEASE PATHOLOGY (2019) (0)
- AMIRASPEC: BLOOD CELL FLUORESCENCE FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (2019) (0)
- articleNeuroinflammation in Lyme neuroborreliosis affects amyloid metabolism (2015) (0)
- PHYSICAL ACTIVITY IS ASSOCIATED WITH LOWER AMYLOID LOAD IN MIDDLE-AGED COGNITIVELY UNIMPAIRED INDIVIDUALS (2019) (0)
- Title CSF neurogranin as a neuronal damage marker in CJD : A comparative study with AD Running head Neurogranin in the CSF and brain of AD and CJD (2019) (0)
- Alzheimer’s disease-associated CSF biomarkers do not correlate with CSF volumes or CSF production rate (2018) (0)
- 0491 Brain health and ageing in retired rugby players, the brain study (2017) (0)
- Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications (2023) (0)
- Impaired default mode network along with increased functional connectivity of the medial temporal lobe as a function of CSF p‐Tau/Ab42 ratio in cognitively unimpaired individuals (2021) (0)
- Plasmatic NFL correlate with cognitive function and brain MRI lesions but not with synaptic biomarkers (2019) (0)
- LONGITUDINAL EFFECT OF BIOLOGICAL VARIABLES ON PLASMA NFL AND T-TAU CONCENTRATIONS ON SUBJECTIVE MEMORY COMPLAINERS (INSIGHT-PREAD-COHORT): A 3-YEAR FOLLOW-UP STUDY (2019) (0)
- CEREBROSPINAL FLUID BIOMARKER PROFILE OF AMYLOID, TAU, SYNAPTIC, MICROGLIAL, AND LYSOSOMAL PATHOPHYSIOLOGY IN COGNITIVELY NORMAL PRECLINICAL INDIVIDUALS STRATIFIED BY AMYLOID-PET STATUS (2016) (0)
- The visual estimation of midbrain to pons ratio combined with cerebrospinal fluid biomarkers improves the diagnostic accuracy of PSP (2015) (0)
- Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment (2020) (0)
- Title: Fatty Acid-Binding Protein 3 in Cerebrospinal Fluid of Hip Fracture Patients with Delirium Authors/affiliations: (2020) (0)
- Neurofilament light protein: a blood biomarker of neurodegeneration in chemotherapy-induced peripheral neurotoxicity. (2018) (0)
- Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2020) (0)
- The Nordic countries meeting on the zebrafish as a model for development and disease 2012. (2013) (0)
- Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease (2018) (0)
- Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data. (2019) (0)
- Role of astrogliosis in the relationship between cerebrovascular burden and Alzheimer’s disease pathology (2022) (0)
- CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease (2020) (0)
- A protective role of lysozyme in Alzheimer disease (2014) (0)
- 0491 Brain health and ageing in retired rugby players, the brain study (2017) (0)
- P.2.e.013 Exploratory analysis of biomarkers in the cerebrospinal fluid of bipolar patients (2012) (0)
- A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases (2023) (0)
- Stability of the novel blood‐based biomarkers under pre‐analytical sample handling conditions: Results of the SABB‐GBSC working group (2021) (0)
- Update of the Original HDLS Kindred: Divergent Clinical Courses (P05.032) (2012) (0)
- Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease (2021) (0)
- EBV-transformed B-cells from an individual homozygously mutated (G329A) in FUT7 do not roll on E-selectin (2012) (0)
- P2-220 CROSS-TALK BETWEEN WNT SIGNALLING ANDAMYLOID PRECURSOR PROTEIN IN NEURONS (2018) (0)
- Biomarkers, bioprediction, and ethics Matthew L. Baum Th (2017) (0)
- Diagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. (2021) (0)
- P1-370 Monitoring the biochemical aftermath of boxing by cerebrospinal fluid analyses (2006) (0)
- Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers (2022) (0)
- The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain (2018) (0)
- COMPARISON OF T-TAU, NEUROGRANIN AND NFL AS CSF NEURODEGENERATION MARKERS IN ALZHEIMER’S DISEASE (2016) (0)
- THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY (2018) (0)
- IL-9 ALTERATIONS ARE LINKED TO ALZHEIMER’S DISEASE IN AFRICAN AMERICANS (2019) (0)
- THE GLOBAL ALZHEIMER’S ASSOCIATION ROUND ROBIN STUDY ON PLASMA AMYLOID BETA METHODS (2019) (0)
- AD‐associated CSF biomolecular changes are attenuated in KL‐VS heterozygotes (2022) (0)
- The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort (2023) (0)
- Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer’s disease (ALFASleep project): protocol for an observational study (2022) (0)
- A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation (2018) (0)
- Study bridges the gap between advanced mass spectrometry and immuno-based multiplex assays. (2008) (0)
- Glial and neuronal markers in CSF predict progression in multiple sclerosis (2014) (0)
- A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome (2021) (0)
- Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study (2022) (0)
- Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry (2021) (0)
- Biomarkers for Alzheimer’s disease beyond amyloid and tau (2019) (0)
- Investigating the genetic architecture of Dementia with Lewy bodies: a genome-wide association study (2018) (0)
- Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. (2023) (0)
- Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection (2013) (0)
- Corrigendum to “Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease” [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82] (2022) (0)
- HOW AD-SPECIFIC ARE AD CSF BIOMARKERS? (2016) (0)
- MILD COGNITIVE IMPAIRMENT STAGING YIELDS BIOMARKER DIFFERENCES, LONGITUDINAL COGNITIVE DECLINE, AND GREY MATTER ATROPHY (2019) (0)
- Predicting progression to Alzheimer’s disease with human hippocampal progenitors exposed to serum (2023) (0)
- Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers (2019) (0)
- Association between plasma homocysteine levels and signs of axonal injury in untreated HIV (2015) (0)
- Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease. (2022) (0)
- STRESS IS ASSOCIATED WITH GREATER INSULIN RESISTANCE, HIGHER CSF PHOSPHORYLATED TAU, AND DECREASED GLUCOSE METABOLISM IN THE MEDIAL TEMPORAL LOBE IN APOE Ε4 CARRIERS (2016) (0)
- Clinical performance and robustness of blood‐based biomarkers for early detection of amyloid pathology associated with Alzheimer’s disease (2022) (0)
- Weight loss predicts Alzheimer’s disease biomarker positivity in cognitively unimpaired middle‐aged adults (2020) (0)
- Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease (2020) (0)
- Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum (2021) (0)
- P 8 Cerebral biomarkers in women developing preeclampsia (2017) (0)
- Whole blood transcript and protein abundance of the vascular endothelial growth factor family relate to cognitive performance (2023) (0)
- Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology (2021) (0)
- Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome (2018) (0)
- FULLY AUTOMATED PLASMA ASSAYS AS SCREENING TESTS FOR EARLY ALZHEIMER-RELATED β-AMYLOID PATHOLOGY (2019) (0)
- Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation (2021) (0)
- A STUDY ON THE RELATION BETWEEN SLEEP AND BETA-AMYLOID-42 IN CEREBROSPINAL FLUID IN 70-YEAR-OLDS (2017) (0)
- Stable Isotope Labeling Kinetics (SILK) tracing of neurofilament light in stem cell‐derived neurons (2022) (0)
- A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease (2022) (0)
- O4-01-04 BENEFICIAL EFFECTS OF ANGIOTENSIN II RECEPTOR BLOCKERS ON METABOLIC DISORDER-INDUCED COGNITIVE IMPAIRMENT (0)
- Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection (2019) (0)
- TOWARD RE-CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ42 IN HUMAN CEREBROSPINAL FLUID (2019) (0)
- Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression (2021) (0)
- Sex-specific metabolic pathways associate with Alzheimer's Disease (AD) endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery (EMIF-AD MBD) cohort (2021) (0)
- P3-263: The kinesin light chain 1 polymorphism rs8702 is associated with elevated CSF levels of secreted forms of amyloid precursor protein (2008) (0)
- Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and biomarkers: CSF (2010) (0)
- Harnessing the potential of plasma biomarkers in precision medicine by efficient control of effects unrelated to disease (2017) (0)
- Self‐reported sleep quality interacts with Alzheimer’s disease biomarkers on brain structure and metabolism in cognitively unimpaired adults (2022) (0)
- Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers (2019) (0)
- Alzheimer’s disease genetic risk variants show brain cell type‐specific associations with protein levels in cerebrospinal fluid (2021) (0)
- Association between plasma phospho-tau181 and cognitive change from age 73 to 82: Lothian Birth Cohort 1936 (2021) (0)
- P1-401: Identification of novel APP/Aβ isoforms in human cerebrospinal fluid (2008) (0)
- Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis (2018) (0)
- Prodromal frontotemporal dementia: clinical features and predictors of progression (2021) (0)
- Associations between semantic memory for proper names in story recall and CSF amyloid and tau in a cognitively unimpaired sample (2022) (0)
- MASS SPECTROMETRY-BASED CANDIDATE REFERENCE MEASUREMENT PROCEDURE FOR QUANTIFICATION OF AB42 IN CEREBROSPINAL FLUID (2014) (0)
- The relationship of cerebral perfusion with age and CSF measures in middle-aged adults at risk for Alzheimer's disease (2013) (0)
- Exome‐wide rare variant analysis of Alzheimer’s disease biomarkers: The EMIF‐AD multimodal biomarker discovery study (2021) (0)
- Troponin T: more than acute myocardial infarction. (2011) (0)
- APOEϵ4 carriership associates with microglial activation independently of Aβ plaques and tau tangles (2022) (0)
- System in Alzheimer Disease Lysosomal - Proteasome System and the Autophagic - The Ubiquitin (2012) (0)
- Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay (2020) (0)
- Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. Running title: Amyloid beta in CSF of ADNIGO/2 participants (2020) (0)
- 67. Aggressive and impulsive personality traits and inflammatory markers in cerebrospinal fluid and serum: Are they interconnected? (2013) (0)
- Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington’s disease (2021) (0)
- Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease (2022) (0)
- Tracking neurodegeneration in frontotemporal dementia and Alzheimer’s disease: A comparative study of plasma tau and neurofilament light chain (2020) (0)
- Neurofilament concentration in CSF correlates with disease severity, survival and imaging measures of neurodegeneration in incident Parkinson disease (2019) (0)
- Neuronal Lipids for Subsequent Immunofluorescent Staining: (2017) (0)
- ASSOCIATION BETWEEN N-ACETYLARGININE AND ALZHEIMER’S DISEASE CSF BIOMARKERS NEUROFILAMENT LIGHT AND YKL-40 (2019) (0)
- SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease. (2023) (0)
- The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients (2021) (0)
- Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer’s disease in late-middle-aged adults (2017) (0)
- The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics (2018) (0)
- LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER’S DISEASE (2019) (0)
- Correlation between cognitive assessment scores and circulating cerebral biomarkers in women with pre-eclampsia and eclampsia. (2022) (0)
- CSF neurofilament light proteins and cognitive performance in middle-aged adults at increased risk for Alzheimer's disease (2012) (0)
- CSF synaptic proteins and plasmatic NFL correlate with cognitive function but reflect different brain lesions : A biomarker study (2019) (0)
- Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia (2020) (0)
- THE NOVEL EFFECT OF CSF AND APOE4 ON THE AGGREGATION KINETICS OF Aβ42 IN ALZHEIMER'S DISEASE (2014) (0)
- Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer’s disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification (2021) (0)
- Blood‐based biomarkers for neurodegeneration in non‐Hispanic Black and White older adults: Results from the Einstein Aging Study (EAS) (2022) (0)
- Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls (2022) (0)
- Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning (2022) (0)
- Identification of plasma metabolites associated with modifiable risk factors and endophenotypes reflecting Alzheimer’s disease pathology (2023) (0)
- Sex differences in CSF biomarkers profile of accelerated biological aging individuals at risk of Alzheimer’s disease (2022) (0)
- P3-070: CSF Total tau and gray matter density in Alzheimer's disease–specific brain regions: A study of normal aging (2008) (0)
- Association of CSF α-synuclein and tau protein concentrations with amyloid mean cortical standard uptake value ratios in preclinical subjective memory complainers stratified by Alzheimer’s disease biomarkers: the INSIGHT-preAD study (2018) (0)
- Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease (2021) (0)
- Reply to “Pathway for ascertaining the role of uric acid in neurodegenerative diseases,” Roman Youssef (2022) (0)
- D10 Neurofilament light protein in blood predicts regional atrophy in huntington’s disease (2018) (0)
- Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology (2022) (0)
- SNAP25 reflects amyloid‐ and tau‐related synaptic damage: Associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic disfunction in the Alzheimer’s disease spectrum (2020) (0)
- Amyloid pathology is associated with extensive myelin alteration in preclinical Alzheimer’s disease: New insights into disease process with novel brain imaging (2015) (0)
- CSF Aβ42 reduction in cognitively intact elderly individuals with major depressive disorder (2011) (0)
- P-002. Evidence of neuroinflammation and injured blood–brain-barrier in eclampsia (2021) (0)
- Biological variation of Alzheimer’s disease plasma biomarkers in healthy individuals (2022) (0)
- Increased cerebrospinal fluid levels of Amyloid beta oligomers in patients with Alzheimer's disease (2011) (0)
- Identification of plasma proteome signatures associated with ATN framework using SOMAscan (2020) (0)
- FV8 An exploratory examination of NeuroToolKit biomarkers across Alzheimers disease stages (2020) (0)
- Age Modifies the Association Between Apolipoprotein E Genotype and Alzheimer's Disease: A CSF Biomarker-Based Multicentric Case-Control Study (2019) (0)
- Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers (2021) (0)
- HOW ACCURATE ARE CEREBROSPINAL FLUID BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER DISEASE? A SYSTEMATIC REVIEW (2016) (0)
- Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample (2023) (0)
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (0)
- No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF (2016) (0)
- The association between diabetes and Alzheimer’s disease pathophysiology (2021) (0)
- DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKER-GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER’S DISEASE (2017) (0)
- Alzheimer’s disease biomarker profiling in a memory clinic cohort without common comorbidities (2022) (0)
- POOR SLEEP QUALITY IS ASSOCIATED WITH CSF MARKERS OF AMYLOID DEPOSITION IN COGNITIVELY HEALTHY ADULTS AT RISK FOR ALZHEIMER'S DISEASE (2016) (0)
- Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. (2022) (0)
- NATIVE GEL OVERLAY WITH FRET SUBSTRATE AND MS OF IN-GEL DIGESTED ACTIVE BANDS SHOW THAT CALPAIN-2 IS RESPONSIBLE FOR TAU CLEAVAGE AT AMINO ACID 224 (2019) (0)
- Objective To determine whether serum neurofilament light (NfL) correlates with CSF NfL, traumatic brain injury (TBI) diagnosis, injury severity, brain volume, and diffusion tensor imaging (DTI) estimates of traumatic axonal injury (2020) (0)
- Contents Vol. 20, 2005 (2005) (0)
- A head‐to‐head comparison of plasma phosphorylated tau assays in the real‐world memory clinic (2022) (0)
- Inhibition of Glycogen Synthase Kinase (GSK–3) Protects Against Oxidative Stress and Attenuates Apoptosis in Human Lens Epithelial Cells and the Mouse Lens in Organ Culure (2005) (0)
- NEURODEGENERATION, AMYLOID, AND LONGITUDINAL VERBAL LEARNING AND MEMORY PERFORMANCE (2018) (0)
- Neurofilament light chain in the vitreous humor of the eye (2020) (0)
- Molecular Imaging Mass Spectrometry for Probing Neuronal Protein Dynamics in Neurodegenerative Disease Pathology (2018) (0)
- Quantitative structural MRI and CSF biomarkers in early diagnosis of Alzheimer's disease (2011) (0)
- MULTIVARIATE PATTERNS OF ASSOCIATION BETWEEN DIFFUSION IMAGING METRICS AND PLASMA NEUROFILAMENT LIGHT IN PRODROMAL ALZHEIMER’S DISEASE (2019) (0)
- CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia (2019) (0)
- Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders (2018) (0)
- Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease (2013) (0)
- Are cerebrospinal fluid levels of neurogranin associated with hippocampal atrophy and brain white matter volume decrease? (2015) (0)
- Sex differences in blood‐based biomarkers in individuals with autosomal dominant Alzheimer’s disease (2021) (0)
- ELEVATED PLASMA NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH REDUCED GREY MATTER DENSITY IN AD AND MCI (2017) (0)
- P3-071: Mass spectrometric characterization of tau in cerebrospinal fluid (2008) (0)
- Subject Index Vol. 19, 2005 (2005) (0)
- Correction: Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration (2018) (0)
- A Validated Method to Prepare Stable Tau Oligomers. (2023) (0)
- P.2.d.022 Cerebrospinal fluid biomarkers of neurodegeneration affect cognitive functions in bipolar disorder but not healthy controls (2014) (0)
- Development of a targeted proteomic multiplex CSF assay for neurodegenerative markers (2015) (0)
- Comparative analytical performance of multiple plasma amyloid‐beta assays and their relationship to amyloid PET (2021) (0)
- P4-109 Variants of CYP46A1 interact with age and APOE to influence CSF Aβ42 and phospho-TAU levels in Alzheimer's disease (2004) (0)
- Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid (2023) (0)
- O3-02-06: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer's disease (2008) (0)
- Blood-brain barrier dysfunction in patients with bipolar disorder Blood-brain barrier dysfunction in patients with bipolar disorder Master thesis in Medicine (2012) (0)
- Cerebrospinal fluid profiles of Aβ-related biomarkers in Alzheimer's disease (2012) (0)
- The levels of neurofilament light at admission and development of axonal pathology in mild traumatic brain injury (2021) (0)
- sentations: P3 P659 P3-101 WITHDRAWN Poster Pre P3-102 APOE-E4 ALLELE STATUS IS ASSOCIATEDWITH FUNCTIONAL LIMITATIONS IN COMMUNITY- DWELLING OLDER ADULTS (2015) (0)
- COMMUTABILITY OF THE CANDIDATE CERTIFIED REFERENCE MATERIALS FOR THE STANDARDIZATION OF Aβ1-42 MEASUREMENTS IN HUMAN CEREBROSPINAL FLUID (2016) (0)
- Imaging stable isotope labelling kinetics (iSILK) for following spatial Aβ plaque aggregation dynamics in evolving Alzheimer’s disease pathology (2020) (0)
- UTILITY OF THE ATN DEFINITION OF BIOMARKER STATUS IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (2017) (0)
- Book Review: Erratum (1995) (0)
- P3-061: A comparison between different β-amyloid assays (2008) (0)
- Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients (2022) (0)
- ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT-LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS (2019) (0)
- CSF Aβ1-42-an excellent but complicated Alzheimer biomarker-the IFCC WG-CSF route to standardisation (2018) (0)
- HETEROGENEITY OF CEREBROSPINAL FLUID BIOMARKER LEVELS IN COGNITIVELY NORMAL INDIVIDUALS WITH A FAMILY HISTORY OF ALZHEIMER'S DISEASE (2014) (0)
- Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations (2023) (0)
- Method and Clinical Validation of Biomarkers for Neurodegenerative Diseases (2021) (0)
- P.2.d.028 Microglial activation in mood stabilised bipolar disorder patients (2014) (0)
- PROTEIN QUANTITATIVE TRAIT LOCI (PQTL) MAPPING OF THE CEREBROSPINAL FLUID PROTEOME (2022) (0)
- Dynamics of selected biomarkers in cerebrospinal fluid during complex endovascular aortic repair - a pilot study: Spinal fluid biomarkers in aortic repair. (2021) (0)
- Associations of dietary patterns and CSF biomarkers for Alzheimer’s disease in a population‐based sample of 70‐year‐olds (2020) (0)
- Cerebrospinal fluid biomarkers in facial nerve palsy caused by Varicella Zoster virus (2015) (0)
- CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING (2018) (0)
- Microglial activation: A process potentially related to Alzheimer's disease and late‐life major depression (2020) (0)
- PLASMA TAU IS ASSOCIATED WITH BASAL FOREBRAIN RATE OF ATROPHY IN OLDER ADULTS AT RISK OF ALZHEIMER’S DISEASE (2019) (0)
- A polygenic risk score for Alzheimer’s disease determines the risk of incident dementia in APOE ɛ4 negative individuals over the age of 95: A population‐based cohort study (2020) (0)
- BLOOD NEUROFILAMENT LIGHT (NFL) – A SENSITIVE BUT SLOW-RELEASE BIOMARKER FOR NEURONAL INJURY IN ACUTE BRAIN DISORDERS (2019) (0)
- Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus (2022) (0)
- NEUROGRANIN PREDICTS LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT (2018) (0)
- RELATIONSHIPS BETWEEN P-TAU AND CHANGES IN MYELIN CONTENT AND COGNITIVE PERFORMANCE (2019) (0)
- INCREASED LEVELS OF CEREBROSPINAL FLUID FATTY ACID BINDING PROTEIN 3 ARE RELATED TO DEMENTIA DEVELOPMENT IN A POPULATION-BASED SAMPLE OF ELDERLY WOMEN FOLLOWED FOR 8 YEARS (2014) (0)
- CSF butyrylcholinesterase and acetylcholinesterase activity and their relationship to pro-inflammatory cytokines in late-life major depression (2019) (0)
- Contents Vol. 63, 2010 (2010) (0)
- Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease Authors: (2020) (0)
- THE CSF SYNAPTIC BIOMARKER BACE1 CORRELATES WITH COGNITION IN MCI AND ALZHEIRMER DISEASE (2019) (0)
- Circulating Brain Injury Biomarkers: A Novel Method for Quantification of the Impact on the Brain After Tumor Surgery. (2023) (0)
- Plasma phospho‐tau in familial Alzheimer’s disease (2020) (0)
- LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER’S DISEASE (2019) (0)
- DEVELOPMENT OF A UNIFIED -OMIC PREPARATION METHODOLOGY: AN ALTERNATIVE, NON-IP APPROACH TO TARGETED LC-MS/MS DETECTION OF SECRETED AMYLOID-β PEPTIDES IN CEREBROSPINAL FLUID AND IPSC-DERIVED FAMILIAL ALZHEIMER’S DISEASE MODELS (2019) (0)
- AD biomarker stability for stored CSF based on immunoassay results (2020) (0)
- DISTINCT COGNITIVE TRAJECTORIES IN LATE MIDDLE-AGE AND THEIR ASSOCIATIONS WITH BRAIN STRUCTURE AND ALZHEIMER'S DISEASE BIOMARKERS: FINDINGS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER’S PREVENTION (2016) (0)
- Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease (2019) (0)
- Comparative Evaluation of MS-based Metabolomics Software and Its Application to Preclinical Alzheimer’s Disease (2018) (0)
- BLOOD-BASED BIOMARKERS FOR CNS INJURY IN MILD TBI: RELATION TO ACUTE INJURY, INJURY HISTORY AND LONG-TERM NEUROBEHAVIORAL OUTCOME (2018) (0)
- CSF BIOMARKER PROFILES IN MIDDLE-AGED ADULTS WITH PARENTAL HISTORY OF AD: THE WISCONSIN ADRC COHORTS (2014) (0)
- CELL FREE SINGLE STRANDED DNA CONCENTRATION IN CSF AS BIOMARKER TO DIAGNOSE ALZHEIMER’S DISEASE STATUS (2019) (0)
- AN ALTERNATIVE FATE OF DEGENERATIVE HIPPOCAMPAL NEURONS REGULATES THE ACTIVATION OF LRP1 RECEPTOR ON THE INTERNALIZATION OF A b 1-42 AND A b 1-42 -INDUCED (0)
- APABETALONE (AN EPIGENETIC BET-INHIBITOR SMALL MOLECULE) AND EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE (2018) (0)
- A candidate reference method for analysis of amyloid beta 1-42 (Aß1-42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer (2015) (0)
- Amyloid Plaque Polymorphism is Associated with Distinct Lipid Accumulations Revealed by Trapped Ion Mobility Mass Spectrometry Imaging (TIMS MSI) (2021) (0)
- MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (2016) (0)
- Plasma p‐Tau181 and p‐Tau231 offer complementary information to identify Alzheimer's disease pathophysiology (2021) (0)
- Translational Inhibition of Multiple Neurotoxic Proteins Leads to Improved Cognition in Alzheimer’s Disease (2022) (0)
- Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 to detect AD related outcomes using fully automated immunoassays (2022) (0)
- Hypertension accentuates reductions in CSF Aβ42 in elderly depressives (2020) (0)
- CELL-FREE, SINGLE-STRANDED DNA CONCENTRATION IN CSF AS BIOMARKER TO DIAGNOSE ALZHEIMER’S DISEASE STATUS (2018) (0)
- Cerebrospinal fluid phosphorylated tau interacts with MMP2 and MMP3: Associations with cognitive performance in older adults (2020) (0)
- Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study. (2022) (0)
- Featured Article Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of b-amyloid (1-42) in human cerebrospinal fluid (2016) (0)
- A NOVEL CSF 16PLEX NEURODEGENERATION ASSAY (2014) (0)
- Ultra‐performance liquid chromatography‐tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture (2020) (0)
- Voxel‐wise Staging of Tau Pathology using [18F]RO‐948 PET in the Early AD Continuum (2022) (0)
- Baseline plasma total tau predicts longitudinal cognitive and functional decline in aging adults (2021) (0)
- Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia (2021) (0)
- Growth factors in Parkinson's disease. (2011) (0)
- Assessing the clinical application of deep-learning-derived CT volumetric measures in neurodegenerative disease diagnostics (2022) (0)
- Correlative Chemical Imaging and Spatial Chemometrics Delineate Alzheimer Plaque Heterogeneity at High Spatial Resolution (2023) (0)
- Head-to-head comparison of amplified plasmonic exosome Aβ42 platform and single-molecule array immunoassay in a memory clinic (2020) (0)
- RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO Aβ, APOE ε4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY (2018) (0)
- THE KINESIN LIGHT CHAIN 1 POLYMORPHISM rs 8702 IS ASSOCIATED WITH ELEVATED CSF LEVELS OF SECRETED FORMS OF AMYLOID PRECURSOR PROTEIN (2008) (0)
- Acute effect on novel Abeta isoforms in cerebrospinal fluid as a response to treatment with gamma-secretase inhibitors and modulators in Alzheimer's disease (2010) (0)
- Csf T‐tau Is Associated with Shorter Survival in Dementia with Lewy Bodies E‐mail (2009) (0)
- Amyloid‐positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume (2020) (0)
- Associations between mean apparent propagator MRI and cerebrospinal fluid markers of AD pathology, neurodegeneration, and glial activation, in cognitively unimpaired adults (2021) (0)
- Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum (2021) (0)
- Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease (2022) (0)
- Amyloid precursor protein-b facilitates cell adhesion during early development in zebrafish (2020) (0)
- [P1–291]: WITHDRAWN (2017) (0)
- TWO-LEVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE (2017) (0)
- Circulating Brain-injury Markers after Surgery for Craniosynostosis. (2023) (0)
- What is the future for CSF biomarkers in the prediction of cognitive decline and Alzheimer's disease? (2008) (0)
- CSF sTREM2 predicts markers of blood brain barrier integrity and amyloid beta metabolism independent of APOE‐ε4 status (2021) (0)
- Age, sex and APOE-ϵ4 modify the balance between soluble and fibrillar β-amyloid in cognitively intact individuals: topographical patterns and replication across two independent cohorts (2020) (0)
- Erratum : Converging pathways of chromogranin and amyloid metabolism in the brain (Journal of Alzheimer's Disease (2010) 20:4 (1039-1048)) (2011) (0)
- P1-484: Combining immunoprecipitation and high accuracy mass spectrometry to study amyloid precursor protein processing pathways in human plasma and cerebrospinal fluid (2008) (0)
- YIELDS BIOMARKER DIFFERENCES , LONGITUDINAL COGNITIVE DECLINE , P 3301 MILDCOGNITIVE IMPAIRMENT STAGING AND GREY MATTER ATROPHY (2019) (0)
- SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES P.178 Development of motor function and changes in NFL in CSF in children with SMA treated with nusinersen (2020) (0)
- P3-198: Haplotype study of the kinesin light chain 1 gene in Alzheimer's disease (2008) (0)
- The extent of neuroradiological findings in COVID-19 shows correlation with blood biomarkers, Glasgow coma scale score and days in intensive care (2021) (0)
- Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients (2022) (0)
- DIETARY PATTERNS AMONG 70-YEAR-OLDS IN RELATION TO CSF BIOMARKERS FOR ALZHEIMER’S DISEASE (2019) (0)
- P3-077: Cerebrospinal fluid levels of Alzheimer's disease biomarkers in term and pre-term newborn infants (2008) (0)
- The relationship between intracranial vascular health and metrics of Alzheimer's disease (2015) (0)
- F4. Alzheimer’s Disease Biomarkers are Associated With Altered White Matter Microstructure (2018) (0)
- BASAL FOREBRAIN RATEOFATROPHY IN OLDER ADULTS AT RISK OF ALZHEIMER’S DISEASE (2019) (0)
- A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease (2017) (0)
- CSF markers of axonal damage, glial activation and immune response in acute myelitis (2016) (0)
- Impact of APOE‐ε4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels (2020) (0)
- Amyloid precursor like protein 1 in Idiopathic Normal Pressure hydrocephalus; expanding the knowledge of an altered amyloid metabolism (2015) (0)
- Prion protein quantification in cerebrospinal fluid as a tool for prion disease therapeutic development (2019) (0)
- Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloid‐positive individuals with subjective cognitive decline (2021) (0)
- Tau phosphorylation is more closely associated with amyloid‐β plaques than with tau neurofibrillary tangles (2022) (0)
- Elevated homocysteine levels are an independent risk factor for atherosclerosis , ischemic stroke (2007) (0)
- Choroid plexus volume is associated with levels of CSF proteins predominantly expressed by the choroid plexus in non‐demented individuals with AD pathophysiology. (2022) (0)
- Biomarker modelling of Alzheimer's disease using in vivo Braak staging (2022) (0)
- Lumbar drains can affect CSF biomarker levels (2018) (0)
- Measuring serum neurofilament light (sNfL) levels to determine correlation with activity of brain metastases (BM) and gliomas (G). (2018) (0)
- Serum neurofilament light as a biomarker for prognosis in patients with newly diagnosed Parkinson disease (2021) (0)
- Distinctive effect of biological sex in AD‐related CSF and plasma biomarkers (2021) (0)
- The ACE gene is associated with dementia and major depression in a population-based cohort of older individuals followed over twelve years (2017) (0)
- PLASMA AMYLOID, TAU AND SERUM NEUROFILAMENT LIGHT CHAIN IN INSIGHT 46: ASSOCIATIONS WITH COGNITION AND BRAIN IMAGING (2019) (0)
- Blood Based Biomarkers Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders (2016) (0)
- MODERATE INTENSITY PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER’S DISEASE (2017) (0)
- MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY (2018) (0)
- CEREBROSPINAL FLUID AB42 IN RELATION TO PRECLINICAL DIAGNOSIS OF ALZHEIMER'S DISEASE (2014) (0)
- The International Concussion and Head Injury Research Foundation Brain health in Retired athletes Study of Ageing and Impact-Related Neurodegenerative Disease. The ICHIRF-BRAIN Study. (2022) (0)
- Association Between Cerebrospinal Fluid Biomarkers of Amyloid and Tau and Neuropsychiatric Symptoms Among Participants from the National Alzheimer’s Coordinating Center Uniform Data Set (P10-6.004) (2023) (0)
- Enhanced xeno-free differentiation of hiPSC-derived astroglia applied in a blood–brain barrier model (2019) (0)
- Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis (2022) (0)
- APOE GENOTYPE AND CSF Aβ42 IN COGNITIVELY HEALTHY INDIVIDUALS (2014) (0)
- Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase (2018) (0)
- β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification (2020) (0)
- Exploring genetic contributors to neuroprotection from AD pathologies: A genome‐wide association study (2020) (0)
- Reduced CSF Aβ42 and Aβ42/Aβ40 ratio during early cerebral amyloid deposition in the App NL‐F knock‐in mouse model of Alzheimer’s disease (2022) (0)
- Cerebrospinal fluid tau levels indicate aberrant neuronal plasticity in Alzheimer disease (2020) (0)
- Increased cerebral biomarkers in plasma and decreased intracerebral magnesium levels are correlated to an impaired blood brain barrier in vitro in preeclampsia (2019) (0)
- Deconvolving Cerebrospinal Fluid Soluble TREM2 Signal and Longitudinal Associations with Cognition (2022) (0)
- STATISTICAL ALGORITHMS FOR HARMONIZING BIOMARKER DISTRIBUTIONS ACROSS DIFFERENT COHORTS, SITES AND ASSAYS: APPLICATIONS TO CSF MEASUREMENTS (2017) (0)
- Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer’s disease biomarkers (2023) (0)
- 15.09 Inherited peripheral neuropathies: analysis of PDXK gene identifies a new treatable disorder (2019) (0)
- Baseline cerebrospinal fluid markers in healthy middle-aged adults predict brain health at three-year follow-up (2011) (0)
- CSF AND PLASMA BIOMARKERS FOR MILD TRAUMATIC BRAIN INJURY (2014) (0)
- Associations between Recall of Proper Names in Story Recall and CSF Amyloid and Tau in a Cognitively Unimpaired Sample (2023) (0)
- CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE (2014) (0)
- CSF Aβ42 CONCENTRATION INDEPENDENTLY PREDICTS POSTOPERATIVE DELIRIUM IN AN ELDERLY ELECTIVE ARTHROPLASTY POPULATION (2017) (0)
- Predicting CSF neurogranin and neurofilament light chain protein levels with a neuropathology‐based APOE genetic risk score (2022) (0)
- Relationship between CSF biomarkers and language fluency in asymptomatic middle-aged adults at increased risk for Alzheimer's disease: The ESPRIT study (2010) (0)
- Derivation of cut‐offs for plasma neurofilament light in clinical routine using healthy subjects aged between 5‐90 (2022) (0)
- APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles (2023) (0)
- Item analysis of adas-cog and cdr system cognitive measures in ad patients on stable treatment with anticholinesterases (2009) (0)
- Sugarman et al. 1 A Longitudinal Examination of Plasma Neurofilament Light and Total Tau for the Clinical Detection and Monitoring of Alzheimer’s Disease (2020) (0)
- Erratum: CSF biomarker variability in the Alzheimer's Association quality control program (Alzheimer's and Dementia (2013) 9 (251-261)) (2015) (0)
- INCREASED CSF AMYLOID-β 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY (2018) (0)
- Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
- NEW PARADIGMS IN TREATING APOE4-DRIVEN DEMENTIA DISEASES: PROOF OF CONCEPT AND TRANSLATIONAL FINDINGS FROM STUDIES WITH THE ABCA1 AGONIST THERAPEUTIC CS6253 (2018) (0)
- Longitudinal Evaluation of Magnetic Resonance Spectroscopy Metabolites as Biomarkers in Huntingtons Disease (2021) (0)
- Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study (2012) (0)
- Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middle‐aged adults with and without evidence of β‐amyloid pathology (2021) (0)
- Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys (2022) (0)
- [Guidelines for brain concussion in sports--how are they to be applied in boxing?]. (2007) (0)
- D09 Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntington’s disease: the hd-csf study (2018) (0)
- Full Title: State-dependent alterations in CSF Abeta42 levels in cognitively intact elderly with late life major depression Short Title: State-dependent alterations in CSF Abeta42 (2016) (0)
- High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis (2023) (0)
- The Influence of Metabolic Syndrome on Simvastatin Therapy In Asymptomatic Adults at Risk for Alzheimer's Disease: The ESPRIT Study (2010) (0)
- Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi‐Cohort Validation Against Biomarkers of Alzheimer’s Disease and Neurodegeneration (2022) (0)
- Neurogranin in Alzheimer's disease and ageing: A human post-mortem study (2023) (0)
- Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals (2022) (0)
- Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease (2021) (0)
- ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER’S DISEASE (2017) (0)
- Amyloid and tau pathologies associate with distinct aspects of the inflammatory cascade (2022) (0)
- Differences in the TREM2 levels in the CSF of Alzheimer’s disease cases and controls (2015) (0)
- BIMODAL DISTRIBUTION OF THE CSF Aβ42/Aβ40 RATIO IN CLINICAL LABORATORY PRACTICE (2018) (0)
- Plasma tau is negatively correlated with frontal lobe CBF in hypertensive adults on the AD spectrum (2020) (0)
- Protein disulfide isomerases as CSF biomarkers for the neuronal response to tau pathology. (2023) (0)
- Biomarker Modelling of Early Molecular Changes in Alzheimer’s Disease (2013) (0)
- Effects of methylprednisolone on blood-brain barrier and cerebral inflammation in cardiac surgery—a randomized trial (2018) (0)
- ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION (2018) (0)
- Molecular biomarkers for diagnosis and evaluation of treatment effects (2009) (0)
- Simultaneous Mass Spectrometric quantification of multiple p‐tau species in plasma – findings along the Alzheimer´s disease continuum (2022) (0)
- TCT-45 Cholinesterase Inhibitors Reduce Mortality in Patients With Myocardial Infarction and Alzheimer´s disease (2022) (0)
- ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT AND WHITE MATTER DENSITY IN ALZHEIMER’S DISEASE (2019) (0)
- Age effects on hippocampal volume and episodic and spatial memory vary as a function of APOE status and sex (2016) (0)
- PN09 Plasma neurofilament light chain levels are raised in patients with inherited peripheral neuropathy and correlate with disease severity (2018) (0)
- γ‐Secretase modulators show selectivity for γ‐secretase–mediated amyloid precursor protein intramembrane processing (2021) (0)
- Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults (2023) (0)
- EBV transformed B cells from an individual homozygously mutated (G329A) in the FUT7 gene do not roll on E- or P-selectins (2003) (0)
- Brain-derived neurotrophic factor in CSF and plasma is not a biomarker for Huntington's disease (2020) (0)
- CSF Aβ42/40 and Aβ42/38 ratios by prm mass spectrometry or elisa: Improved biomarkers of Alzheimer’s disease (2015) (0)
- THE PREVALENCE OF PATHOLOGICAL CSF ABETA-42 AND ITS RELATION TO EDUCATION IN A POPULATION SAMPLE OF OLDER PEOPLE FROM SWEDEN (2016) (0)
- THE CSF AB42/40 RATIO DOES NOT MITIGATE MISINTERPRETATION OF AB LOSS UPON SERIAL TUBE TRANSFERS (2016) (0)
- EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE (2014) (0)
- Building Pace and Scale in the Fight Against Alzheimer’s: The Road to 2025 and Beyond (2016) (0)
- Effect of Pathway-specific Polygenic Risk Scores for Alzheimer’s Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals (2023) (0)
- Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration (2019) (0)
- DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT (2017) (0)
- Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease (2022) (0)
- Translational Inhibition of Multiple Neurotoxic Proteins Leads to Improved Motor Function in Parkinson’s Disease (2022) (0)
- PRESENTATION OF A ROUTINE-USE PRE-ANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS (2019) (0)
- CORTICAL NEURONS AND CEREBRAL ORGANOIDS FROM APP AND PSEN1 MUTATION CARRIERS REVEAL MUTATION-SPECIFIC EFFECTS ON Aβ PRODUCTION (2019) (0)
- Independent information from PET, CSF and plasma biomarkers of tau pathology in Alzheimer’s disease (2021) (0)
- A novel neurofilament light chain Simoa assay that can quantify age‐dependent changes in control plasma samples over small time periods (2022) (0)
- Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts (2023) (0)
- An LC-MS/MS-based method for quantification of beta-amyloid-1-38, beta-amyloid-1-40 and beta-amyloid-1-42 in the cerebrospinal fluid of Alzheimer's patients and healthy controls (2012) (0)
- CSF metabolites associated with biomarkers of Alzheimer's disease pathology (2022) (0)
- NEUROFILAMENT LIGHT PROTEIN IS ASSOCIATED WITH COGNITIVE DECLINE WITHIN THE ATN MODEL (2018) (0)
- PREDICTION PERFORMANCE OF ALPHA-SYNUCLEIN PROTEIN IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY AD BIOMARKERS: THE INSIGHT-PRE AD STUDY (2017) (0)
- Plasma neurofilament light chain in cognitively unimpaired late middle‐aged & older adult APOE ε4 homozygotes, heterozygotes, & non‐carriers from the Arizona APOE Cohort (2022) (0)
- Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) (0)
- Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study. (2023) (0)
- STABILITY OF AMYLOID-BETA (1–42) IN FRESH VERSUS FROZEN HUMAN CEREBROSPINAL FLUID SAMPLES AS MEASURED WITH THE ELECSYS® B-AMYLOID(1–42) IMMUNOASSAY (2016) (0)
- Sleep oscillation-specific associations with Alzheimer’s disease CSF biomarkers: novel roles for sleep spindles and tau (2019) (0)
- LOWER NEURITE DENSITY AND ORIENTATION DISPERSION WITHIN GRAY AND WHITE MATTER IN THE ALZHEIMER’S DISEASE PATHOLOGIC FRAMEWORK (2019) (0)
- Cerebrospinal fluid neurofilament light protein as a diagnostic and prognostic biomarker in mitochondrial diseases with CNS involvement (2017) (0)
- COMPARISON OF A FULLY AUTOMATED BEAD-BASED SYSTEM WITH AN ENZYME-LINKED IMMUNOSORBENT ASSAY AND AN ELECTROCHEMILUMINESCENT ASSAY FOR MEASUREMENT OF CORE AD BIOMARKERS (2019) (0)
- Clas-amyloid metabolism in multiple sclerosis β Cerebrospinal fluid biomarkers of (2012) (0)
- CSF CHOLINE ACETYLTRANSFERASE SHOWS DIFFERENTIAL LEVELS AMONG HEALTHY CONTROLS AND PATIENTS WITH AD AND MCI (2018) (0)
- Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets – Amyloid, Tau, Synapse Formation -unsuccessful Phase Iii Study Does Not Mean the End of Anti-amyloid Therapies (0)
- CEREBROSPINAL FLUID/PLASMA ALBUMIN RATIO PREDICTS POSTOPERATIVE DELIRIUM IN AN OLDER ELECTIVE ORTHOPAEDIC POPULATION (2018) (0)
- Aging and sex impact plasma NFL and t‐Tau trajectories in individuals at risk for Alzheimer’s disease (2020) (0)
- 308 Increased acute exposure to soccer ball heading shows no response from biochemical markers for axonal injury (2021) (0)
- Revealing the combined roles of Aβ and tau in Alzheimer’s disease via a pathophysiological activity decoder (2023) (0)
- Coagulation of cerebrospinal fluid—the Nonne–Froin sign (2013) (0)
- Pilot study of intrathecal immunoreactivity in healthy people with or without previous infectious mononucleosis (2019) (0)
- Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology (2019) (0)
- Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease. (2023) (0)
- Elevated CSF neurofilament levels are associated with risk of Mild Cognitive Impairment among individuals with and without low CSF amyloid-beta (P3.028) (2018) (0)
- CEREBROSPINAL FLUID AND PLASMA NEUROFILAMENT LIGHT ELEVATIONS CORRESPOND TO WORSE COGNITIVE PERFORMANCE IN AGING ADULTS (2019) (0)
- Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease (2018) (0)
- Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia (2014) (0)
- High Numbers Of Activated CD8+ T Cells Targeting HIV Antigens Are Present In Cerebrospinal Fluid In Hyperacute HIV Infection (2017) (0)
- Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- CSF BIOMARKER CORRELATES OF ARTAG NEUROPATHOLOGY (2019) (0)
- Prospective Investigation of Markers of Elevated Delirium Risk (PRIMED Risk) study protocol: a prospective, observational cohort study investigating blood and cerebrospinal fluid biomarkers for delirium and cognitive dysfunction in older patients (2020) (0)
- Cognitive composites for genetic frontotemporal dementia: GENFI-Cog (2022) (0)
- Alzheimer’s Disease Proteinopathy and Synaptic Integrity: The Protective Role of Physical Activity (2022) (0)
- A sex-stratified analysis of neuroimmune gene expression signatures in Alzheimer’s disease brains (2022) (0)
- Serum glial fibrillary acidic protein is a marker of disease severity in 1 frontotemporal lobar degeneration (2020) (0)
- NEUROFILAMENT LIGHT IN ISOPOTENTIAL STEM CELL-DERIVED NEURONS WITH FAMILIAL AD MUTATIONS AS A MARKER OF NEURODEGENERATION (2019) (0)
- The effects of apolipoprotein genotype on the diagnostic accuracy of cerebroispinal fluid biomarkers for Alzheimer's disease (2012) (0)
- CARDIAC WORKLOAD IS ASSOCIATED WITH CSF BIOMARKERS IN COGNITIVELY NORMAL LATE-MIDDLE-AGED ADULTS AT RISK FOR ALZHEIMER’S DISEASE (2019) (0)
- CXCL13 in patients with facial palsy caused by varicella zoster virus and Borrelia burgdorferi: a comparative study. (2020) (0)
- A systematic review of progranulin concentrations in biofluids in over 7,000 people: Assessing the pathogenicity of GRN mutations and other influencing factors (2021) (0)
- Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- Neurofilament light in blood – What more is needed for clinical implementation in multiple sclerosis? (2020) (0)
- Is APOE e4 a risk factor for dementia also among the oldest old? Findings from the Gothenburg 95+ Study (2011) (0)
- Plasma p‐tau231 in the Alzheimer’s disease continuum: A multi‐cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application (2021) (0)
- Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- Found in translation: a blood-based test for Niemann-Pick type C1. (2011) (0)
- Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study (2022) (0)
- Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimer’s disease in the UK (2021) (0)
- Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- Epileptic seizures and CSF concentrations of neurofilament light and tau proteins in patients with subarachnoid hemorrhage. (2017) (0)
- PLASMA BETA-SECRETASE 1 CONCENTRATIONS IMPACT PLASMA NFL CONCENTRATIONS IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR AD: CROSS-SECTIONAL AND LONGITUDINAL STUDIES (2019) (0)
- CSF proteomic profiling of mild cognitive impairment individuals with suspected nonâ•’Alzheimerâ•Žs disease pathophysiology: Developing topics (2020) (0)
- Contents Vol. 6, 2009 (2010) (0)
- CSF Markers of Inflammation and Neurodegeneration in Two Hereditary Diffuse Leukoencephalopathy with Spheroids (HDLS) Families with Diverging Genotype and Phenotype (P5.268) (2016) (0)
- Quanti fi cation of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry (2022) (0)
- APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease (2020) (0)
- DIFFERENT CEREBROSPINAL FLUID BIOCHEMICAL PATTERNS IN PATIENTS WITH DEMENTIA WITH SUBCORTICAL WHITE MATTER LESIONS AND PURE ALZHEIMER'S DISEASE (2011) (0)
- Neurofilament-light chain (NfL) in the Vitreous Humor and its Correlation with Biomarkers Associated with Neurodegenerative Diseases (2020) (0)
This paper list is powered by the following services:
Other Resources About Henrik Zetterberg
What Schools Are Affiliated With Henrik Zetterberg ?
Henrik Zetterberg is affiliated with the following schools:
